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Abstract 
Metastasis is the major problem in clinical management of cancer, including prostate 
cancer (PCa). Biochemical conditions in tumour microenvironment (especially O2 
and Ca
2+
 levels) are important for modulating metastatic cell behaviours (MCBs). 
Ionic mechanisms, in particular voltage-gated sodium channel (VGSC) and 
intracellular Ca
2+
 activities, were shown previously to be involved in MCBs in PCa. 
This PhD tested the hypotheses (1) that MCBs would be sensitive to hypoxia and be 
inhibited by VGSC blockers including those selective for the persistent current and 
(2) that VGSC activity would control intracellular Ca
2+
 signalling. Experiments were 
carried on a variety of model cell lines in a comparative approach: strongly 
metastatic Mat-LyLu and weakly metastatic AT-2 rat PCa cells, and analogous 
human PCa cell lines (PC-3M and LnCaP, respectively). Experiments on Mat-LyLu 
cells showed that hypoxia (2 % O2, 24 h) increased mRNA expression of Nav1.7, the 
predominant VGSC α-subunit expressed in PCa; however, both plasma membrane 
and intracellular VGSC protein levels were reduced. There was no change in cellular 
proliferation, Matrigel invasion or lateral motility, whilst transverse migration 
increased significantly. Treatment (24 h) with the VGSC blockers ranolazine, 
riluzole, lidocaine and procaine (micromolar concentrations) decreased Nav1.7 
mRNA and total VGSC protein levels, and suppressed Matrigel invasion in both 
normoxia (~21 % O2) and hypoxia. PC-3M (but not LNCaP or Mat-LyLu) cells 
showed spontaneous, transient elevations of intracellular Ca
2+
 (“Ca2+ oscillations”). 
Ionic substitution and pharmacological experiments suggested that Ca
2+
 influx and 
release from intracellular stores both contributed to the oscillations. Importantly, 
acute treatment with tetrodotoxin and ranolazine decreased the oscillation amplitude 
and frequency.  Thus, both hypotheses were confirmed, i.e. (1) that hypoxia increases 
 - 6 - 
PCa (Mat-LyLu) cell migration and VGSC expression and (2) that intracellular Ca
2+
 
oscillations are downstream to VGSC activity. Overall, the thesis concludes that 
VGSC blockers could serve clinically as anti-metastatic agents. 
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on spontaneous Ca2+ oscillations in PC-3M cells. Bright field images DVD 
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Abbreviations 
AIS Axon initial segment 
AnkG Ankyrin G 
ANOVA Analysis of variance 
AP  Action potential 
ATX-II Anemone toxin II 
AU Arbitrary unit 
BAC Bovine adrenal chromaffin 
BCa Breast cancer 
BFA Brefeldin A 
Bp Base pair 
BSA Bovine serum albumen 
[Ca
2+
]i Intracellular calcium concentration 
CaC Cervical cancer 
CAM Cell adhesion molecule 
CaM  Calmodulin 
CaMK Calmodulin-dependent protein kinase 
cAMP Cyclic adenosine monophosphate 
CELEX Cellular excitability 
CHO Chinese hamster ovary 
CNS  Central nervous system 
con A Concanavalin A 
Cytb5R Cytochrome b5 reductase 
D Domain of voltage-gated sodium channel 
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dbcAMP Dibutyryl cyclic AMP 
DEKA Aspartate-glutamate-lysine-alanine 
DMSO Dimethyl sulfoxide 
DRG Dorsal root ganglion 
EBNA Epstein-Barr virus nuclear antigen 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EEDD Glutamate-glutamate-aspartate-aspartate 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EGTA Ethylene glycol tetraacetic acid 
ER Endoplasmic reticulum 
FBS Foetal bovine serum 
FITC Fluorescein isothiocyanate 
HEK  Human embryonic kidney 
HIF Hypoxia-inducible factor 
HRP Horseradish peroxidase 
IC50 50% inhibition concentration 
ID Inter-domain linker of voltage-gated sodium channels 
IFM Isoleucine-phenylalanine-methionine 
Ig Immunoglobulin 
IGSF Immunoglobulin superfamily  
INa  Na
+
 current 
INaP Persistent Na
+
 current 
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INaT Transient  Na
+
 current 
IP3R Inositol 1,4,5-triphosphate receptor 
LEMS Lambert–Eaton myasthenic syndrome 
MAPK Mitogen-activated protein kinase 
MCB Metastatic cell behaviour 
MMP Matrix metalloproteinase 
MPS Mammalian physiological saline 
MRI Magnetic resonance imaging 
mRNA Messenger RNA 
MTT  Thiazolyl blue tetrazolium bromide 
MW Molecular weight 
NCX Na
+
/Ca
2+
 exchanger 
NESOpAb Polyclonal nNav1.5-specific antibody  
NGF Nerve growth factor 
nNav1.5  „neonatal‟ Nav1.5 
NSCLC  Non small cell lung carcinoma 
NTC No treatment control 
OD Optical density 
PBS Phosphate buffered saline 
PC12 Pheochromocytoma 12 
PCa  Prostate cancer 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
PKA Cyclic AMP-dependent protein kinase  
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PKC  Protein kinase C 
PKCI Protein kinase C inhibitor peptide 
P-loop Pore-loop 
PNS Peripheral nervous system 
PMCA Plasma membrane Ca
2+
 ATPase 
RE1 Repressor element 1 
REST RE1 binding silencer protein 
RNAi RNA interference 
RPMI-1640 medium Roswell Park Memorial Institute 1640 medium 
rt-PCR Real-time PCR 
RyR Ryanodine receptor 
S Segment of voltage-gated sodium channel 
SBFI Sodium-binding benzofuran isophthalate  
SCLC Small cell lung carcinoma 
ScTX Scorpion toxin 
SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
SEM Standard error  
SERCA Sarcoplasmic-endoplasmic reticulum Ca
2+
 ATPase 
siRNA  Small-interfering RNA 
SS Short-segment 
STX Saxitoxin 
TBE Tris-HCl-borate-EDTA 
TRP Transient receptor potential 
T-tubules Transverse tubules 
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TTX Tetrodotoxin 
TTX-R Tetrodotoxin-resistant 
TTX-S Tetrodotoxin-sensitive 
UV Ultra-violet 
V0 Coefficient of voltage-dependence of time to peak 
VEGF Vascular endothelial growth factor 
VGCC Voltage-gated calcium channel 
VGPC Voltage-gated potassium channel 
VGSC Voltage-gated sodium channel 
Vm Membrane potential  
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This General Introduction is subdivided into three sections. The first two sections 
summarize the structure and regulation of voltage-gated sodium channels (VGSCs). 
The third section introduces metastatic disease and discusses current evidence on the 
involvement of VGSCs and other ion channels in metastatic progression. The main 
emphasis is upon prostate cancer (PCa).  
 
1.1 Voltage-gated sodium channels 
VGSCs are widely expressed in „excitable‟ tissues (e.g. neurons and muscle), where 
they mediate the initiation and propagation of actions potentials (APs) (e.g. Ogata 
and Ohishi, 2002). Increasing evidence suggests, however, that VGSCs are also 
expressed in classically „non-excitable‟ cell types, including glia, endothelial cells, 
fibroblasts and metastatic cancer cells of epithelial origin, where their functional role 
is less well defined (Diss et al., 2004). For instance, in metastatic colon cancer cells, 
functional VGSC activity was recently shown to regulate gene expression levels and 
patterns, the conclusion being that “… VGSC is a key regulator of a gene 
transcriptional network that controls cancer invasion” (House et al., 2010). In 
vascular endothelial cells, Na
+
 influx through VGSCs was found to upregulate 
intracellular Ca
2+
 level (i.e. via Na
+
/Ca
2+
 exchange), which in turn played a key role 
in angiogenesis (Sage et al., 1991; Gosling et al., 1998). 
 
1.1.1 Basic structure and molecular diversity 
VGSCs are multimeric membrane proteins comprising a central α-subunit (VGSCα) 
and one or more auxiliary β-subunit(s) (Catterall, 2000). Basic channel functionality 
is achieved by the VGSCα, which forms the channel pore. VGSCβs modulate the 
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electrophysiological properties of VGSCαs and regulate their functional expression 
levels (Brackenbury and Isom, 2008). 
 
1.1.1.1 VGSCα 
The pore-forming VGSC α-subunit (220-260 kDa) is composed of four structurally 
homologous domains (D1-D4), each containing six α-helical transmembrane 
segments (S1-S6) of 19-27 amino acids (Figure 1.1A) (Yu and Catterall, 2003). The 
S4 segments in each of the four domains, which contain positively charged amino-
acid residues (Arg or Lys) at every third position, serve as the voltage-sensors for 
activation (Swartz, 2008). Extracellular re-entrant pore-loops (P-loops or SS1-SS2 
region) between helices S5 and S6 form the narrow entry to the Na
+
-conducting pore 
and act as an ion-selectivity filter containing a critical amino acid sequence: 
aspartate-glutamate-lysine-alanine (DEKA) (Catterall, 2000). The wider intercellular 
end of the pore is formed mainly by the inner S6 residues (Goldin et al., 2000; 
Catterall, 2010). Mutations in the DEKA motif have been shown to affect ion 
selectivity and permeability (Sun et al., 1997), such that a change from DEKA to 
EEEE switched selectivity of a VGSCα from Na+ to Ca2+ (Heinemann et al., 1992). 
The 3-dimensional (3D) image of the VGSCα, obtained from helium-cooled 
cyro electron microscopy and single-particle image analysis, revealed four 
transmembrane masses (i.e. D1-D4) arrayed symmetrically around a central 
hydrophilic pore (Figure 1.1B; Sato et al., 2001). The VGSCα protein appeared bell-
shaped, with 24% of its mass on the extracellular side and 47% on the intracellular 
side of the membrane (Catterall, 2001). Most of the intracellular mass was attributed 
to the large N- and C-termini and the large intracellular linkers connecting D1, D2 
and D3 (Figure 1.1.A; Catterall, 2001). In addition, Sato et al. (2001) found that the 
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Figure 1.1 Structure of voltage-gated Na
+
 channels 
(A) VGSC α-subunit is shown together with the β1-subunit. VGSCα has four 
domains (D1-D4), each with six α-helical transmembrane segments (S1-S6). S5-S6 
(pink) are the pore-lining segments and the S4 helices (yellow) form the voltage-
sensors. The extracellular domain of the β1 is shown as an immunoglobulin-like fold, 
which interacts non-covalently with the α-subunit. Adapted from Onkal and 
Djamgoz, 2009. (B) 3D illustration of VGSCα structure: a, central ion permeation 
pore; b, gating pores. Modified from Ogata and Ohishi (2002).  
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central ion permeation pore branched into four „inlets‟ and „outlets‟ on both sides of 
the membrane rather than connecting directly to the intracellular and extracellular 
spaces (Figure 1.1B) (Catterall, 2001).  
The VGSCα pore is permeable to several monovalent cations in the order of 
Na
+
 ~ Li
+
 > Tl
+
 > K
+
 > Rb
+
 > Cs
+
 (Hille, 1972, 2001). The channel is also permeable 
to a number of non-metallic cations including hydroxylamine and guanidinium but 
impermeable to organic cations such as choline (Hille, 1971). Five classes of toxins, 
including the highly specific guanidine-based natural toxin, tetrodotoxin (TTX), bind 
to VGSCα at various sites and modify its activity by discrete modes of action (Table 
1.1) (Cestèle and Catterall, 2000; Catterall et al., 2007). In addition, various small-
molecule VGSC blocker drugs, including local anaesthetics, anticonvulsants and 
antiarrhythmics, bind to a „drug-pocket‟ formed by multiple residues in inner D1:S6, 
D3:S6 and D4:S6 (Table 1.1) (England, 2008; Clare, 2010).  
To date, ten VGSCα subunits (Nav1.1-Nav1.9 and Nax) have been identified, 
each having subtle but potentially significant electrophysiological and 
pharmacological variability due to variable amino acid sequences (Table 1.2) 
(Plummer and Meisler 1999; Catterall, 2000; Diss et al., 2004). Additional VGSCα 
diversity is achieved at transcriptional, pre-translational (i.e. alternative splicing) and 
post-translational levels (i.e. phosphorylation), and these are detailed separately in 
Section 1.2. VGSCαs can be broadly characterized by their biophysical (e.g. 
activation/inactivation kinetics) properties and sensitivity to TTX. Thus, most 
VGSCαs (Nav1.1-Nav1.4, Nav1.6 and Nav1.7) are blocked by nanomolar 
concentrations of TTX (TTX-S), activate around -40 mV and have fast inactivation 
kinetics (Diss et al., 2004). On the other hand, a second subset of VGSCαs (Nav1.5, 
Nav1.8, Nav1.9) show sensitivity to TTX only at micromolar concentrations (TTX-
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Table 1.1 VGSCα -binding toxins and drugs 
 
Abbreviations: D, domain; S, segment; SS, short-segment. Modified from Catterall et al. (2007). 
 
Site # Agent (Toxin / Drug) Effect Binding site 
1 Tetrodotoxin, saxitoxin, μ-conotxoin Blockage of pore: inhibition of conductance SS1-SS2 
2 Aconitine, veratridine, batrachotoxin, grayanotoxin Hyperpolarization of activation: persistent activation D1&D4:S6 
3 α-scorpion toxin, β-pompilidotoxin, sea anemone toxin Prevention of outward movement of D4:S4  D4:S3-S4 
4 β-scorpion toxins Trapping of D2:S4 in outward position D2: S3:S4 
5 Brevetoxins, ciguatoxins Hyperpolarization of activation: persistent activation DI:S6, D4:S5 
6 Local anaesthetics, antiarrythmic drugs, antiepileptic drugs Resting and use-dependent blockage of conductance D1&D3&D4: S6 
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Table 1.2 VGSC α-subunit gene family 
 
VGSCα subunit Former names Gene symbol Chromosomal location Major site of expression 
Nav1.1 rat I, HBSCI, GPBI, Scn1a SCN1A M: 2; H: 2q24 CNS 
Nav1.2 rat II, HBSCII, HBA SCN2A M: 2; H: 2q23-24 CNS 
Nav1.3 rat III  SCN3A M: 2; H: 2q24 CNS, PNS 
Nav1.4 SkM1, μ1 SCN4A M: 11; H: 17q23-25 Skeletal muscle 
Nav1.5 SkM2 SCN5A M: 9; H:3p21 Heart 
Nav1.6 NaCh6, PN4, Scn8, CerIII SCN8A M: 15; H: 12q13 CNS 
Nav1.7 NaS, hNE-Na, PN1 SCN9A M: 2; H: 2q24 PNS 
Nav1.8 SNS, PN3, NaNG SCN10A M: 9; H: 3p22-24 DRG 
Nav1.9 NaN, SNS2, PN5, NaT, SCN12A SCN11A M: 9; H: 3p21-24 DRG 
Nax Nav2.2, NaG, SCL11, Nav2.3 SCN6A, SCN7A M: 2; H: 2q21-23 Heart, uterus, skeletal muscle 
Abbreviations: CNS, central nervous system; PNS, peripheral nervous system; DRG, dorsal root ganglia. Modified from Goldin et al. 
(2000). 
 
  
- 37 - 
 
 
R), activate at more hyperpolarized potentials (-60 mV or more negative) and exhibit 
slower inactivation kinetics (Plummer and Meisler 1999; Goldin, 2001). Sensitivity to 
TTX is determined by an aromatic residue (Tyr or Phe) in the D1:S5-S6 loop; TTX-R 
VGSCαs have a polar residue (Cys or Ser) in this position (Figure 1.1A) (Satin et al., 
1992; Heinemann et al., 1992; Fozzard and Lipkind, 2010).  
Expression of different VGSCαs is tissue-specific and can be developmentally 
regulated (Table 1.2; Plummer and Meisler 1999; Catterall 2000). For instance, 
Nav1.1, Nav1.2 and Nav1.6 are expressed predominantly in central nervous system 
(CNS); Nav1.6 is mainly present in axon initial segments (AIS) and nodes of Ranvier; 
Nav1.2 is expressed in unmyelinated axons and AIS in myelinated axons; and Nav1.1 
is localized mainly in the somata (Trimmer and Rhodes, 2004; Mantegazza et al., 
2010). Nav1.3 is expressed in the CNS and also in dorsal root ganglion (DRG) 
neurons following peripheral nerve damage (Waxman et al., 1994; Black et al., 1999; 
Whitaker et al., 2001). Nav1.4 is the major VGSCα in adult skeletal muscle (Kraner 
et al., 1989), and Nav1.5 is the cardiac VGSCα (Gellens et al., 1992). Finally, 
Nav1.7, Nav1.8 and Nav1.9 are mainly expressed in the peripheral nervous system 
(PNS), where their function is thought to be critical for nociception (Toledo-Aral et 
al., 1997; Dib-Hajj et al., 1998; England, 2008). Thus, expression of multiple VGSCα 
isoforms can occur in single cells (both „excitable‟ and „non-excitable‟), and it is 
thought that specific cell types may achieve their unique functional output based on 
the subtle functional differences in the VGSCα isoform(s) that they express (Goldin, 
2001; Diss et al., 2004). In other words, controlled expression of a combination of 
different isoforms of VGSCs is hypothesized to allow a cell to modulate and „fine-
tune‟ its response patterns (Waxman, 2007).  
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VGSCs have 3 main functional states: 1) closed, (2) open/activated and (3) 
inactivated, and cycle between these states depending on the value of the membrane 
potential and time (Figure 1.2). According to the “sliding helix” model of activation, 
upon membrane depolarization, the spiral outward movement of the S4 helices 
initiates the conformational change of the protein structure that leads to the opening 
of the channel pore (Tombola et al., 2006; Catterall, 2010). Fast inactivation of the 
VGSC occurs within milliseconds of channel opening and the highly conserved 
hydrophobic amino acid triad known as the “IFM motif” (Iso-Phe-Met) in the short 
intracellular loop between D3 and D4 (ID3-4) mediates rapid inactivation of the 
channel (Figure 1.3) (Yu and Catterall, 2003). Thus, the „hinged-lid‟ IFM motif folds 
into the inner mouth of the channel pore, occluding it and hence inactivating Na
+
 
conductance during sustained depolarization of the membrane (West et al., 1992; 
Goldin, 2003). The fast inactivation gate is believed to derive its voltage dependence 
through coupling to the outward movement of the D4:S4 during channel activation 
(Kontis and Goldin, 1997). Upon membrane repolarisation, VGSCs recover from 
inactivation due to relaxing of the inactivation gate (Figure 1.2) (Catterall, 2000). In 
the case where membrane repolarises before inactivation has occurred, VGSCs could 
undergo deactivation, directly transiting from open/activated to the closed state 
(Figure 1.2) (Kuo and Bean, 1994). In the case of the depolarization of the membrane 
for an extended period of time, VGSCs may undergo a separate form of inactivation, 
termed „slow‟ inactivation (Vilin and Ruben, 2001; Goldin, 2003); this type of 
inactivation does not involve the fast inactivation particle in the ID3-4 linker and is 
hypothesized to result from a structural rearrangement of the pore (Goldin, 2003; 
Tikhonov and Zhorov, 2007). However, further studies are required to elucidate the 
precise mechanism and molecular determinant of slow inactivation.   
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Figure 1.2 Functional states of voltage-gated sodium channels 
Schematic representation of the three functional modes of voltage-gated Na
+
 
channels. At rest, the channels are in their resting (closed) state. Upon 
depolarization, channels activate (a) and then inactivate (aa) within milliseconds of 
activation. The inactivated state of the VGSCs through the binding of the 
inactivation gate (IFM motif) to the channel pore structure is indicated by (*). 
From the inactivated state, channels recover from inactivation (aaa) upon 
membrane repolarization. „Reverse‟ transitions between these gating states are also 
possible (b, bb, bbb), but occur much less frequently: b, deactivation; bb, 
activation, bbb, closed-state inactivation.  
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Figure 1.3 Mechanism of fast inactivation  
The cytoplasmic linker between domains 3 and 4 (ID3-4) forms a „hinged lid‟ that 
is responsible for fast inactivation of the VGSC. The critical Phe
1489
 within the 
hydrophobic IFM motif (Ile
1488
-Phe
1489
-Met
1490
) occludes the intracellular mouth of 
the pore during the inactivation process (right). Adapted from Yu and Catterall 
(2003). 
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As described above, upon membrane depolarization, VGSCs typically activate, 
rapidly inactivate, and remain closed/non-conducting until repolarization occurs. 
However, it has become increasingly apparent that a small portion of VGSCs may 
inactivate and re-open during prolonged depolarisations, thereby resulting in a small 
but persisting Na
+
 current (INaP). Such INaP could be recorded from neurons and 
cardiomyocytes as well as in heterologous systems expressing a single VGSCα 
subtype (Crill, 1996; Maltsev et al., 1998; Magistretti et al., 1999; Qu et al., 2001; 
Taddese and Bean, 2002; Maltsev and Undrovinas, 2006; Saint, 2008; Aman et al., 
2009). Notably, INaP typically has a magnitude of < 1% of the peak Na
+
 current; 
however, because it is very-slowly inactivating (or non-inactivating), the amount of 
charge (i.e. Na
+
) it carries is considerable (Saint et al., 1992; Maltsev et al., 1998; 
Zygmunt et al., 2001). Furthermore, various (patho)physiological conditions can 
significantly enhance INaP in cardiomyocytes and neurons; among these are 
inactivation-modifying neurotoxins (e.g. sea anemone toxin ATX-II; Chahine et al., 
1996), hypoxia (Ju et al., 1996), and Nav1.5 mutations associated with the long QT-3 
syndrome (Bennett et al., 1995; Fredj et al., 2006).  
 
1.1.1.2 VGSCβ 
Whilst the VGSCα subunit is sufficient for functional expression, it is usually 
complexed with one or more smaller auxiliary VGSCβs (Figure 1.1), which can (1) 
modulate several aspects of VGSC function including channel activation/inactivation 
by shifting the voltage dependence of activation and inactivation, and (2) increase the 
level of functional VGSC expression on the plasma membrane through enhancing the 
intracellular trafficking of the VGSCα protein to the plasma membrane and/or 
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through increasing the cell surface stability of VGSCαs via association with 
cytoskeletal molecules such as ankyrin (Isom et al., 1994; Brackenbury et al., 2008).  
To date, four VGSCβ isoforms have been identified: β1-4 (33-45 kDa) (Table 
1.3). The β1- and β3- subunits associate non-covalently with the α-subunit, whereas 
β2- and β4- subunits are covalently linked to a cysteine residue on an extracellular 
linker of the α-subunit (Isom et al., 1992, 1995; Morgan et al., 2000; Yu et al., 2003). 
Each VGSCβ possesses an extracellular N-terminal domain with an immunoglobulin 
(Ig)-like fold, a single membrane-spanning segment, and a cytoplasmic C-terminal 
region (Isom 2001; Chahine et al., 2005). Importantly, VGSCβs are unique among 
ion channel subunits in containing Ig-like folds, giving them structural homology to 
certain types of cell-adhesion molecules (CAMs). This property was first discovered 
for β2 (whose Ig-like domain shares 45% sequence homology with one of the six Ig 
motifs in the extracellular domain of neuronal CAM, contactin; Isom et al., 1995). 
Further experiments showed that VGSCβs can function as Ig superfamily cell 
adhesion molecules (IGSF-CAMs), e.g. both β1 and β2 were shown to interact trans-
homophilically, facilitating cellular aggregation and ankyrin recruitment to cell-to-
cell contacts (Malhotra et al., 2000, 2002). Moreover, heterophilical interaction of β1 
has been documented with contactin, NrCAM, N-cadherin, neurofascin-155, 
neurofascin-186 and VGSCβ2, and shown to potentiate functional VGSC expression 
in plasma membrane (Kazarinova-Noyes et al., 2001; McEwen and Isom, 2004; 
McEwen et al., 2004). Finally, both β1 and β2 were found to interact with and 
repelled from tenascin-C and tenascin-R (both extracellular matrix (ECM) 
molecules), thereby suppressing cell migration (Srinivasan et al., 1998; Xiao et al., 
1999). 
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Table 1.3 VGSCβ isoforms 
 
 
Abbreviations: CNS, central nervous system; DRG, dorsal root ganglion; PNS, peripheral 
nervous system. Modified from Brackenbury et al. (2008).  
 
Isoform MW (kDa) 
Gene 
symbol 
Chromos
omal 
location 
Tissue location 
β1 36 SCN1B 19q13 
Heart, skeletal muscle, CNS, 
glia, PNS 
β1A 45 SCN1B 19q13 
Heart, skeletal muscle, 
adrenal gland, PNS 
β2 33 SCN2B 11q22 CNS, PNS, heart, glia 
β3 36 SCN3B 11q23 
CNS, adrenal gland, kidney, 
heart, PNS 
β4 38 SCN4B 11q23 
Heart, skeletal muscle, CNS, 
PNS 
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VGSCβ diversity is achieved by developmental and tissue-specific expression 
of the four subtypes as well as alternative splicing (Table 1.3) (Isom, 2001; Meadows 
and Isom, 2005). For instance, a partially developmentally regulated intron retention 
event generates the β1A splice variant, which (i) shares little amino acid homology 
with β1 apart from the N-terminal Ig domain, and (ii) is developmentally down-
regulated and replaced by β1 in rat brain (Kazen-Gillespie et al., 2000). As with 
VGSCαs, multiplicity of VGSCβ expression occurs in given cell types, where each 
isoform may have a distinct role (e.g. modulation of particular VGSCαs or interaction 
with differing sets of extracellular matrix of cytoskeletal proteins) (Table 1.3) (Isom, 
2001; Chahine et al., 2005; Brackenbury et al., 2008).  
 
1.2. Regulation of VGSCs 
Regulation of VGSC expression/activity is highly complex and occurs at multiple 
stages: (1) transcriptional, (2) pre-translational (e.g. alternative splicing), and (3) post-
translational (e.g. glycosylation, phosphorylation, association with other membrane-
bound proteins) (Figure 1.4).  
 
1.2.1 Transcription 
VGSC gene expression can be regulated by various stimuli such as electrical activity 
(Sashihara et al., 1994), hormones (Tabb et al., 1994) and growth factors (Black et 
al., 1997; Toledo-Aral et al., 1995; Choi et al., 2001; Fanger et al., 1997), Some of 
these effects may occur during injury (Black et al., 1999; Iwahashi et al., 1994; 
Waxman et al., 1994), For example, nerve growth factor (NGF) induced expression 
of Nav1.7 was shown in PC12 cells (Rudy et al., 1987; Toledo-Aral et al., 1995). On 
the other hand, NGF induced upregulation of Nav1.8 and down regulation of Nav1.3 
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 Figure 1.4 Levels of regulation of VGSC expression and activity 
Regulation of VGSCs occur at (A) transcriptional level (e.g. transcriptional factors), 
followed by pre-translational modifications (B) (e.g. mRNA trafficking and splicing). 
Then, the channel protein is synthesized, and trafficked to the plasma membrane. 
Post-translation modifications (C) include phosphorylation, glycosylation, and 
interaction with other proteins including VSGCβs. Recycling and degradation of 
VGSC protein (c) is another important factor in keeping a steady-state balance of 
available functional VGSCs at the plasma membrane. 
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was reported for DRG neurons (Black et al., 1997). Interestingly, some pathological 
transcriptional re-expression of VGSCs can involve embryonic splice variants, as in 
the case of kainic acid-induced damage to mammalian brain and Nav1.3 (Gastaldi et 
al., 1997; Waxman et al., 1994) 
Transcriptional factors are principal modulators of gene expression, and one 
transcription factor has been shown to effect expression of a VGSCα subtype (Chong 
et al., 1995). Nav1.2 expression was restricted to neurons by REST, a transcription 
silencer (Chong et al., 1995). REST is expressed in most tissues and binds to a 
specific receptor element 1 (RE-1) in the promoter region of Nav1.2 and causes 
suppression of its expression (Chong et al., 1995). On the other hand, absence of 
REST in neurons permits expression of Nav1.2 in these cells (Marban et al., 1998; 
Chong et al., 1995). Functioning of REST is also depends on other co-repressor 
proteins, CoREST and mSin3A (Andres et al., 1999; Grimes et al., 2000). 
Furthermore, another transcription factor Brn-3a, a POU-family homeobox protein, 
was shown to upregulate Nav1.7 expression in PC-3 cell line (Diss et al., 2006). 
Recent work has also characterized the transcriptional promoter region of Nav1.7 
(Diss et al., 2008). 
 
1.2.2 Alternative splicing 
Functional diversity of the VGSC α-subunits is significantly increased by alternative 
mRNA splicing, which generates two or more different mRNAs from a single gene 
(McKeown, 1992; Blencowe, 2006). Within the modulatory region of the VGSCα 
subunit, there exist five major sites where alternative splicing is known to occur 
(Table 1.4) (Diss et al., 2004). Variability among the splice variants can be generated 
by inclusion, exclusion or substitution of amino acid residues in the coding sequence. 
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Table 1.4 Alternative splice variants of VGSCαs 
Site Nav Event Functional consequence Reference 
D1:S3 1.1, 1.2, 1.3, 1.5, 
1.6, 1.7 
Substitution of negative Asp in „adult‟ to 
a neutral or positive residue in „neonatal‟ 
Modify voltage-dependence and kinetics 
activation/inactivation 
Copley et al., 2004; Sarao et al. 1991; Gustafson 
et al., 1993; Chioni et al., 2005; Plummer et al., 
1998; Belcher et al., 1995. 
ID1-2 1.1., 1.3, 1.6, 
1.7 
Multiple splice forms with different ID1-
2 regions 
Modify (add / remove) phosphorylation 
sites 
Schaller et al., 1992; Dietrich et al., 1998; 
Thimmapaya et al., 2005; Plummer et al., 1998; 
Toledo-Aral et al., 1997; Raymond et al., 2004. 
ID2-3 1.5, 1.8 Shortened ID 2-3 Modify voltage-dependence of 
activation/inactivation; produce non-
functional proteins 
Gersdorff-Korsgaard et al., 2001; Zimmer et al., 
2002; Camacho et al., 2006; Makielski et al., 
2003 
D3 1.1, 1.6 Alternative exon 18 Predominantly produce truncated „fail-
safe‟ proteins 
Plummer et al., 1997; Oh and Waxman 1998; 
Schaller et al., 1995. 
D4:S3 1.5, 1.9 Shortened intron in D4:S3 Produce truncated proteins Gellens et al., 1992; Jeong et al., 2000 
 
Abbreviations: D, domain; S, segment; ID, interdomain region. 
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These may be the consequence of (i) the alternative usage of 5‟ (donor) / 3‟ (acceptor) 
splice sites, (ii) exon skipping events (involving one or more exons) in the coding 
region, (iii) mutually exclusive exon usage, (iv) the alternative usage of 5‟ or 3‟ 
untranslated regions, and (v) intron to exon conversion events  (McKeown, 1992; 
Chen and Manley, 2009).  
Alternative splicing of the VGSCα genes results either in full-length, 
functional proteins that exhibit regulatory, electrophysiological and/or 
pharmacological variability (e.g. Dietrich et al., 1998; Onkal et al., 2008), or quite 
commonly, in highly truncated non-functional proteins (e.g. Schaller et al., 1992; 
Plummer et al., 1997) (Table 1.4). The role of the truncated VGSCαs has not been 
fully explained, but could involve the following: (1) functional interaction and 
association with other truncated VGSCαs in the right orientation to form 
„heteromeric‟ sodium channels, and/or (2) a „fail-safe‟ mechanism producing 
truncated proteins, preventing the synthesis and/or activity of functional, full-length 
VGSCα channels (Plummer et al., 1997; Diss et al., 2004; Schroeter et al., 2010). 
Alternative splicing resulting in modified but full-length VGSCαs contributes 
significantly to functional VGSC diversity (Table 1.4) (Schroeter et al., 2010). Since 
cytoplasmic ID linkers are crucial for channel modulation (e.g. via phosphorylation or 
protein-protein interactions; Figure 1.5), splicing in ID1-2 and ID2-3 would be 
expected to produce VGSCα splice isoforms with differing functional characteristics. 
Indeed, an alternative splice form of Nav1.5 (Nav1.5c), which was first detected in 
mouse DRG neurons, was found to encode an extra glutamate residue in the ID2-3 
linker region, which disrupted a putative casein kinase 2 (CK2) phosphorylation site 
(Kerr et al., 2004). Also, splicing in the ID1-2 linker resulted in splice variants of 
Nav1.1, Nav1.3, Nav1.6 and Nav1.7 with shortened ID1-2 linkers, which excluded 
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Figure 1.5 VGSC regulatory sites 
Serine residues (S) phosphorylated by PKA or PKC are numbered (Nav1.2 numbering). Arrows indicate possible interaction sites 
between the VGSC α- and β-subunits. Abbreviations: An II, annexin II; Ub, ubiquitin; CaM, calmodulin; AnkG, ankyrin G; Gβγ, 
G-protein β-γ complex; Modified from Chahine et al. (2005). 
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multiple sites for putative PKA and PKC phosphorylation (Table 1.4 and Figure 1.5) 
(Diss et al., 2004). Moreover, Thimmapaya et al. (2005) over-expressed these Nav1.3 
ID1-2 splice variants in Xenopus oocytes and showed that they exhibit slightly 
different (3-5 mV) voltage-range for activation and inactivation. 
Apart from the modulatory effects of splicing in ID linkers, alternative 
splicing within the transmembrane VGSCα regions generally produce variants with 
significant electrophysiological distinction. A particularly important splicing site in 
this regard is D1:S3/S4 (Table 1.4) (Diss et al., 2004). Developmentally controlled 
splicing of two mutually exclusive alternative exons in D1:S3/S4 was first described 
for Nav1.2 and Nav1.3 in rat brain (Sarao et al., 1991; Gustafson et al., 1993). The 
two alternative exons encode part of the transmembrane segment S3, most of S4, and 
the S3/S4 extracellular linker (Diss et al., 2004; Chioni et al., 2005; Onkal and 
Djamgoz, 2009). The transcripts with the upstream (5‟) exon were found to be 
expressed predominantly during the neonatal period, whilst the transcripts with the 
downstream (3‟) exon were expressed only in the adult. Accordingly, for Nav1.2 and 
Nav1.3, the upstream exon was designated „neonatal‟ and the counterpart 
downstream „adult‟. Similar D1:S3 splicing has also been reported for Nav1.1, 
Nav1.5, Nav1.6 and Nav1.7 (Diss et al., 2004).  
Except for Nav1.5, the „adult‟ and „neonatal‟ exon 6 variants differ by 19-21 
nucleotides resulting in only 1-3 amino acids changes; a single amino acid in the 
extracellular S3-S4 linker changes consistently from a neutral to a negatively-
charged residue during development (Plummer and Meisler, 1999; Diss et al., 2004). 
On the other hand, Nav1.5 D1:S3 variants differ from each other by 31 nucleotides 
and 7 amino acids, where the key amino acid switch in the extracellular D1:S3/S4 
linker is a charge-reversing one: from a positive lysine in „neonatal‟ to a negative 
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aspartate in the „adult‟ (Fraser et al., 2005; Ou et al., 2005). Because of these larger 
differences, Chioni et al. (2005) could generate a polyclonal antibody (NESOpAb) 
that was selective for „neonatal‟ Nav1.5. Using NESOpAb in immunohistochemical 
studies, these authors also confirmed the developmental regulation of Nav1.5 D1:S3 
splicing in mouse heart (Chioni et al., 2005). 
Human Nav1.7 is expressed primarily in sensory neurons of the peripheral 
(i.e. DRG) and sympathetic nervous systems, and in Schwann cells (Goldin, 2001). 
D1:S3 splice variants of Nav1.7 were identified in human (Klugbauer et al., 1995, 
Raymond et al., 2004), rabbit (Belcher et al., 1995), and rat (ToledoAral et al., 
1997). D1:S3 splice variants of Nav1.7 differ in 21 of their 92 nucleotides. The 
resulting „adult‟ and „neonatal‟ Nav1.7 proteins differ by two amino acids, i.e. at 
positions 201 (Leu in „neonatal‟ and Val in „adult‟) and 206 (Asn in „neonatal‟ and 
Asp in „adult‟) (Belcher et al., 1995; Diss et al., 2004). The low expression of the 
„adult variant‟ in neonatal rabbits suggested that the D1:S3 splicing in Nav1.7 is 
developmentally regulated, as for Nav1.2, Nav1.3 and Nav1.5 (Sarao et al., 1991; 
Gustafson et al., 1993; Belcher et al., 1995; Chioni et al., 2005). Interestingly, 
expression of Nav1.7 „adult‟ and „neonatal‟ variants appears to be tissue-specific in 
humans: the „neonatal‟ isoform is preferentially expressed in the PNS and CNS of 
adult tissues, whereas the „adult‟ variant is found predominantly in the DRG neurons 
(Raymond et al., 2004). Interestingly, Fraser et al. (2005) reported that strongly 
metastatic MDA-MB-231 breast cancer cell line selectively expressed relatively high 
levels of D1:S3 „neonatal‟ splice form Nav1.7 mRNA (which subsequently 
contributed ~ 20% of total Na
+
 current), indicating that this „neonatal‟ isoform may 
be involved in the progression of metastasis in breast cancer cells (Section 1.3.3). 
Furthermore, in particular relevance to the present project, the predominant „culprit‟ 
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VGSCα expressed in strongly metastatic human (PC-3M) and rat (Mat-LyLu) 
prostate cancer cells in also the „neonatal‟ D1:S3 variant of Nav1.7 (Section 1.3.3) 
(Diss et al., 2001; Onkal and Djamgoz, 2009). 
At present, mechanisms controlling alternative splicing of VGSCα (and other 
ion channel) genes is not fully known but could involve changes in membrane 
potential (Xie and Black, 2001), growth factors (Akopian et al., 1999), and 
phosphorylation (Shipston, 2001) (reviewed in Diss et al., 2004). For instance, in 
adult rat DRG neurons, nerve growth factor (NGF) was found to upregulate a splice 
variant of Nav1.8 that contained a partial repeat of domain 2 (Akopian et al., 1999). 
In GH3 pituitary cells, membrane depolarization by adding KCl was shown to 
repress splicing of „STREX‟, an exon conferring Ca2+ sensitivity in large-
conductance K
+
 (BK) channel mRNAs (Xie and Black, 2001). Notably, alternative 
splicing of VGSCα mRNAs can be regulated by various mechanisms in different cell 
types. Thus, for example, in spinal cord astrocytes, the expression of three Nav1.6 
D3 splice variants was upregulated by 48 h exposure to the membrane-permeant 
dibutyryl cAMP (dbcAMP), whereas a similar treatment had no effect in cerebral 
astrocytes (Oh and Waxman, 1998).  
 
1.2.3 Post-translational modification: Glycosylation 
All VGSCαs possess number of potential extracellular glycosylation sites located at 
the putative pore lining regions of D1 and D3 (Bennett, 2002 and Marban et al., 
1998). Five of these sites are highly conserved and therefore it was proposed that 
carbohydrate have essential role in structure and localisation of VGSC (Diss et al., 
2004). The extend of glycosylation is subtype specific. For example, Nav1.1 - 
Nav1.4 are 15 - 30 % glycosylated whilst Nav1.5 and Nav1.9 are 5 % glycosylated 
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(Marban et al., 1998; Tyrrell et al., 2001). In addition, β1 and β2 subunits of VGSC 
are heavily glycosilated (Isom et al., 1992). Glycosylation was shown to effect 
electrophysiological properties of VGSC (Bennett et al., 1997). For instance, 
addition of negatively charged carbohydrate molecules has been shown to 
hyperpolarize voltage –dependence of VGSC gating (Marban et al., 1998; Cronin et 
al., 2005). Reduced sialyation depolarized the gating of Nav1.4 but not Nav1.5 in 
transfected Chinese hamster ovary (CHO) cells indicating that functional effect of 
glycosylation is subtype specific (Bennett, 2002). In addition, in CHO cells, highly 
sialylated β1-subunit hyperpolarizes the voltage dependence of Nav1.2, Nav1.5 and 
Nav1.7 but non- sialylated β1 had no effect (Johnson et al., 2004). 
 
1.2.4 Protein synthesis and trafficking 
Regulation of mRNA levels and protein level can be controlled separately and 
independently (Orphanides and Reinberg, 2002).  For example, Brackenbury and 
Djamgoz (2006) showed that TTX treatment decreased Nav1.7 mRNA expression in 
Mat-LyLu cells but did not change total protein level. On the other hand, TTX 
induced increase in VGSCα expression at plasma membrane of Mat-LyLu suggested 
the role of trafficking. In separate study it was suggested that activation of cAMP –
dependent protein kinase A (PKA) increased plasma membrane VGSC level via 
protein synthesis in BAC cells (Yuhi et al., 1996). However it should be noted that 
trafficking could play a role in this process. 
 VGSC protein level at plasma membrane can be regulated by protein 
trafficking via vesicular exocytosis (Herfst et al., 2004). It was show that PKA 
activity regulates VGSC externalisation from ER (Muniz et al., 1996, 1997; Zhou et 
al., 2000, 2002). For example, application of cAMP (1 h) resulted in elevation in 
  - 54 - 
 
functional expression of VGSC in Nav1.5 expressing Xenopus oocytes (Frohnwieser 
et al., 1997). In addition, disruption of intracellular protein trafficking with monensin 
and chloroquine (Tietze et al., 1980; Mollenhauer et al., 1990) diminished the PKA-
induced increase in functional expression of VGSC in Xenopus oocytes (Zhou et al., 
2000). 
 Ca
2+
 signalling has been shown to play role in VGSC trafficking. For instance, 
cytosporin-A induced inhibition of calcineurin (a Ca
2+
-and calmodulin–dependent 
protein phosphatase 2B) resulted in increase binding of [
3
H]STX to VGSC at BAC 
cell surface. Furthermore, co-application of cytosporin-A and trans-Golgi network 
transport inhibitor brefeldin A (BFA) reduced cell surface VGSC level implying that 
calcineurin plays role in reduction in externalisation of newly synthesised proteins 
(Shiraishi et al., 2001b). In another study, increase in [Ca
2+
]i with A23287, a Ca
2+
 
ionophore, was documented to reduce BAC cell surface expression of VGSC 
(Shiraishi et al., 2001a). On the other hand, this decrease in cell surface expression 
was prevented by Ca
2+
-dependent PKC (PKC-α) inhibition (Shiraishi et al., 2001a). 
In addition, in the presence of BFA, activation of PKC-α with thymeleatin (TMX) 
reduced [
3
H]STX binding therefore it was proposed that PKC-α promote endocytotic 
internalisation in BAC cells (Yanagita et al., 2000; Kobayashi et al., 2002). In 
addition, A23187 induced decrease in cell surface VGSC level was abolished by 
calpastatin peptide, a calpain (a family of Ca
2+
-dependent cycteine proteases) 
inhibitor (Shiraishi et al., 2001a). 
 It was proposed that interaction between VGSC and scaffolding proteins 
affects channel trafficking (Herfst et al., 2004). For example, it was documented that 
N-terminal of Nav1.8 binds to light chain (p11) of the cytoskeletal binding protein 
annexin II (Figure 1.5) and expression of p11 in stably transfected CHO cells 
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promotes trafficking of Nav1.8 to plasma membrane  (Okuse et al., 2002). In 
addition, it was shown that Nav1.5 is coupled to dystrophin and the actin cytoskeleton 
via scaffolding protein syntropin (Ou et al., 2003). Co expression of CAM contactin 
and Nav1.9 in CHO cells was show to increase cell surface expression of Nav1.9 
(Shah et al., 2004).The membrane skeletal protein ankyrin G (AnkG) was shown to be 
essential for clustering of VGSC to axon initial segment (AIS) (Zhou et al., 1998). In 
addition, mutation in AnkG binding site (E1053K at ID2-3 linker, Figure 1.5) caused 
reduced and disorganised expression of Nav1.5 at the sarcolemma, intercalated discs 
and T-tubules in cardiomyocytes (Mohler et al., 2004) 
  In addition, VGSC activity was show to effect protein trafficking. For 
example, long term treatment with VGSC „opener‟ veratridine, batrachotoxin and α-
scorpion toxin (α-ScTX) was shown to decrease cell surface expression of VGSCs in 
feta rat brain (Dargent and Couraud, 1990). Furthermore, reduction in cell surface 
expression of VGSC by [125I] α-ScTX was proposed to be mediated by increased 
internalisation (Dargent et al., 1994; Paillart et al., 1996). On the other hand, 
Brackenbury and Djamgoz (2006) showed by electrophysiology and confocal 
immunocytochemistry experiments that in strongly metastatic prostate cancer (PCa) 
Mat-LyLu cells long-term TTX application reduced plasma membrane expression of 
VGSC whilst not effecting total protein level. Similarly, long-term application of 
TTX reduced plasma membrane VGSC expression while not effecting total protein 
level in strongly metastatic human breast cancer (BCa) MDA-MB-231 cells (Chioni 
et al., 2010). 
 VGSCβs were also suggested to be involved in trafficking of VGSCα (Isom, 
2002). For example, co-expression of β1 and Nav1.5 in human embryonic kidney 
(HEK) 293 cells revealed that they form complex in ER and β1 facilitate trafficking 
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of Nav1.5 to plasma membrane (Zimmer et al., 2002a). In addition, β2-knockout mice 
experiments revealed that DRG neurons have decreased VGSC expression at the 
plasma membrane (Chen et al., 2002). Therefore, it was suggested that β2 plays role 
in trafficking of VGSCs. Furthermore, mutagenesis experiments revealed that β3 
interacts and masks ER-retention signal located on Nav1.8 and increase cell surface 
expression (Zhang et al., 2008).  
 
1.2.5 Protein degradation  
An important process mediating internalization and subsequent degradation of 
VGSCs is ubiquitination (Herfst et al., 2004; Shao et al., 2009). Thus, for example, 
Nedd4 family of ubiquitin-protein ligases were found to interact with the PY motifs 
in the C-termini of VGSCαs, targeting the channel protein for degradation via 
ubiquitination (Figure 1.5) (Ingham et al., 2004). In particular, when co-expressed 
with Nav1.5 in Xenopus oocytes, Nedd4 reduced peak current density, suggesting 
removal of functional channels from the plasma membrane (Abriel et al., 2000). In 
addition, in HEK-293 cells, cell surface expression of Nav1.5 was reduced upon co-
expression with Nedd4-2, and this effect occurred faster upon co-application of the 
trans-Golgi network transport inhibitor, brefeldin A (BFA), suggesting that Nedd4-2 
accelerated VGSC internalisation (van Bemmelen et al., 2004; Rougier et al., 2005). 
Furthermore, Nedd4-2 was shown to have a similar „depressing‟ effect on functional 
expression of other VGSCαs, indicating that ubiquitination is a general mechanism 
for VGSCα internalisation and degradation. For instance, Nedd4-2 co-expression has 
been found to reduce the peak current amplitude of Nav1.2 and Nav1.3 in HEK-293 
cells (van Bemmelen et al., 2004; Rougier et al., 2005) and Nav1.2, Nav1.7 and 
Nav1.8 in Xenopus oocytes (Fotia et al., 2004).  
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1.2.6 Phosphorylation 
VGSCαs are phosphorylated by major kinases, including cAMP-dependent protein 
kinase  (PKA), protein kinase C (PKC), calcium calmodulin kinase II (CAM kinase 
II) and tyrosine kinase (Cantrell and Catterall, 2001; Carr et al., 2003; Chahine et al., 
2005). Phosphorylation by PKA can occur on five sites (serine residues) in the 
intracellular loop connecting domains 1 and 2 (Figure 1.5) (Murphy et al., 1993; 
Marban et al., 1998). PKA has VGSCα subtype-specific effects; it typically reduces 
current amplitude of TTX-S VGSCαs whilst increasing that of TTX-R channels, 
without drastically affecting voltage dependence and kinetics of VGSCα gating 
(Catterall, 2000; Zhou et al., 2000, 2002; Carr et al., 2003; Diss et al., 2004). In 
particular, PKA phosphorylation was found to reduce the current amplitude of 
Nav1.1, 1.2 and 1.7 (Li et al., 1992; Smith and Goldin 1997, 1998; Vijayaragavan et 
al., 2004), whilst the effect of Nav1.5 and 1.8 was the opposite (Marban et al., 1998; 
Zhou et al., 2000, 2002; England et al., 1996). The differential effect of PKA on 
different VGSCαs is thought to be due to the dual effect of PKA: (1) direct 
phosphorylation of serine residues in the ID1-2 linker, and (2) modulation of VGSCα 
trafficking via phosphorylation of yet unidentified modulatory proteins (e.g. Section 
1.2.3) (Chahine et al., 2005; Brackenbury and Djamgoz, 2006; Shao et al., 2009).  
VGSCαs are also phosphorylated by PKC at a conserved serine residue in the 
ID3-4 linker (located near the inactivation gate particle „IFM‟) (West et al., 1991; 
Murray et al., 1997; Chahine et al., 2005). PKC phosphorylation was found to slow 
inactivation and reduce peak current amplitude of several heterologously expressed 
VGSCαs including Nav1.2, Nav1.4, Nav1.5, Nav1.7 and Nav1.8 (Schreibmayer et 
al., 1991; Bendahhou et al., 1995; Cantrell et al., 1996; Murray et al., 1997; 
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Tateyama et al., 2003; Vijayaragavan et al., 2004). Notably, Murray et al. (1997) 
showed that mutating the ID3-4 linker serine to alanine in Nav1.5 expressed in 
Xenopus oocytes reduced but did not abolish the effect of PKC on channel function, 
suggesting that additional PKC phosphorylation site(s) may exist. Consistently, 
mutagenesis studies in Nav1.2 revealed that maximal reduction of current amplitude 
required PKC phosphorylation of multiple serine residues in the ID1-2 linker as well 
as the „classic‟ PKC site the ID3-4 linker (Cantrell et al., 2002). This was in 
agreement with the observation that PKA and PKC phosphorylation may interact, in 
a convergent manner, in modulating VGSC activity (Cantrell et al., 2002; Chahine et 
al., 2005; Chen et al., 2006). Thus, for example, in rat DRG neurons, PKC inhibitor 
peptide PKCI19-36 attenuated the PKA-induced increase in VGSC current, suggesting 
convergence of PKA and PKC effects (Gold et al., 1998). Furthermore, mutagenesis 
experiments revealed that the inhibitory effect of PKA on Nav1.2 expressed in 
Chinese hamster ovary (CHO) cells was enhanced by PKC phosphorylation of two 
serine residues in the ID1-2 and ID3-4 linkers (Li et al., 1993; Cantrell et al., 2002). 
 
1.3. Metastatic disease 
Altered expression/activity of VGSCs contributes to several pathologies, such as 
neuropathic pain, epilepsy, cardiac conduction disorders, and metastatic disease (Diss 
et al., 2004; Onkal and Djamgoz, 2009). Such pathologies can occur as a result of 
either (i) genetic mutations in the VGSC protein (e.g. long QT syndrome, epilepsy) or 
(ii) dysregulation of VGSC gene expression (e.g. chronic pain, metastatic cancer) 
(Meisler et al., 2002; Waxman, 2007). Given its central importance to this PhD 
project, involvement of VGSCs in metastatic disease is described in detail as follows. 
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Worldwide, cancer is a leading cause of death, second only to cardiovascular 
diseases. In the developed Western countries, one in every four deaths is due to 
cancer (Edwards et al., 2005; Jemal et al., 2010). The most commonly diagnosed 
forms of cancer in males and females are prostate and breast cancers, respectively, 
and these cancer types have mortality rates second only to lung cancer in both 
genders (Edwards et al., 2005; Pruthi et al., 2007; Jemal et al., 2010). Most simply, 
normal cells become cancerous and form tumours as a result of genetic mutations 
(i.e. in proto-oncogenes or tumour suppressor genes) and/or epigenetic changes (i.e. 
hypo- or hyper-methylation) occurring in their DNA, which can result in the cells 
losing the control of their proliferative state (i.e. they become hyper-proliferating and 
apoptosis resistant) (Hanahan and Weinberg, 2000). In addition, it was proposed that 
cancerous cells would not be able to acquire metastatic phenotype by only genetic 
alteration without supporting microenvironment (Chung et al., 2005). Following 
primary tumorigenesis, tumor cells with invasive (metastatic) potential spread to 
local or distant sites and, ultimately, form secondary neoplasms (i.e. metastasis). 
Overall, cancer cell genotype was described by at least 6 essential alterations in 
normal cell physiology that result in tumorigenesis and malignant spread/growth 
(Hanahan and Weinberg, 2000). These “hallmarks of cancer” include: (1) self-
sufficiency in growth signals, (2) insensitivity to growth-inhibitory (antigrowth) 
signals, (3) evasion of programmed cell death (apoptosis), (4) unlimited replicative 
potential, (5) sustained angiogenesis, and (6) tissue invasion and metastasis (Section 
1.3.2) (Hanahan and Weinberg, 2000). It is important to note that primary 
tumorigenesis (steps 1-5 above) and metastasis (step 6) are two distinct processes, 
which depend on separate sets of molecular/cellular determinants; supporting this 
phenomenon is the existence of a number of metastasis suppressor genes that 
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block/inhibit metastasis without affecting primary tumor formation (Steeg, 2003; 
Weigelt et al., 2005).  
Most therapeutic strategies against cancer include excision of the primary 
tumour usually after some initial chemotherapy. Surgery may be followed by further 
pharmaco-, radio- and/or immuno-therapy to destroy any residual cancer cells 
(Vaidya and Welch, 2007). Metastasis, which is the spreading of cancer from the 
primary neoplasm to form tumours in secondary sites, is the cause of cancer-related 
deaths in approximately 90% of cases and is usually inoperable (Stetler-Stevenson et 
al., 1993; Sporn, 1996; Pantel and Brakenhoff, 2004). The discovery of metastasis 
suppressors (Berger et al., 2004; Vaidya and Welch, 2007) has raised the possibility 
that metastatic disease may also be treatable by drugs. Accordingly, much research 
time and effort has been directed in determining the genes/proteins and signalling 
pathways that regulate the metastatic behaviour of cancer cells (Schwirzke et al., 
1999; Weigelt et al., 2005). In this regard, ion channels have emerged as promising 
novel targets (Prevarskaya et al., 2010). In particular, VGSCs, which are expressed 
and functionally expedient in a wide variety of metastatic carcinomas, have become 
an exciting new class of novel anti-metastatic drug targets (Roger et al., 2006; Onkal 
and Djamgoz, 2009). In the following, we aim to describe the evidence regarding (i) 
VGSC expression in metastatic carcinomas and (ii) functional contribution of 
VGSCs to metastatic cell behaviours (MCBs). 
 
1.3.1 The case of prostate cancer  
Prostate cancer (PCa) is a heterogeneous and complex disease and is generally 
accepted to start as a prostatic intraepithelial neoplasia (PIN) (Tennant et al., 2000; 
Maitland and Collins, 2005). PIN is characterized by cancer-related genetic and 
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phenotypic changes, but is non-invasive (initially); it can be detected by biopsy only 
(Bostwick and Qian, 2004). Typically, the subsequent metastatic adenocarcinoma 
develops within 10 years and this may be paralleled by an increased level of prostate 
specific antigen (PSA) (Bostwick and Qian, 2004).  Prostate cancer treatment 
strategies are designed according to prognostic evaluation of PCa. Mainstream 
prognostic indicators  are (i) clinical stage, (ii) prostate specific antigen (PSA) levels 
in blood, and (iii) histological stage, i.e. Gleason grade (Rosenthal and Sandler, 
2010). According to these analyses, one or a combination of the following treatment 
methods may be used: 
I. Active surveillance (watchful waiting): This method involves constant 
surveillance of progression of cancer. If risk of cancer increases then other 
treatment options can be considered. 
II. Prostatectomy: Early-stage PCa could be treated by surgically removal of all 
or part of the prostate with some surrounding tissue. 
III. Radiation therapy: In this method cancer cells are destroyed by using directed 
radiation (X-rays) or radioactive seeds (“brachytherapy”). 
IV. Chemotherapy: Use of chemical to kill or stop growing of PCa. 
V. Hormone therapy: Androgen-deprivation therapy (ADT) is the main therapy 
for PCa treatment. Huggins and Hodges (1941) showed that surgical 
castration or oestrogen injection induced PCa tumour regression. In the same 
study, androgen was shown to increase growth of prostate tumours. 
Therefore, surgical castration was used as an ADT with decreasing popularity 
with time because of irreversibility and gradual availability of 
pharmacological drugs that induce chemical castration by reducing level or 
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activity of testosterone (Schulman et al., 2010).  Chemical castration can  be 
achieved as follows: 
i. Luteinising hormone-releasing hormone (LHRH) receptor agonist: 
LHRH receptor (found in pituatary gland) induces release of 
luteinising hormone (LH) which in turn induces secretion of 
testosterone. LHRH can be downregulated by its agonist after initial 
increase in activity. Downregulation of LHRH receptor expression 
causes reduction in LH release and therefore in testosterone levels and 
androgen receptor (AR) activity. 
ii. LHRH receptor antagonist: These antagonists compete with LHRH 
binding to its receptor and reduce endogenous LHRH receptor 
activity. This reduced receptor activity results in reduction of LH and 
testosterone levels. 
iii. Antiandrogens: These drugs reduce directly androgen receptor activity 
by competing with testosterone and reducing its binding to AR. 
In addition to castration, oestrogen therapy was shown to be effective against 
PCa growth (Huggins and Hodges, 1941). Therefore, oestrogen was used for 
PCa therapy. It was first applied orally but because of its side effects such as 
gynecomastia and cardiovascular toxicity, popularity of this therapy declined 
(Rosenthal and Sandler 2010). On the other hand, recent advances in 
application techniques resulted in renewed interest in this therapy (Langley et 
al., 2010). 
ADT in combination with radiation therapy is the recommended treatment strategy 
for advanced PCa (Schulman et al., 2010). However, following ADT, because of the 
presence of some ADT-resistant cells, PCa can return as more aggressive castration-
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resistant prostate cancer (CRPC).  CRPC cells are resistant to ADT because of 
mutations, overexpression or genomic amplification of AR (Koochekpour, 2010). 
Interestingly, the androgen receptor cascade of some CRPC cells can be activated by 
subcastration level of androgens, produced by adrenal cortex and prostate cancer 
itself (Brawer, 2008). In combination with improved chemotherapy, this technique 
became popular treatment for CRPC (Rosenthal and Sandler 2010). 
 In a subset of PCa tumours, cells may undergo neuroendocrine 
differentiation, which results in (i) castration resistance, (ii) growth factor 
dependence, and (iii) an aggressive phenotype (invasive / metastatic potential) (Kim 
et al., 2002). Aggressive PCa cells metastasize mainly to bone, which is presumed to 
provide a hospitable microenvironment (e.g. growth factor and  high Ca
2+
 content) 
that favours secondary tumour formation (Keller et al., 2001; Fidler, 2002; Liao et 
al., 2006).  
 
1.3.2 The metastatic cascade 
Metastasis is a complex process involving a series of interactive  steps, in which 
primary tumour cells spread to secondary sites, where they ultimately form 
secondary tumours if provided with a favourable microenvironment with the right 
chemotactic agents and growth factors (i.e. „seed and soil hypothesis‟) (Paget, 1889; 
Fidler, 2003). Only some tumour cells have ability to metastasize and only a minority 
of these metastatic cells (~ 0.01%) survive the multi-step metastatic cascade to form 
secondary tumours in distant body part(s) (Hunter, 2004). Moreover, each step of the 
metastatic cascade can be rate-limiting and failure to complete any of the steps can 
stop the entire process (Fidler, 2003). Notably, metastasis of solid tumours is 
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different than that of blood cancers (i.e. leukaemias), which do not require all the 
essential stages of metastasis described as follows (Figure 1.6): 
1. Single cells or cell aggregates detach from primary tumour and degrade the 
basement membrane, by releasing proteolytic enzymes, and invading through 
local host stroma.  
2. Intravasation: embolization of single or aggregated tumour cells through 
endothelium into vascular and/or lymphatic systems. Thin-walled lymphatic 
channels provide the most common route for tumour-cell entry into the 
circulation, since they offer little resistance to penetration by tumour cells. 
3. Transport in circulation. After entering circulation, cells may be subject to 
immune defence and mechanical stress, and will often aggregate with other 
cancer cells or platelets, which may help their survival.  
4. The surviving tumour cells become arrested in the capillary beds of distant 
organ(s) (secondary sites) and re-attach to the endothelial cells. 
5. Extravasation and invasion into secondary sites (i.e. organ parenchyma). 
Extravasation requires the tumour cells that are attached to the endothelium to 
release certain protolytic enzymes and migrate through the basement membrane 
surrounding the blood vessel. 
6. Invading tumour cells then migrate through stroma and proliferate within the 
organ parenchyma, which results in the formation of secondary tumours 
(micro-metastases”).  
7. Angiogenesis: secondary tumor growth requires development of a new vascular 
network, which facilitates the growth by supplying O2, survival factors, etc. and 
removing waste products. This essentially completes the metastatic process. 
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Figure 1.6 The metaststic cascade 
a, Cellular transformation and primary tumorigenesis; b, extensive vascularization 
and tumor expansion; c, migration and invasion through local stroma; d, detachment 
and embolization followed by circulation and adherance to capillary endothelium of 
single or aggregated tumor cells; e, extravasation; f, secondary tumorigenesis and 
tumor expansion following angiogenesis. Adapted from Fidler (2003). 
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The tumour cells can then re-enter the circulation and produce additional 
metastases.  
In spite of this cascade appearing well-organized, in fact, metastasis is a highly 
inefficient process (Hunter, 2004). A generally held “progression” model of 
metastasis explains this insufficiency, stating that a primary tumour progress to a 
premalignant state from which cells with metastatic ability arise due to stochastic 
genetic events (Fidler and Kripke, 1977; Hunter, 2004). Discovery of at least 11 
metastasis suppressor genes, which inhibit the metastatic cascade without interfering 
primary tumourigenesis supports this model (Berger et al., 2004; Vaidya and Welch, 
2007). The finding of consistent chromosomal aberrations specifically associated 
with malignant rather than benign tumours also supports this hypothesis (Goodison et 
al., 2005). However, more recent evidence has challenged the progression model, 
suggesting that metastatic ability may be “pre-coded” in primary tumours (Bacac and 
Stamenkovic, 2008, Bernards and Weinberg, 2002). For example, gene expression of 
a subset of primary tumours was found to be similar to that of metastatic secondary 
tumours, suggesting that metastatic potential may be encoded within the primary 
tumour tissue (Ramaswamy et al., 2003). In addition, 5% of metastatic disease cases 
have no clinically detectable primary tumour, which is also in support of the “pre-
coded” model of metastasis (Hunter, 2004).  
An „integrative‟ model reconciles the two conflicting theories of metastasis 
(Hynes, 2003; Hunter, 2004; Weigelt et al., 2005). According to this model, primary 
tumours can be distinguished according to their metastatic potential, but rare 
subpopulations of variant cells, which are capable of forming metastases, are found 
within the primary tumours. The „integrative‟ model encompasses three principles, as 
follows. First and foremost, tumour cells constitute a very heterogeneous population 
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in terms of their metastatic potential (Nguyen and Massague, 2007). For example, it 
has been shown that genes/proteins associated with various steps of metastasis such 
as proliferation, angiogenesis, cohesion, motility and invasion vary among different 
regions of neoplasms (Poste and Fidler, 1980; Simone et al., 1998). Second, during 
disease progression, the pre-existing metastatic tumour acquire further genetic 
variability, which may result in additional changes in their metastatic potential 
(Fidler, 2003; Vecchi et al., 2008; Gupta et al., 2007). Third, the cross-talk between 
the variant, metastasizing cells and the homeostatic mechanisms of the surrounding 
microenvironment can also influence the biologic behaviour of the metastatic cells 
(Fidler, 2002; Hunter, 2004). For instance, O2 deprivation (hypoxia), a major tumour 
microenvironmental stress condition, has been associated with increased risk of 
metastatic dissemination in vivo (Pouyssègur et al., 2006; Bertout et al., 2008) and 
was shown to enhance invasiveness of several cancer cells in vitro (e.g. via 
upregulating expression/activity of various matrix metalloproteinase (MMPs) and 
cathepsins) (Canning et al., 2001; Burke et al., 2003; Brat et al., 2004; Ridgway et 
al., 2005). Furthermore, it has been shown that cancer cells prepare a “fertile ground” 
for their arrival in the secondary sites (Kaplan et al., 2005, Vaidya and Welch, 2007). 
Thus, melanoma cells were found to release soluble factors that stimulated lung 
fibroblasts to secrete fibronectin, thereby creating an attachment site for the arrival of 
vascular endothelial growth factor receptor (VEGFR) positive hematopoietic 
progenitor cells (Kaplan et al., 2005). These progenitor cells then secreted 
metalloproteinases that attracted chemokine receptor 4 (CXCR4) positive tumour 
cells (Kaplan et al., 2005).  
Collectively, the observations summarised above  support the view that new 
therapies and prognostic markers of metastasis should be targeted against not only 
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the metastatic cancer cells but also the surrounding microenvironmetal (host) factors 
that interact with metastasizing tumour cells, promoting different stages of metastasis 
(Fidler, 2002).  A better understanding of the metastasis as a multi-step process, with 
respect to such host homeostatic factors, could lead to identification of more 
effective diagnostic and/or therapeutic anti-metastasis targets. Clearly, therefore, an 
important task would be to identify novel genes/proteins involved in the mediation of 
the metastatic cascade. One promising target in this regard is the VGSC (Onkal and 
Djamgoz, 2009). 
 
1.3.3 VGSC expression in metastatic disease 
1.3.3.1 In vitro 
Functional VGSC expression has been shown to be up-regulated significantly in 
metastatic cancers of various epithelial origins (i.e. breast, prostate) both in vitro and 
in vivo, and correlated with the potentiation of a number of metastatic cell behaviours 
(MCBs) in vitro (e.g. invasion, adhesion, etc.) (Table 1.5; Roger et al., 2006; 
Brackenbury et al., 2008; Onkal and Djamgoz, 2009). Functional VGSC expression 
in metastatic cancer cells was initially detected in the Dunning rat model of PCa, 
whereby strongly metastatic Mat-LyLu cells expressed TTX-S Na
+
 currents, whereas 
the weakly metastatic AT-2 cells did not (Grimes et al., 1995). Similarly, strongly 
metastatic human PCa cell line, PC-3, expressed functional VGSCs whereas there 
was no/little expression of VGSCs in weakly metastatic LNCaP cells (Laniado et al., 
1997). Furthermore, TTX-R VGSCs were found in the strongly metastatic MDA-
MB-231 human breast cancer (BCa) cells, but not in the weakly metastatic MCF-7 
cells (Fraser et al., 2005). To date, VGSC expression has also been evidenced in 
several other carcinomas in vitro and, in some cases, in vivo, including, melanoma  
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Table 1.5 Expression/activity of VGSCs in metastatic cancer cells 
 
 
Cancer (cell line) Major VGSC(s)
1
 MCB(s) Reference(s) 
BCa (MDA-MB-231) 
nNav1.5 (1800x), Nav1.6, 
Nav1.7 
Transwell migration, Matrigel invasion, 
lateral motility, galvanotaxis, endocytic 
membrane activity 
Fraser et al. (2005); Roger et al. (2003); Brackenbury 
et al. (2007); Gillet et al. (2009); Chioni et al. (2010) 
PCa (PC-3M, LNCaP, Mat-LyLu) 
nNav1.7 (1100x), Nav1.2, 
Nav1.3, Nav1.6 
Process extention, galvanotaxis, lateral 
motility, endocytosis; detachment, gene 
expression, Matrigel invasion 
Fraser et al. (1999, 2003); Djamgoz et al. (2001); 
Mycielska et al. (2003, 2005); Palmer et al. (2008); 
Grimes et al. (1995); Laniado et al. (1997); Bennett et 
al. (2004); Nakajima et al. (2009) 
SCLC (H69, H209, H510) 
TTX-R
2
, Nav1.3, Nav1.5, 
Nav1.6, Nav1.9 
Endocytic membrane activity Blandino et al. (1995) ; Onganer and Djamgoz (2005)  
NSCLC (H23, H460, Calu-1) Nav1.5, Nav1.6, Nav1.7 Matrigel invasion Roger et al. (2007) 
Lymphoma (Jurkat) 
Nav1.5, Nav1.6, Nav1.7, 
Nav1.9 
Matrigel invasion Fraser et al. (2004) 
Mesothelioma (MPM)  Nav1.2, Nav1.6, Nav1.7 Lateral motility Fulgenzi et al. (2006) 
Colon cancer Nav1.5 Matrigel invasion House et al. (2010) 
Ovarian cancer (Caov-3, SKOV-3) 
Nav1.5, Nav1.2, Nav1.4, 
Nav1.7 
Matrigel invasion, Transwell migration Gao et al. (2010) 
Neuroblastoma (nB1) nNav1.5 ND Ou et al. (2005) 
Cervical cancer (JP, 085, 354)  
Nav1.2, Nav1.7 Nav1.4, 
Nav1.6  
ND Diaz et al. (2007) 
Melanoma  (C8161, C8146) ND ND Allen et al. (1997) 
Abbreviations: BCa, breast cancer, MCB, metastatic cell behaviour; ND, not determined; nNav1.5, neonatal Nav1.5; NSCLC, non-small cell lung cancer; PCa, prostate 
cancer; SCLC, small cell lung cancer; VGSC, voltage-gated sodium channel. 
1 
Pre-dominant isoforms are denoted in bold. Number in brackets indicates fold upregulation 
compared with corresponding weakly metastatic cells. 
2 
Predominant isoform unknown, but IC50 for TTX was 215 nM (Blandino et al., 1995). Modified from Onkal and 
Djamgoz (2009). 
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(Allen et al., 1997), small-cell lung cancer (SCLC) (Blandino et al., 1995; Onganer et 
al., 2005), non-small-cell lung cancer (NSCLC) (Roger et al., 2007), lymphoma 
(Fraser et al., 2004), neuroblastoma (Ou et al., 2005), cervical cancer (Diaz et al., 
2007), mesothelioma (Fulgenzi et al., 2006), ovarian cancer (Gao et al., 2010) and 
colon cancer (House et al., 2010) (Table 1.5). 
 As regards the molecular identity of the VGSCα(s) expressed in metastatic 
PCa and BCa cell-lines, the predominant subtypes were Nav1.7 and Nav1.5, 
respectively, with much lower expression of various other VGSCα subtypes, as 
detailed in Table 1.5 (Diss et al., 2001; Fraser et al., 2005; Onkal and Djamgoz, 
2009). Nav1.7 mRNA expression was ~1000-fold higher in strongly metastatic Mat-
LyLu and PC-3 cell-lines, compared with the corresponding weakly metastatic cells 
(Diss et al., 2001). Similarly, Nav1.5 expression was found to be upregulated ~1800-
fold in MDA-MB-231 cells, compared with the weakly metastatic MCF-7 cells 
(Table 1.5; Fraser et al, 2005; Chioni et al., 2009). Interestingly, in both Mat-LyLu 
and MDA-MB-231 cells, Nav1.7 and Nav1.5 were expressed primarily in their D1:S3 
„neonatal‟ splice-forms (Diss et al., 2001; Chioni et al., 2005; Fraser et al., 2005). In 
particular, there are 7 amino acid differences between „neonatal‟ and „adult‟ Nav1.5 
in D1:S3/S4 linker region of the channel protein, which enabled the generation of a 
novel „neonatal‟ Nav1.5 selective polyclonal antibody, NESOpAb that was used to 
confirm that functional „neonatal‟ Nav1.5 expression was higher in MDA-MB-231 vs. 
MCF-7 cells (Section 1.2.2; Diss et al., 2004; Chioni et al., 2005; Fraser et al., 2005). 
„Neonatal‟ Nav1.5 mRNA expression has also been detected in human neuroblastoma 
cells (Ou et al., 2005). As regards PCa, „neonatal‟ and „adult‟ D1:S3 splice variants of 
Nav1.7 differ only by two amino acids (Section 1.2.2), which would make the 
production of an antibody selective for „neonatal‟ Nav1.7 more difficult. 
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1.3.3.2 In vivo 
Consistent with in vitro evidence, „neonatal‟ Nav1.5 expression was found to be 
upregulated in metastatic BCa biopsy samples using immunohistochemistry with 
NESOpAb (Fraser et al., 2005). Real-time PCR data revealed that Nav1.7 was 
upregulated at the mRNA level in PCa biopsy samples compared with normal 
epithelium and benign hyperplasia (Diss et al., 2005; Onkal and Djamgoz, 2009). 
Moreover, immunohistochemical staining of normal prostate and metastatic PCa 
specimens on a tissue microarray slide has shown that overall VGSC expression was 
upregulated in a subset of metastatic PCa tissues (Abdul and Hoosein, 2002). Similar 
immunohistochemical results were also obtained using SCLC biopsies (Onganer et 
al., 2005). Diss et al., (2005) performed an analysis of “receiver operator 
characteristics” of Nav1.7 mRNA expression in PCa samples concluded that Nav1.7 
has sufficient selectivity and sensitivity to be viable prognostic marker of metastatic 
PCa. More recently, (i) multiple VGSCαs (i.e. Nav1.2, 1.4, 1.6, 1.7) have been 
identified in primary cultures as well as biopsy samples of cervical cancer (Diaz et 
al., 2007), (ii) strong immunohistochemical Nav1.5 staining have been detected in 
colon cancer specimens but not in normal colon tissues (House et al., 2010), and (iii) 
Nav1.5 and Nav1.4 expression have been found by real-time PCR to be upregulated 
in cancerous vs. normal ovarian tissue; immunohistochemistry experiments also 
revealed that grade and metastasis of ovarian cancer correlated well with VGSC 
expression (Gao et al., 2010).  
 
1.3.4 Involvement of VGSCs in metastatic disease 
There is substantial evidence, obtained using various independent techniques, for 
VGSC-mediated upregulation of a range of MCBs in vitro (Table 1.5). On the main 
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part, TTX, a highly selective VGSC blocker, has been employed to show that VGSC 
activity potentiates cellular behaviours related to metastatic cascade, including 
process extension (Fraser et al., 1999), galvanotaxis (Djamgoz et al., 2001; Fraser et 
al., 2005), lateral motility (Fraser et al., 2003), Transwell migration (Roger et al., 
2003; Fraser et al., 2005), detachment (Palmer et al., 2008; Chioni et al., 2009), gene 
expression (Mycielska et al., 2005; House et al., 2010), secretory membrane activity 
(Mycielska et al., 2003), and Matrigel invasion (Grimes et al., 1995; Laniado et al., 
1997; Bennett et al., 2004; Fraser et al., 2005; Brackenbury and Djamgoz, 2006, 
2007; Brackenbury et al., 2007; Gillet et al., 2009; Chioni et al., 2010; House et al., 
2010). 
 Changes in cell morphology is important in terms of migratory activities of 
cancer cells and TTX has been shown to reduce cellular process extension of strongly 
metastatic Mat-LyLu, but not weakly metastatic AT-2 rat PCa cell line, which do not 
express functional VGSCs (Fraser et al., 1999). Such effect of VGSCs on cell 
morphology has also been described in neurons (e.g. Wilkemeyer and Angelides 
1996). VGSCs also play a role in motility of metastatic cancer cells; TTX (1 μM) 
decreased lateral motility of Mat-LyLu cells by 47% whilst aconitine (a VGSC 
„opener‟) increased motility by 15%; neither drug had any effect on motility of AT-2 
cells (Fraser et al., 2003). The directional movement of Mat-LyLu cells in direct-
current electric field („galvanotaxis‟) was also dependent on VGSC activity, since it 
was suppressed by TTX and enhanced by veratridine (another VGSC „opener‟ drug) 
(Djamgoz et al., 2001). TTX also suppressed galvanotaxis and Transwell migration of 
highly metastatic MDA-MB-231 BCa cells (Roger et al., 2003; Fraser et al., 2005; 
Brackenbury et al., 2007; Chioni et al., 2009, 2010). Possible mechanisms of in vitro 
involvement of VGSC activity in motility of metastatic cancer cells can be explained 
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as follows: 1) Intracellular enzymes implicated in cellular motility, such as protein 
kinase C (PKC) (Glauthier et al., 2003) and/or protein kinase A (PKA) (Chioni et al., 
2010) may be stimulated by VGSC activity. (2) Cell-surface pH may change (acidify) 
which may promote proteolytic enzyme (e.g. cathepsin) activity, digestion of the 
tumour periphery and invasion (Gillet et al., 2009; Li et al., 2011). (3) Association 
with cytoskeletal elements, e.g. through VGSCβs which has significant structural 
homology with immunoglobulin-type cell adhesion molecule (CAM) (Brackenbury 
and Isom, 2008). (4) VGSC-mediated regulation of expression of genes involved in 
cellular motility, such as CAMs (Itoh et al., 2004; House et al., 2010). 
 Cancer cells are known to synthesize and release protolytic enzymes during 
various stages of the metastatic cascade, particularly during the process of local 
invasion (Fidler, 2002; 2003; Nguyen and Massague, 2007; Roger et al., 2007). 
Secretory membrane activities of Mat-LyLu and AT-2 cell lines were investigated by 
employing a non-cytotoxic secretory tracer, horseradish peroxidase (HRP) (Mycielska 
et al., 2003). It was shown that HRP uptake into strongly metastatic Mat-LyLu cells 
was approximately twice that of weakly metastatic AT-2 cells. Importantly, TTX 
significantly reduced uptake into Mat-LyLu cells without affecting that of AT-2 cells, 
which suggested a role for VGSCs in secretory (endocytic) membrane activities of 
metastatic cancer cells (Mycielska et al., 2003). Similar results were obtained from 
SCLC cell lines (Onganer and Djamgoz, 2005). In addition, Krasowska et al. (2004) 
showed that VGSC activity was also involved in patterning of endocytic/vesicular 
activity of rat PCa cell lines. Also, in LNCaP and PC-3 human PCa cell lines, it was 
found using immunoanalytical techniques that VGSC-blocking anticonvulsants 
carbamazepine and phenytoin inhibited secretion of PSA (Abdul and Hoosein, 2001).  
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 There is also strong evidence that VGSC activity enhances invasiveness of 
metastatic cancer cells. Originally, Grimes et al. (1995) showed that treatment of 
Mat-LyLu cells with TTX (600 nM) significantly reduced the Matrigel invasiveness 
of this cell line in vitro. The same dose of TTX had no effect on weakly metastatic 
AT-2 cells. Parallel studies on human PCa cells (highly metastatic PC-3 and lowly 
metastatic LNCaP) revealed similar results (Laniado et al., 1997; Smith et al., 1998). 
In a particularly significant study, three human PCa LNCaP cell lines with increasing 
invasive potential (/LC, C4 and C4-2) were shown to express corresponding 
increasing levels of VGSC protein (Bennett et al., 2004). Importantly, transient 
expression of Nav1.4 in these three cell lines significantly enhanced their invasive 
potential, whilst treatment with TTX reduced their invasiveness back to control 
levels. This suggested that functional VGSCs are “necessary and sufficient” to 
enhance invasive phenotype of metastatic cancer cells (Bennett et al., 2004). An 
important implication of this study was that although the predominant VGSCα 
expressed in metastatic human PCa cells is Nav1.7, over-expression of another 
VGSCα isoform (Nav1.4) was adequate to enhance invasiveness. This raised the 
question of whether the precise VGSCα subtype expressed is important to 
enhancement of MCBs or whether functional expression of any VGSC would suffice 
(Onkal and Djamgoz, 2009).  
VGSC activity was also shown to play a role in the invasive behaviour of 
highly metastatic MDA-MB-231 BCa cells (Roger et al., 2003; Fraser et al., 2005; 
Gillet et al., 2009). Both of these studies have shown that Matrigel invasion of MDA-
MB-231 cells was reduced by up to some 50% following TTX treatment. Importantly, 
„neonatal‟ Nav1.5, the predominant VGSCα in metastatic BCa cells (Fraser et al., 
2005; Chioni et al., 2005), has been shown to be primarily responsible for the VGSC-
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dependent enhancement of migration and invasion of MDA-MB-231 cells 
(Brackenbury et al., 2007; Chioni et al., 2010). Suppression of „neonatal‟ Nav1.5 
activity with (i) small interfering RNA (siRNA) or (ii) NESOpAb alsoreduced 
migration of MDA-MB-231 cells by ~40 %. Both treatments also significantly 
reduced Matrigel invasion of MDA-MB-231 cell line (Brackenbury et al., 2007). 
Consistently, the role of VGSC in cell invasiveness has also been reported for Jurkat 
cells, a human T-cell leukemia cell line (Fraser et al., 2004). In NSCLC cell lines, 
H23, H460 and Calu-1, where multiple isoforms of VGSCs are expressed 
(predominantly Nav1.5, Nav1.6 and Nav1.7), TTX reduced in vitro invasion by 40-
50% (Roger et al., 2007). This study proposed that VGSCs may play a role in the 
enhancement of metastatic processes, such as invasion, through their involvement in 
the regulation of intracellular [Na
+
] homeostasis (Roger et al., 2007). More recently, 
through TTX and siRNA experiments, VGSCs were found also to control 
invasiveness in ovarian and colon cancer cell lines in vitro (Gao et al., 2010; House et 
al., 2010).  
The cellular mechanism(s) though which VGSCs participate in the modulation 
of invasiveness remains unknown. VGSCs have been shown to be involved in 
secretory activities of cancer cells (as noted above; also Mycielska et al, 2003). Thus, 
VGSC activity may control additional substances, such as presently unidentified 
proteases, growth factors etc. The invasive properties of non-small cell lung cancer 
(NSCLC) cell lines, as well as the metastatic breast cancer cell line MDA-MB-231 
have been shown to be under control of proteolytic enzymes, such as 
metalloproteinases (MMPs) and cathepsins (Egeblad and Werb, 2002; Roger et al., 
2003; Gillet et al., 2009, 2011). Moreover, VGSC („neonatal‟ Nav1.5) activity was 
shown to result in acidification of the „perimembrane‟ pH, which in turn enhanced the 
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proteolytic activity of secreted cysteine cathepsins, thereby ultimately upregulating 
the invasiveness of MDA-MB-231 BCa cells (Gillet et al., 2009, 2011).  
It has also been suggested that VGSC activity is involved in hyper-
proliferative state of cancer cells. For example, various VGSC blockers (e.g. 
hydroxyamides and hydantoin) have been shown to inhibit PC-3 cell proliferation in a 
reversible, non-cytotoxic manner (Anderson et al., 2003). VGSC blocking drugs 
riluzole and flunarizine were found to inhibit the proliferation of LNCaP, MDA-PCA-
2B, PC-3 and DU145 PCa cell lines, whereas the VGSC „opener‟ veratridine 
increased proliferation, suggesting a role for VGSC in the hyper-proliferating state of 
cancer cells (Abdul and Hoosein, 2002). However, these drugs are not specific for 
VGSC and are known to affect other ion channels (e.g. Duprat et al., 2000; Fraser et 
al., 2000). In fact, when the highly specific VGSC blocker TTX was applied to Mat-
LyLu, PC-3 or MDA-MB-231 cells, no effect on proliferation was seen (Laniado et 
al., 1997; Fraser et al., 2000; Roger et al., 2003; Fraser et al., 2005; Chioni et al., 
2009, 2010; Nakajima et al., 2009).  
In contrast to the plethora of evidence for functional VGSC expression in 
metastatic cancer cells, the mechanism(s) responsible for the upregulation of VGSCs 
in these cells is not fully known. It has recently been shown that epidermal growth 
factor (EGF) increased VGSC current density and was partially responsible for the 
enhancement of migration in Mat-LyLu cell line (Ding et al., 2008). Serum factors 
are also known to be important in the upregulation of VGSCs in Mat-LyLu cells 
(Ding and Djamgoz, 2004). Increasing serum concentration from 0% to 5% for 24 h 
reduced VGSC current density and increased TTX sensitivity, which suggests that 
serum components may be responsible for transcriptional and/or post-translational 
modifications of VGSC expression in vitro. It has been shown that nerve growth 
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factor (NGF) upregulated the total VGSC α-subunit protein level, increased VGSC 
current density in a dose- and time- dependent manner, and produced currents with 
faster kinetics of activation (Brackenbury and Djamgoz, 2007). This study also 
showed that PKA activity was involved in NGF induced increase in VGSC current 
density, since PKA inhibitor KT5720 completely abrogated the effect of NGF on 
VGSC current enhancement (Brackenbury and Djamgoz, 2007). In addition, in the 
strongly metastatic Mat-LyLu cell line, activity dependent (auto) upregulation of 
VGSCs (Nav1.7) was described, and this shown to occur via a positive feedback 
mechanism involving PKA as a signalling intermediate (Brackenbury and Djamgoz, 
2006). A similar positive auto-regulatory loop was also reported for functional VGSC 
(„neonatal‟ Nav1.5) expression in MDA-MB-231 BCa cells (Chioni et al., 2010). 
Overall, VGSC autoregulation through positive feedback is unusual, and would 
suggest that blockage of VGSC activity in the short-term could lead to suppression of 
functional VGSC activity and expression in the long term. Clearly, this characteristic 
could contribute to VGSCs being an ideal anti-metastatic target. 
 
1.3.5 Other ion channels expressed in prostate and breast cancers 
Ion channels other than VGSCs have been shown to be involved in metastatic BCa 
and PCa. Both Mat-LyLu and AT-2 rat PCa cell lines expressed delayed-rectifier 
type voltage-gated potassium channel (VGPC) currents; however, the VGPC current 
density was significantly bigger for the weakly metastatic AT-2 cell line, in contrast 
to the higher / functional VGSC expression / activity in strongly metastatic Mat-
LyLu cells (Fraser et al., 2000; 2003). Similar results were obtained in human PCa 
cell lines; weakly metastatic LNCaP cells possessed a larger VGPC current density 
compared to the corresponding strongly metastatic PC-3 cell line (Laniado et al., 
2001). Fraser et al (2003) reported that the predominant VGPC isoform was Kv1.3, 
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alongside Kv1.4 and Kv1.6 in rat and human PCa cell lines. Consistently, in human 
BCa cells, weakly metastatic MCF-7 cells expressed much larger outward currents 
(consistent with VGPCs) as compared to small outward currents of the strongly 
metastatic MDA-MB-231 cells (Fraser et al., 2005). Combined pharmacology and 
immunocytochemistry data revealed that the primary isoform expressed in MCF-7 
cell line was Kv1.1 (Ouadid-Ahidouch et al., 2000). Importantly, Kv1 family 
specific blocker α-dendrotoxin (α-DTX) reduced proliferation of MCF-7 cells, 
suggesting a role for Kv1.1 in growth regulation in this cell-line (Ouadid-Ahidouch 
et al., 2000). Several other studies have also observed this VGPC-dependent 
upregulation of proliferation in cancer cells (Wonderlin and Strobl, 1996; Fraser et 
al., 2000; 2003). It has been proposed that VGPCs may control/promote progression 
through the cell cycle G1 checkpoint by hyperpolarizing the membrane potential, 
which, in turn, might promote Ca
2+
 release from intracellular stores, and/or Na
+
-
dependent membrane transport (Wonderlin and Strobl, 1996; Pardo et al., 2005). 
Taken together, weakly metastatic cells have higher VGPC, but lower VGSC 
expression/activity, compared to strongly metastatic PCa and BCa cells. 
Interestingly, a similar phenomenon occurs also in the case of NSCLC (Roger et al., 
2007). This implies that there may be swift down-regulation of VGPCs, concomitant 
with the upregulation of VGSCs during the progression of the metastatic disease 
(Onkal and Djamgoz, 2009). It would follow from such pairing of channel activities 
that the reduced VGPC activity may depolarize the resting membrane potential, 
which would favour VGSC activity (Onganer and Djamgoz, 2005; Fraser et al., 
2005; Prevarskaya et al., 2007). Based on these observations, a “cellular excitability” 
(CELEX) hypothesis of cancer metastasis was recently proposed (Djamgoz and 
Isbilen, 2006; Onkal and Djamgoz, 2009); this agrees favourably with the well-
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evidenced „neuronal‟ phenotype of aggressive cancer cells (Liotta and Clair, 2000; 
Hagel and Stavrou, 2007; Brackenbury et al., 2008; Onganer et al., 2005). Another 
important aspect of the pairing between VGSC-VGPC activities is that the proposed 
role of VGPCs in proliferation might be important in terms of tumourigenesis, whilst 
the VGSC activity has been shown to enhance various metastatic cell behaviours, 
including motility and invasion. This is a clear example of primary tumourigenesis 
and metastatic being driven by non-identical sets of molecular controls. 
Targeting/inhibition of VGSC expression and activity may thus present novel 
diagnostic markers and therapeutic approaches that are specifically directed at the 
metastatic disease (Sikes et al., 2003; Rogers et al., 2006; Onkal and Djamgoz, 
2009). 
Apart from VGSCs and VGPCs, Ca
2+
 channel and pump activity has also 
been implicated in metastatic behaviour of cancer cell lines such as those of prostate 
cancer, breast cancer, head and neck squamous cell carcinoma, pulmonary 
adenocarcinoma, rhabdomyoblastoma, fibrosarcoma and retinoblastoma (Wang et 
al., 2010; Liao et al., 2006; Huang et al., 2004; Zhong et al., 2010; Wu et al., 1997; 
Amuthan et al., 2002; Amuthan et al., 2001; Cook and Lockyer, 2006; Wertz and 
Dixit, 2000; Lehen‟kyi et al., 2007). Changes in intracellular Ca2+ level have been 
shown to play important role in cellular processes including fertilization (Ozil and 
Swann, 1995), cell cycle (Ding et al., 2010), apoptosis (Norberg et al., 2008), 
mitochondrial redox state (Hajnóczky et al., 1995), differential gene expression 
(Wang et al., 2010; Liao et al., 2006; Dolmetsch et al., 1998; Li et al., 1998; 
Haisenleder et al., 2001; Buonanno and Fields, 1999; Olson and Williams, 2000), 
motility / invasion (Amuthan et al., 2002; Wei et al., 2009; Huang et al., 2004; 
Komuro and Rakic, 1996), muscle contraction (Baylor and Hollingwoth, 2010), 
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pacemaker activity (Méry et al., 2005), growth cone turning / migration (Gomez et 
al., 1995; Gomez et al., 2001), axonal growth (Tang et al., 2003), development of 
neurotransmitter phenotype (Ciccolini et al., 2003), formation of nodules in plant 
root hairs (Ehrhardt et al., 1996), development of muscles (Ferrari et al., 1998), 
release of cytokines (Uhlén et al., 2000), exocytosis (Tse et al., 1993), adhesion 
(Giannone et al., 2002; Liao et al., 2006), chemotaxis (Mycielska et al., 2004), and 
synaptic plasticity (Parkash and Asotra, 2010; Berridge, 1998, 2009). 
Basal [Ca
2+
]i is tightly controlled and maintained at ≤ 100 nM (higher level / 
long periods of [Ca
2+
]i rise can be cytotoxic), while extracellular Ca
2+
 concentration 
is at mM level. The intracellular Ca
2+
 is maintained by a complex set of mechanisms 
including channels, exchangers and pumps (Parkash and Asotro, 2010; Berridge et 
al., 2003; Berridge et al., 1998). Accordingly, Ca
2+
 signals must be re mediated only 
by brief changes in [Ca
2+
]i (Parkash and Asotro, 2010; Rey et al., 2010; Clapman, 
2007; Berridge et al., 1998). These brief changes can be mediated by influx of 
extracellular Ca
2+
 and/or release of Ca
2+
 form intracellular stores (Roderck and Cook, 
2008; Clapham, 2007; Berridge et al., 2003; Berridge et al., 1998). Channels that are 
responsible for influx of Ca
2+
 can be divided into three groups: Voltage-gated, 
receptor-operated and store-operated Ca
2+
 channels (Berridge et al., 1998). Another 
significant mediator of Ca
2+
 influx is Na
+
 - Ca
2+
 exchanger (NCX) operating in 
reverse-mode. Under resting conditions, following an increase in  [Ca
2+
]i, NCX 
works by extruding one Ca
2+
 ion in exchange of three Na
+
 ions (Blaustein and 
Lederer, 1999). Importantly, it was shown that influx of Na
+
 through opening of 
VGSCs can significantly raise localized intracellular Na
+
 concentration and can 
consequently slow or reverse NCX activity and thus significantly increase the 
intracellular Ca
2+
 concentration (Sagel et al., 1991; Gosling et al., 1998) as well as 
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TRP channels (Poburka, et al., 2007; Eder et al., 2005; Rosker et al., 2004; Arnon et 
al., 2000). In addition, two channels, ryanodine receptor (RyR) and inositol-
triphosphate receptor (IP3R) have been implicated in release of Ca
2+
 from 
intracellular stores (Campbell et al., 1987; Streb et al., 1983). Furthermore, 
sarcoplasmic-endoplasmic reticulum Ca
2+
-ATPase (SERCA), plasma membrane 
Ca
2+
-ATPase (PMCA) and mitochondrial Ca
2+
 uniporter can also contribute to Ca
2+
 
signalling (Berridge et al., 2003; Berridge et al., 1998). 
Changes in expression profiles of these Ca
2+
 channels and pumps have been 
documented in various cancer types (Table 1.6) and it has been proposed that such 
changes can play an important role in carcinogenesis (Parkash and Asotor, 2010; 
Monteith et al., 2007). For example, various cation-permeant transient receptor 
potential (TRP) channel family members, including TRPC1, TRPC3, TRPC4, 
TRPV2, TRPV6 and TRPM8, were detected in PCa cells (Abeele et al., 2003a; 
Abeele et al., 2003b; Abeele et al., 2004; Fixemer et al., 2003; Schmidt et al., 2006; 
Thebault et al., 2005). Importantly, increases in TRPM8 (Tsavaler et al., 2001; 
Fuessel et al., 2003; Schimidt et al., 2006) and TRPV6 (Zhuang et al., 2002; Fixemer 
et al., 2003; Wissenbach et al., 2001; Peng et al., 2001) mRNA expression were 
documented in prostate cancer tissue samples. Interestingly, in Mat-LyLu and AT-2 
cells, voltage gated calcium channel (VGCC) activity was not present (Ding et al., 
2008). However, using Indo-1 microfluorimetry, AT-2 cells were found to have 
higher [Ca
2+
]i than Mat-LyLu cells (Ding et al., 2008). That study also found that 
raising extracellular [Ca
2+
] increased while raising extracellular [K
+
] decreased 
[Ca
2+
]i in AT-2 but had no effect on Mat-LyLu cells. It was proposed, therefore, that 
the weakly metastatic AT-2 cells possessed a voltage-independent Ca
2+
 permeation 
mechanism, which was down-regulated/absent in the strongly metastatic Mat-LyLu 
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CaV, voltage-gated Ca
2+
 channel; TRPC, transient receptor potential canonical; TRPM, 
transient receptor potential melastatin; TRPV, transient receptor potential vanilloid; 
SERCA, sarcoplasmic/endoplasmic reticulum Ca
2+
-ATPase; PMCA, plasma membrane 
Ca
2+
-ATPase; RyR, ryanodine receptor; IP3R, inositol 1,4,5-triphosphate receptor; n.d., not 
determided; ↑, increase; ↓, decrease. Modified from Parkash and Asotro, 2010. 
Table 1.6 Changes in expression of Ca
2+
 channels and pumps in cancer 
Ca
2+
 
Channel/pump 
Type of cancer 
mRNA 
level 
Protein 
level 
Reference(s) 
Voltage gated channels 
CaV1.2 Colon cancer ↑ n.d. Wang et al., 2000 
CaV1.1 Colorectal cancer ↑ n.d. Zhang et al., 1997 
CaV3.1 
Glioma ↑ n.d. Latour et al., 2004 
Colorectal cancer ↓ n.d. Toyota et al., 1999 
CaV3.3 Colon cancer ↓ n.d. Paz et al., 2003) 
TRP channels     
TRPV1 
Bladder cancer n.d. ↓ Lazzeri et al., 2005 
Glioma ↑ ↑ Contassot et al., 2004 
TRPV6 
Prostate, breast, 
ovary, thyroid and 
colon cancer 
↑ n.d. 
Fixemer et al., 2003; 
Zhuang et al., 2002 
TRPM1 Melanoma ↓ n.d. Deeds et al., 2000 
TRPM8 
Prostate, 
colorectal cancer 
↑ n.d. 
Schmidt et al., 2006 ; 
Tsavaler et al., 2001 
Pumps     
SERCA2 
Colon and lung 
cancer 
↓ n.d. Korosec et al., 2006 
Tyroid, oral, 
cancer; squamous 
cell carcinoma 
↓ ↓ 
Pacifico et al., 2003; Endo 
et al., 2004 
Colorectal cancer ↑ n.d. Chung et al., 2006 
SERCA3 Colon cancer n.d. ↓ Brouland et al., 2005 
PMCA 
Skin and lung 
cancer 
n.d. ↓ Reisner et al., 1997 
PMCA1 
Oral cancer, 
squamous cell 
carcinoma 
↓ ↓ Saito et al., 2006 
Breast cancer ↑ n.d. Lee et al., 2002 
Skin cancer ↓ n.d. Reisner et al., 1997 
PMCA2 Breast cancer ↑ n.d. Lee et al., 2005 
PMCA4 Skin cancer  ↓ n.d. Reisner et al., 1997 
Store-release channels 
RyR1 Thyoma ↓ n.d. Kusner et al., 1998 
IP3R2 
Non-small-cell 
lung cancer 
↑ n.d. Heighway et al., 1996 
IP3R3 Gastric cancer ↑ ↑ Sakakura et al., 2003 
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cells (Ding et al., 2008). On the other hand, VGCC expression was detected in 
LNCaP cell line in one study (Mariot et al., 2002; Toyota et al., 1999; Steinsapir et 
al., 1991), but not in another (Skryma et al., 1997). 
It was suggested that extracellular Ca
2+
 concentration is a possible mediator 
of PCa bone metastasis (Liao et al., 2006). Thus, Liao et al. (2006) showed that 
extracellular Ca
2+
 enhanced proliferation of skeletal metastatic PC-3 and C4-2B cells 
but not non-skeletal metastatic LNCaP human prostate cells. In addition, 
extracellular Ca
2+
 was shown to increase adhesion of PC-3 cells via the anti-
apoptotic Akt signalling pathway (Liao et al., 2006). As mentioned above, Ca
2+
 
signalling was shown to be important in MCBs of cancer cell lines, including in PCa 
(Wang et al., 2010; Monet et al., 2010; Gkika et al., 2010; Liao et al., 2006; 
Mycielska and Djamgoz, 2003; Mycielska and Djamgoz, 2004). For example, 
Mycielska and Djamgoz (2003, 2004) proposed that Ca
2+
 signalling plays important 
role in galvanotaxis and endocytosis membrane activity of Mat-LyLu cells. In 
addition, Ca
2+
 signalling was shown to regulate PCa cell motility via the 
Ca
2+
/calmodulin-dependent protein kinases II (CaM kinases II) pathway (Wang et 
al., 2010).  TRP channels were shown to be involved in MCBs of PCa cells. For 
instance, silencing of TRPV2 by siRNA reduced growth and invasion of PC-3 cells 
(Monet et al., 2010). On the other hand, TRP8M activation by PSA was reported to 
decrease motility of PC-3 cells (Gkika et al., 2010). 
 
1.3.6 Possible downstream mechanisms involved in VGSC activity-dependent 
promotion of MCBs 
The possible cellular mechanism(s) which are downstream to VGSC activity that 
lead to modulation of MCBs remains unknown. However, a number of possible 
mechanisms can be suggested, as follows: 
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I. VGSC mediated change in gene expression: House et al.  (2010) 
showed that Nav1.5, predominant VGSCα subunit functionally 
expressed in colon cancer cells, activity regulates genes 
expression including genes involved in cell migration, invasion 
and cycle control. 
II. Association with other proteins: Multiple proteins were shown to 
interact with VGSC such as ankyrin, calmodulin, VGSCβ and 
annexin and these were suggested to play role in MCBs. For 
example, VGSCβs that have homology with immunoglobulin 
CAMs can associate with cytoskeletal elements (Brackenbury and 
Isom 2008). 
III. Activating of the cAMP/PKA pathway: Blackenbury and 
Djamgoz (2006) showed that increase in intracellular Na
+
 
(including by VGSC activity) leads to increase in phosphorylated 
PKA level. In turn, the increase in PKA activity could 
phosphorylate cytoskeletal proteins that is involved in MCBs 
(Mycielska et al., 2003).  
IV. VGSC mediated change in pH: Na+ influx through activity of 
VGSC was  suggested to be capable of altering  intracellular pH 
by disrupting activity of Na
+
/H
+
 exchange (Mycielska et al., 
2003). On the other hand, Gillet et al., (2009) showed that VGSC 
activity results in perimembrane acidification and intracellular 
alkalization which leads to increased proteolytic activity of 
cathepsins and therefore increased invasiveness of MDA-MB-231 
cells. 
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V. Modulation Ca2+ signalling by VGSC activity: The influx of Na+ 
can slow or even reverse Na
+
/Ca
2+
 exchanger (NCX) activity 
which, in turn, can result in  increased intracellular Ca
2+
 ([Ca
2+
]i) 
(Poburko et al., 2007; Eder et al., 2005; Rosker et al., 2004; 
Arnon et al., 2000; Blaustein and Lederer, 1999; Matsuka and 
Hilgemann; Miura and Kimura, 1989). This increase in [Ca
2+
]i 
may activate Ca
2+
-sensitive signalling mechanisms and modulate 
MCBs (Parkash and Asotro, 2010; Monteith et al., 2007). For 
instance an increase in [Ca
2+
]i on  the anodal side was
 
suggested to 
determine the directionality
 
of galvanotaxis in metastatic cells 
(Mycielska and Djamgoz 2004). Similarly, Mycielska and 
Djamgoz (2003) proposed that an increase in [Ca
2+
]i  could lead to 
increased endocytosis and secretion by activation of protein kinase 
C and/or CaM kinase. 
 
1.4 Aims and scope of the present study 
It is clear from this Introduction that ionic mechanisms such as VGSC 
expression/activity and Ca
2+
 signalling are important in the control of MCBs in PCa. 
Therefore, it was suggested that targeting ionic mechanisms could be useful in cancer 
therapy. Importantly, Ca
2+
 signalling may be downstream to VGSC activity leading 
to potentiation of MCBs. In addition, microenvironmental factors, such as O2 level, 
were proposed to regulate VGSC expression/activity. The main aim of this study was 
to elucidate cellular / ionic mechanisms related to functional VGSC expression in 
PCa cells. A multi-faceted approach was used, including real-time PCR (to measure 
changes in mRNA expression), Western blotting (to measure total protein level), 
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immunocytochemistry and confocal microscopy (to measure sub-cellular distribution 
of proteins), live Ca
2+
 imaging (to measure changes in intracellular Ca
2+
 level), and 
in vitro lateral motility, transverse migration, and Matrigel invasion assays (to 
evaluate effects on MCBs). The specific aims were as follows: 
1. To investigate VGSC α- and β- subunit regulation by long-term hypoxia (24 
h, 2 % O2) in strongly metastatic (Mat-LyLu) and weakly metastatic (AT-2) 
rat PCa cell lines; 
2. To evaluate possible effects of clinical pharmacological blockers of VGSCs 
on (i) VGSC α expression and (ii) MCBs in Mat-LyLu cells under normoxic 
(21 % O2) and hypoxic (2 % O2) conditions; and 
3. To characterise intracellular Ca2+ signalling and its dependence on VGSC 
activity in human metastatic PCa PC3M cells. 
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Chapter 2 
 
MATERIALS AND METHODS 
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The present study employed a variety of materials and techniques. These are detailed 
in this chapter. 
  
2.1 Cell lines and culture conditions 
The following prostate cancer (PCa) cell lines were used: Dunning rat, AT-2 and 
Mat-LyLu, and human LNCaP and PC-3M. Mat-Lylu and PC-3M cells are strongly 
metastatic; AT-2 and LNCaP are weakly/non-metastatic (Isaacs et al., 1981; Chu et 
al., 2001). The Dunning cell lines at least partially reflect clinical behaviour. Mat-
LyLu cells are strongly metastatic whilst AT-2 cells are weakly metastatic cells, 
corresponding to a central issue in clinical management of PCa, i.e. which tumour 
cells would metastasise and which would not. A possible limitation of the Dunning 
(Mat-LyLu) cells is that, when injected into Copenhagen rats, they tend not to 
metastasise to bone, one of the main secondary sites of human PCa. Human PC-3M 
cells were used in order to increase the clinical relevance of the effects observed. All 
cells were seeded into 100 mm Falcon tissue culture dishes (Becton Dickinson Ltd.) 
and grown in an incubator (Sanyo, IncuSafe MCO-18AIC) at 37 
o
C, 100 % relative 
humidity and 5 % CO2. Cells were grown to confluence and serially passaged every 
24 h using fresh culture medium. In „chronic hypoxia‟ experiments, cells were grown 
in a dedicated hypoxia chamber (RSBioptech, Galaxy 14S), which maintained 2 % 
O2 by flow of nitrogen which was regulated by built-in calibrated O2 meter. In order 
to avoid passage-dependent effects on cultured cells‟ phenotype, passage numbers of 
cells were restricted to a maximum of 15. In addition, cell lines were monitored 
routinely by checking morphology and expression/activity of VGSC, as indirect 
controls for any change in phenotype. Finally, our collaborators at Istanbul 
  - 89 - 
 
University showed routinely that Mat-LyLu cells injected subcutaneously into 
Copenhagen rats induced extensive lung metastases (within about 3 weeks). 
 
2.1.1 Dunning rat PCa cell lines 
AT-2 and Mat-LyLu were derived originally from a spontaneously occurring 
prostatic tumour of a Copenhagen rat; the tumour was well-differentiated, slow 
growing and heterogeneous, i.e. composed of both androgen–dependent and 
androgen–independent tumour cells (Dunning 1963; Isaacs et al., 1981). Both AT-2 
and Mat-LyLu cells are androgen-insensitive, fast-growing and anaplastic. AT-2 
cells are associated with a low rate of metastasis (less than 1 %); Mat-LyLu cells are 
strongly metastatic (75-90 %) (Isaacs et al., 1981). The cells were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen) supplemented 
with 2 mM L-glutamine (Invitrogen), 250 nM dexamethasone (Sigma-Aldrich) and 1 
% foetal bovine serum (FBS) (Invitrogen), as described previously (e.g. Grimes et 
al., 1995). These cells lines were selected since they are well characterized, had 
markedly different metastatic ability (as mentioned above) and had significantly 
different VGSC expression/activity profiles. In particular, the strongly metastatic 
Mat-LyLu cells express a high level of functional VGSC (Grimes et al., 1995). 
Intracellular Ca
2+
 measurements were made on PC3M cells, which also express 
functional VGSCs (Laniado et al.,1997), in order to be able to relate increase the 
clinical relevance of the data. 
 
2.1.2 Human PCa cell lines 
The PC-3M cells were originally isolated from a liver metastasis produced in nude 
mice by injection of the parental human PCa PC-3 cells (Kaighn et al., 1979; 
Kozlowski et al., 1984). The LNCaP cell line was isolated originally from a lymph 
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node metastasis of a 50-year old Caucasian male PCa patient (Horoszewicz et al., 
1980). LNCaP cells are generally much less aggressive than the PC-3M cells (Chu et 
al., 2001).  Both PC-3M and LNCaP cells were maintained in RPMI 1640 medium 
(Invitrogen) supplemented with 4 mM L-glutamine (Invitrogen) and 10 % foetal 
bovine serum (FBS) (Invitrogen), as described previously (Laniado et al., 2001). 
Intracellular Ca
2+
 measurements were made on PC3M cells, which also express 
functional VGSCs (Laniado et al.,1997), in order to be able to relate increase the 
clinical relevance of the data. 
 
2.2 Pharmacology 
2.2.1 Pharmacological agents 
Pharmacological agents were prepared as stock solutions in appropriate solvents 
(Table 2.1) and stored at -20 
o
C.  Stock solutions were diluted to working 
concentration in culture medium or mammalian physiological saline (MPS) minutes 
before application. In all treatments that lasted longer than 24 h, culture medium ± 
pharmacological agents was replaced every 24 h. 
 
2.2.2 Toxicity assay 
In order to determine the possible cellular toxicicity of the pharmacological agents 
used at their working concentrations, trypan blue exclusion assay was used as 
described previously (Fraser et al., 2003). Briefly, cells were plated into 35 mm 
Falcon tissue culture dishes at a density of 3 x 10
4
/ml and allowed to settle overnight 
before treatment. Cell culture medium ± pharmacological agent was then replaced 
with 0.1 % trypan blue (Sigma-Aldrich) in normal medium. Following incubation for 
10 min at 37 
o
C, the solution was replaced with 1 ml fresh cell culture medium and 
the cells were viewed at 40x magnification under an inverted microscope (Carl   
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Drug Solvent Working concentration Supplier 
TTX Water/MPS 1 μM Alomone 
Lidocaine Water 1 – 1000 μM Sigma 
Procaine Water 1 – 1000 μM Sigma 
Ranolazine Water 20 – 300 μM Sigma 
Riluzole DMSO (30%) in water 1 – 100 μM Sigma 
Thapsigargin MPS 5  μM Sigma 
Caffeine MPS 10  mM Sigma 
Ryanodine MPS 50  μM Sigma 
 
Abbreviations: TTX (tetrodoxin), MPS (mammalian physiological saline), DMSO 
(dimethyl sulfoxide) 
 
 
 
 
 
 
Table 2.1 Summary of pharmacological agents used in the present study. 
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Zeiss). For each treatment, the percentage of dead cells was determined from 30 
randomly selected fields of view which had at least 30 cells. This procedure was 
repeated in three separated dishes. Data are presented as averages of 3x30 
measurements. 
 
2.3 Polymerase chain reaction (PCR)  
2.3.1 RNA extraction 
Total RNA was extracted from cells using TRIzol
®
 reagent (Invitrogen), according to 
the manufacturer‟s instructions. Briefly, after washing the cells with ice-cold 
phosphate buffered saline (PBS) (Invitrogen), cells were lysed by adding 1 ml of 
TRIzol
®
 reagent and homogenised by pippetting several times. Samples were mixed 
with 0.2 ml chloroform (Sigma-Aldrich) after 5 min incubation at room temperature. 
Following centrifugation (Labofuge 400R, Heraus) at 12,000 x g for 15 min at 4 
o
C, 
the top aqueous phase, which contains the RNA, was transferred to a fresh tube and 
mixed with 0.5 ml isopropyl alcohol (Sigma-Aldrich).  Samples were incubated at 
room temperature for 10 min and centrifuged at 12,000 x g for 10 min at 4 
o
C. After 
removing supernatant, precipitated RNA was washed with 1 ml of 75 % (v/v) ethanol 
(Sigma-Aldrich) and centrifuged at 7,500 x g for 5 min at 4 
o
C. Supernatant was 
removed and RNA samples were air dried for 30 min before redissolving in RNase 
and DNase free water (Invitrogen). RNA samples were treated with DNaseI 
(Amersham Biosciences) in order to remove any DNA contamination. The quantity 
of the extracted RNA was checked by spectrophotometric absorbance at 260 nm 
(NanoDrop 1000A, Thermo Scientific). The quality of the RNA was confirmed by 
the 260 : 280 nm spectrophotometric absorbance ratio, where a value of ≥ 2.0 
indicated good quality of extracted RNA (Sambrook et al., 1989). In addition, RNA 
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quality was assessed visually by agarose gel electrophoresis by observing 28S and 
18S rRNA bands ( Section 2.3.4; Figure 2.1). All RNA samples were stored at -20 
o
C 
for 1 month. 
 
2.3.2 cDNA synthesis 
One µg of RNA was used as a template for reverse-transcription into cDNA, as 
described previously (Mycielska et al., 2005). Each reaction contained 1 µg RNA, 
250 ng random hexamer mix (Amersham Biosciences), 1 µl Superscript II reverse-
transcriptase (Invitrogen), 2 µl 0.1 M DTT (Invitrogen), 4 µl Superscript II first 
strand buffer (x5) (Invitrogen), 1 µl 10 mM dNTP mix (Pharmacia Biotech), 1 µl 
(33.8 U) porcine RNA guard (Amersham Biosciences), and DNase and RNase free 
distilled water to make up final volume to 20 µl. For each sample, a control reaction 
was performed in which Superscript II reverse transcriptase was replaced with H2O 
as a control for any genomic contamination. Synthesized cDNA was stored at -20 
o
C 
after it was diluted (x5) in DNase and RNase free distilled water. 
 
2.3.3 Real-time PCR 
Real-time PCR employing SYBR I Green technology was used to study and quantify 
gene expression, as described previously (Mycielska et al., 2005). Briefly, 10 µl of 
QuantiTech SYBR Green PCR mix (Qiagene), 5 µl cDNA, 0.5 µM of both sense and 
antisense primers (Eurofin MWG) were mixed. Final volume was made up to 20 µl 
with RNase and DNase free distilled water. Amplification was performed using the 
DNA Engine Opticon 2 System (MJ Research). Reaction was started by heating at 95 
o
C for 15 minutes to activate HotStar Taq. This was followed by 3-step 40 cycles of 
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 Figure 2.1 Visual assessment of RNA quality by agarose gel electrophoresis. 
The quality of the extracted RNA was characterized by observing higher intensity of 
28S rRNA band and low intensity 18S rRNA band. 5 µl of total RNA from AT-2 cells 
(lane 1) and Mat-LyLu cells (lane 2) were run on a 0.8 % agarose gel. 
rRNA 28S 
rRNA 18S 
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95 
o
C for 30 seconds, annealing temperature depending on the primer used for 30 
seconds (Table 2.2) and 72 
o
C for 30 seconds. After each cycle, the fluorescence 
emitted by incorporation of SYBR Green to double stranded DNA was measured 
(Figure 2.2A-D). In order to verify the product composition, a melting curve was 
carried out from 65 
o
C to 95 
o
C with 0.3 
o
C steps at the end of the reaction (Figure 
2.2E-H).  For each cDNA sample, duplicate reactions were performed for both the 
target gene and the normalizing (control) gene (Cytb5R/ β-actin) simultaneously. 
Each set of reaction also included a non-template control, where the cDNA was 
replaced by DNase- and RNase-free distilled water. Standard calibration curve for 
each target gene using four serial dilutions of a cDNA template was also carried out 
(Figure 2.3). PCR product sizes were controlled by agarose gel electrophoresis (see 
Section 2.3.4).  Opticon Monitor 2 software (MJ Research) was used to determine 
the threshold amplification cycles (Cт). The 2
-ΔΔCт
 method (Livak and Schmittgen, 
2001) was used to analyze the data using following equation:  
    controlCmeanCmean TTy
 2
                            equation 2.1 
where y is the target gene mRNA level relative to control sample, and ΔCт is the 
difference in amplification threshold cycle numbers between target and normalizing 
genes. The relative target gene levels were expressed as mean ± standard error 
(SEM) from at least three separate repeats. 
 
2.3.4 Agarose gel electrophoresis 
PCR products were separated by agarose gel electrophoresis. Five µl samples were  
mixed with 1 µl of loading buffer (x6; containing bromophenol blue and glycerol) 
and loaded on 0.8 % (w/v) agarose (Sigma-Aldrich), 1 x Triz-HCl-Borate EDTA 
(TBE; Invitrogen) gel containing 5 µl of SYBRSafe
тм
 DNA gel stain (Invitrogen).  
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Target gene Primer sequence  Ta (°C) Product size (bp) Reference(s) 
rNav1.7 
Sense 
Antisense 
5‟-TGACTTGGAAGCTGGGAAAC-3‟ 
5‟-TTCCAAGGGTCACGGAGGA-3‟ 
60 414 - 
VGSCβ1 
Sense 
Antisense 
5‟-AACCACTCTGGCGACTACGA-3‟ 
5‟-TTCCGAGGCATTCTCTTGTG-3‟ 
60 258 Seda et al.  (2007) 
VGSCβ2 
Sense 
Antisense 
5‟-TGGACTTACCAGGAGTGTAGCAA-3‟ 
5‟-AGGCACCCACGATGACTG-3‟ 
60 295 Seda et al.  (2007) 
VGSCβ3 
Sense 
Antisense 
5‟-TCCTCACCTTGTGGCTGTTT-3‟ 
5‟-ACCTGGGGCACTTCCTGATA-3‟ 
60 233 Seda et al.  (2007) 
VGSCβ4 
Sense 
Antisense 
5‟-TCCTACAATAACAGCGAAACATCC-3‟ 
5‟-TCCTTCTCCTTGGGGTTCCT-3‟ 
60 215 Seda et al.  (2007) 
β-actin 
Sense 
Antisense 
5‟-TCCCTGGAGAAGAGCTACGA-3‟ 
5‟-ATCTGCTGGAAGGTGGACAG-3‟ 
60 362 Seda et al.  (2007) 
Cytb5R 
Sense 
Antisense 
5‟-ACACGCATCCCAAGTTTCCA-3‟ 
5‟-CATCTCCTCATTCACGAAGC-3‟ 
60 425 
Diss et al. (2001) 
Brackenbury et al. (2007) 
Table 2.2 PCR primer related details. 
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Figure 2.2 Real-time PCR amplification and melting curves (typical examples). 
Fluorescence from SYBER green incorporation to double stranded DNA was measured 
after each PCR cycle (A-D). PCR product composition was verified by heating from 65 
o
C 
to 95 
o
C in 0.3 
o
C steps at the end of the PCR amplification (E-H). These experiments 
carried out using x1, x10, x100 and x1000 diluted cDNA which was synthesized from RNA 
of Mat-LyLu cells grown (24 h) at control conditions. Amplified products were, Cytb5R (A 
and E), β-actin (B and F), Nav1.7 (C and G) and VGSCβ1 (D and H). 
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Figure 2.3 Standard calibration (dilution) curves to validate PCR efficiency. 
Four dilutions (x1, x10, x100, and x1000) of cDNA, synthesised from Mat-LyLu cells 
which were grown in control conditions, were amplified using PCR reaction in order 
to determine efficiency of each primer set used. Two sample ΔCт calibration curves 
are shown, where target genes are Nav1.7 (A) and VGSCβ1 (B), and normalizing 
gene is β-actin. ΔCт was calculated by subtracting threshold amplification cycle of 
normalizing gene from target gene. Data are presented as means ± SEM (n = 3) and 
were fitted using linear regression analysis (solid line).  Slopes of linear regression 
lines were statistically (non-paired t-test, p >0.05) not different from zero, indicating 
that efficiency of primers used are similar, validating the 2
-ΔΔCт
 method (Livak and 
Schmittgen, 2001). 
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Samples were visualised with an ultraviolet (UV) imager (Uvitec system, Jencons-
Pls). 
 
2.4 Western blotting 
2.4.1 Extraction of total protein 
Cells from 70-80 % confluent 35 mm Falcon tissue culture dishes were washed twice 
in ice cold PBS and lysed in ice-cold lysis buffer (Upstate Biotechnology) containing 
50 mM Tris-HCl (pH 7.4), 1 % NP-40, 0.25 % Na-deoxycholate, 150 mM NaCl, 1 
mM EDTA, 1 mM NaF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin and 
1 mM phenylmethanesulfonylfluoride (PMSF) as described previously (Laniado et 
al., 1997). Lysate was gently mixed on a rocker for 15 min at 4 
o
C. Lysates were 
centrifuged (Labofuge 400R, Heraus) at 13000 x g at 4 
o
C for 15 min and 
supernatant was transferred to a fresh tube. Protein yield was determined using a 
Bradford dye binding assay (Bio-Rad) according to manufacturer‟s instructions. 
Briefly, cell lysates were mixed with Bradford assay dye reagent and 
spectrophotometric absorbance at 595 nm was recorded (Cecil, CE 1020). Protein 
yield was calculated from standard calibration curve produced by measuring 
absorbance of serial dilutions of bovine serum albumin (BSA; Sigma-Aldrich) at 595 
nm (Figure 2.4). 
 
2.4.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting 
Unles otherwise stated, all chemicals were from Sigma-Aldrich. Equivalent amounts 
of protein from different lysates samples (50 µg) and a wide- range prestained 
molecular marker (Page Ruler protein ladder; Fermentas) were separated as 
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Figure 2.4 Protein  standard calibration curve.  
Eleven dilutions (0 to 100 µg) of BSA were used to construct standard calibration 
curve with a Bradford dye binding assay (BioRad). Spectrophotometric absorbance 
was measured at 595 nm. For each experiment, a new curve was constructed. Data 
were fitted using linear regression analysis (solid line). 
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described previously (Brackenbury and Djamgoz, 2006). Protein samples were 
mixed with LAEMMLI sample buffer incubated for 10 min at 37 
o
C and boiled for 5 
min immediately before loading. Samples were separated using a 5 % acrylamide 
stacking gel and a 7.5 % acrylamide running gel, in a buffer containing 25 mM Tris, 
192 mM glycine and 0.1 % (w/v) SDS at 100 V for 2 h and electroblotted onto 
nitrocellulose membrane (Hybond ECL, GE Healthcare) at 4 
o
C in a buffer 
containing 25 mM Tris and 192 mM glycine at 80 V for 2 h. Following the transfer, 
blots were blocked for 1 h in 5 % (w/v) non-fat dried milk (Marvel) in PBS and 30 
min in 2 % (w/v) BSA/PBS. Blots were than incubated with primary antibodies (all 
antibodies were diluted in 2 % BSA/PBS; Table 2.3) for 16 h at 4 
o
C. Blots were 
washed three times in 0.2 % (v/v) Tween-20/PBS for 15 min before incubating with 
appropriate horseradish peroxidise (HRP)-conjugated secondary antibodies (Table 
2.4) for 1 h at room temperature. Finally, blots were washed three times in 0.2 % 
(v/v) Tween-20/PBS for 15 min.  The following negative controls were used: (i) 
blots were probed with pan-VGSC that had been pre-absorbed with 5x excess 
immunizing peptide for 30 min at room temperature, and (ii) blots were incubated 
with 2 % (w/v) BSA/PBS with no primary antibody added. 
 
2.4.3 Densitometry 
Blots were developed using the ECL chemiluminescence (Amersham) and protein 
bands were visualized by exposure to Super RX100NF film (Fujifilm). Densitometric 
analysis was performed using ImageJ software (NIH) on 600 dpi scanned images. 
Anti-actinin antibody was used as loading control and the pan-VGSC signal intensity 
was normalized to anti-actinin intensity. The linearity of the  relationship between 
protein loading and signal intensity was confirmed for the pan-VGSC and the anti-
actinin antibodies using serial dilution of protein extracts (20-100 µg) (Figure 2.5). 
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Primary 
antibody 
Species 
Stock 
concentration 
Dilution 
for 
ICC 
Dilution 
for 
WB 
MW 
(kDa) 
Source Reference 
Pan-VGSC 
Rabbit 
polyclonal 
1 µg/µl 1:100 1:1000 220 Upstate 
Brackenbury et al. 
(2007) 
VGSCβ1 
Rabbit 
polyclonal 
- 1:500 - 36 L. Isom 
Malhotra et al. (2000); 
Xiao et al. (1999) 
Anti-
actinin 
Mouse 
monoclonal 
1 µg/µl - 1:1000 100 Sigma - 
Table 2.3 Primary antibodies. 
ICC: Immunocytochemistry; WB: Western blot; MW: Molecular weight; kDa: Kilo daltons 
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Secondary antibody Species 
Stock 
Concentration 
Dilution Source 
Anti-rabbit Alexa 568 (H+L) Goat 2 mg/ml 1:100 Invitrogen 
Anti-rabbit HRP Goat 13.1 µg/µl 1:10000 Sigma 
Anti-mouse HRP Goat 1 µg/µl 1:1000 DAKO 
Table 2.4 Secondary antibodies. 
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Figure 2.5 Protein dilutions and standard curves used to study Western blot 
band intensities.  
Examples of Western blotting images of pan-VGSC and anti-actinin bands for serial 
dilution of protein extracted from Mat-LyLu cells (A). Band intensity, determined 
using ImageJ software, was plotted against protein concentration and fitted by linear 
regression line (solid line) for pan-VGSC (B) and anti-actinin (C).  Data are presented 
as means ± SEM (n = 3). Linear relationship between protein level and band intensity 
within working range (50 µg) validated densitometric analysis. 
A 
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2.5 Immunocytochemistry 
Unles otherwise stated, all chemicals were from Sigma-Aldrich. Cells (5 x 10
4
) were 
plated onto 0.025 mg/ml poly-L-lysine coated glass coverslips (13 mm, BDH) in 24-
well Falcon tissue culture plates (Becton Dickinson) and allowed to settle overnight. 
After treatment samples were fixed in 4 % paraformaldehyde (PFA)/PBS for 15 min. 
Where appropriate, cells were labelled with 20 µg/100 µl fluorescein isothiocyanate 
(FITC)-conjugated concanavalin A, prepared in 5 % (w/v) BSA/PBS, for 45 min as a 
plasma membrane marker (Brackenbury and Djamgoz, 2006). Coverslips were 
washed three times with PBS for 10 min before permeabilization in 0.1 % (w/v) 
saponin/PBS for 4 min.  Following permeabilization, samples were washed three 
times with PBS for 10 min. Cells were blocked for 1 h with 5 % BSA/PBS at room 
temperature and incubated with primary antibody (Table 2.3), prepared in 5 % (w/v) 
BSA/PBS, for 1 h. Coverslips were washed three times with PBS for 10 min, and 
then incubated with Alexa-568 conjugated goat anti-rabbit secondary antibody 
(Table 2.4), prepared in 5 % (w/v) BSA/PBS, for 1 h.  Coverslips were washed three 
times in PBS and once in water. Vectashield mounting medium (Vector 
Laboratories) was used for mounting the samples. Mounted samples were stored at 4 
o
C in dark for 16 h before microscopy. The following negative controls were used: 
 
i. Primary antibody specificity: Immunocytochemistry was performed as 
above except that primary antibody was substituted with an equal amount 
of 5 % BSA/PBS. 
ii. Non-specific rabbit IgG: Immunocytochemistry was performed as above 
except that primary antibody was substituted with 0.002-0.004 µg/µl non-
specific rabbit IgG (Dako). 
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iii. Pre-absorbed primary antibody: Immunocytochemistry was performed as 
above except that the pan-VGSC primary antibody was pre-absorbed with 
5x excess of the immunizing peptide for 30 min at room temperature.  
 
2.5.1 Confocal microscopy 
Immunostained cells were examiner using a Leica SP5 MP microscope under oil 
immersion (x63 magnifications). Fluorescence was studies using a Leica Confocal 
laser scanner (Leica TCS-NT with an Ar/He laser). Antibodies conjugated with 
FITCY and/or Alexa568 were exited with the 488 nm and 568 nm laser lines, 
respectively. Images (1024 x 1024 pixels) were obtained simultaneously from the 
two channels using a Confocal pinhole of 229.96 µm. The following densitometric 
analyses were performed using the Leica LAS AF Lite software (Brackenbury and 
Djamgoz, 2006): 
a. Freeform line profile. This determined the cell-surface expression of 
protein. For this function, the cell periphery was traced using the 
concanavalin A staining as a guide. Data were presented as total staining 
in arbitrary unit (AU) per µm. Measurements were taken from randomly 
chosen cells (n ≥ 30) per condition, from at least three independent repeat 
experiments. 
b. Area histogram. This covered a 16 µm2 rectangular section of cytoplasm 
avoiding the nucleus and was used to measure the intracellular protein 
level (Brackenbury and Djamgoz, 2006; Chioni et al., 2010). Data were 
presented as total staining (AU). Measurements were taken from 
randomly chosen cells (n ≥ 30) per condition, from at least three 
independent experimental repeats. 
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c. Cross-sectional profile. For this function, a straight line was drawn 
across the cell avoiding nucleus in order to study the relative subcellular 
distribution of the protein under investigation (Okuse et al., 2002; Shah et 
al., 2004, Brackenbury and Djamgoz, 2006).  Peripheral (i.e. plasma 
membrane region) signal intensity was set to cover 1.5 µm inward from 
the edge of the concanavalin A staining. Internal (i.e. cytoplasmic) signal 
intensity was specified as the central 30 % of the line profile. Both 
peripheral and internal protein signals were normalised to total staining 
and expressed as percentages. Measurements were taken from randomly 
chosen cells (n ≥ 15) per condition, from at least three independent 
experimental repeats. 
 
2.6 Morphological analysis 
Possible morphological effects of pharmacological treatment on several cellular 
parameters were studied as described previously (Fraser et al., 1999) with some 
modifications. Briefly, cells (3 x 10
4
/ml) were plated in to 35 mm Falcon tissue 
culture dishes and allowed to settle overnight. After treatment, randomly selected 
cells were viewed under an inverted microscope (Axiovert 200, Carl Zeiss) and 
photographed under x200 magnification with a digital camera (Power-Shot G5, 
Canon). Images were quantitatively analysed using ImageJ software (NIH). The “cell 
body diameter” was defined as the diameter of the largest circle that could be fitted 
into the cell body (Figure 2.6A). An extension from a cell body which was at least 
one and half times the diameter of the cell body was accepted as a cell process. 
“Process length” was determined as the distance between tip of the process and 
centre of the cell body (Figure 2.6B). “Process thickness” was determined at the
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Figure 2.6 Micrographs of a Mat-LyLu cell illustrating morphologic parameters 
used.  
Cell body diameter (A) - diameter of the largest circle that could be fitted in to the 
cell. Process length (B) - distance between tip of the process and centre of the cell 
body. Process thickness (C) - thickness of the process at its half length; cell area (D). 
Scale bar (20 µM) applicable to all panels. 
20 µm 
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halfway point in the length of process (Figure 2.6C). Finally, the total “cell area” was 
calculated by tracing the cell outline (Figure 2.6D). 
 
2.7 Measurement of cell number - MTT assay 
Any change in cell number after long-term pharmacological treatment was assessed 
by the colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) (Alfa Aesar) assay as described previously (Grimes et al., 1995). Briefly, 
cells (4 x 10
4
) were plated in 12-well Falcon tissue culture plates (Becton Dickinson) 
allowed to settle 24 h and treatment was applied.  After the treatment period, culture 
medium was replaced with a control medium containing 1 mg/ml MTT and 
incubated at 37 
o
C for 2 h. MTT was removed and replaced with 0.89 ml DMSO and 
0.11 ml glycine buffer (0.1 M glycine and 0.1 M NaCl, pH 10.5). Following 10 min 
incubation at room temperature, absorbance at 570 nm was measured on a multi-well 
plate reader (ELx800, BioTek Instruments). The measurements were carried out in 
dark in duplicates and each treatment was repeated at least three times. 
Spectrophotometric absorbance readings were normalized to the zero-hour recording 
measured after the initial 24 h. Standard calibration curves was created in order to 
verify linear relationship between cell number and absorbance at 570 nm (Figure 
2.7). Briefly, eleven serial dilutions of cells (from 1200000 cells) were plated in to 
12-well plates, allowed to settle for 4 h and MTT assay was performed as described 
above. For every freshly prepared MTT solution, the calibration was performed three 
times.  
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Figure 2.7 Examples of typical standard curves for MTT assay. 
Relationship between cell number and absorbance at 570 nm was determined by MTT 
assay for (A) Mat-LyLu and (B) AT2 cells.  Data are presented as means ± SEM (n ≥ 
4) and were fitted using linear regression analysis (solid line).   
 
A 
B 
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2.8 Lateral motility (wound-heal) assay 
Lateral motility of the cells was assessed as described previously (Fraser et al., 
2003). Briefly, three parallel vertical lines and fifteen intersecting lines were marked 
under the 35 mm culture dishes. Cells were seeded into these dishes and incubated 
for 24 h which produced a near-monolayer culture. Then, three wounds of 0.5 - 0.8 
mm width were created, guided by the vertical lines, using a sterile 200 µl Gilson 
pipette tips. The medium was replaced with fresh medium ± pharmacological agent 
and the wounds (3 x 15) were photographed using a digital camera (Power-shot G5, 
Canon) mounted on an inverted microscope (Axiovert 200, Zeiss) at x10 
magnification. Wound widths were measured from these images using ImageJ 
software (NIH). Media (± treatment) were replaced and wounds were re-
photographed every 24 h. Each experiment was carried out in triplicate and repeated 
at least three times. Lateral motility was calculated as the motility index (MoI), 
defined as follows: 
 







0
1
W
W
MoI t                                    equation 2.2 
 
where Wt is the width of the wound at time t (24 or 48 h), while W0 is the initial 
wound width (time = 0 h). Thus, as limits, MoI = 0 corresponded to no movement of 
cells into the wound, whilst MoI = 1 represented complete closure of the wound. 
 
 
 
2.9 Transwell migration assay 
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Migration of Mat-LyLu cells were studied using Transwell migration assays. Briefly 
cells (4 x 10
5
) were plated on to Transwell migration filters (8µm pores) (Becton 
Dickinson). Cells were incubated in medium ± pharmacological agent in 0.5-5 % 
FBS chemotactic gradient for 24 h. Following the treatment, non-migrated cells were 
removed by swapping the upper surface of the Transwell filter. Migrated cells were 
stained with 0.5 % (w/v) crystal violet (Sigma-Aldrich) in 25 % methanol for 15 min 
at room temperature after fixation with 100 % ice-cold methanol for 15 min. 
Transwell filters were washed in water and let to air dry for 1 h. For each inserts 
randomly selected 3 fields of view were photographed using a digital camera 
(Power-shot G5, Canon) mounted on an inverted microscope (Axiovert 200, Zeiss) at 
10x magnification. Images were analysed using ImageJ software (NIH). Experiments 
were performed in duplicates. Average of cell counts obtained from six fields of 
view (2 duplicate x 3 fields of view) represents one repeat. Experiments were 
repeated at least 3 times and results were normalised to corresponding controls. 
 
2.10  Matrigelтм invasion assay 
Invasion of Mat-LyLu cells were studied using Matrigel
тм
 invasion assays. Briefly 
cells (4 x 10
5
) were plated on to Transwell migration filters (8µm pores) (Becton 
Dickinson) which were coated with 1.25 mg/ml Matrigel
тм
 basement membrane 
matrix (Becton Dickinson) and incubated at 37 
o
C for 30 min before cell plating as 
described previously (Zhu et al., 2009). Cells were incubated in medium ± 
pharmacological agent in 0.5-5 % FBS chemotactic gradient for 24 h. Following the 
treatment, non-invaded cells were removed by swapping the upper surface of the 
Transwell filter. Invaded cells were stained with 0.5 % (w/v) crystal violet in 25 % 
methanol for 15 min at room temperature after fixation with 100 % ice-cold 
methanol for 15 min. Transwell filters were washed in water and let to air dry for 1 h. 
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For each inserts randomly selected 3 fields of view were photographed using a digital 
camera (Power-shot G5, Canon) mounted on an inverted microscope (Axiovert 200, 
Zeiss) at 10x magnification. Images were analysed using ImageJ software (NIH). 
Experiments were performed in duplicates. Average of cell counts obtained from six 
fields of view (2 duplicate x 3 fields of view) represents one repeat. Experiments 
were repeated at least 3 times and results were normalised to corresponding controls. 
 
2.11 Intracellular calcium imaging 
Changes in the concentration of intracellular free calcium ion ([Ca
2+
]i) were 
measured using a membrane soluble fluorescent Ca
2+
-indicator dye (Fluo-4 AM; 
Invitrogen) as described previously (Lioudyno et al., 2008). Cells (5 x 10
4
) were 
plated on a glass coverslip, embedded on a 35 mm tissue culture dish (MatTek 
corporation), after coverslip was coated with 0.25 µg/ml poly-L-lysine (Sigma).  
Cells were allowed to settle for 24 h. An hour before recording, cells were washed 
three times with MPS and incubated in 4 µM Fluo-4 AM for 30 min in the dark. The 
cells were then rinsed twice and bathed in MPS for 30 min in the dark before 
imaging started. Cells were placed on a 37 
o
C heated chamber and imaged with a 
Leica SP5 confocal microscope with a x20 objective. Excitation of fluo-4 AM was 
provided by the 488 nm line of an argon laser. Images were acquired at 1 sec 
intervals. Data were analysed by Leica LAS AF Lite software. For each cell under 
investigation, mean intensity of fluorescence (F) was calculated for a sampling area 
of 9 x 9 µm
2
, located centrally in the cell. The baseline reading was subtracted and 
the change in [Ca
2+
]i was calculated as follows: 
 
 
0
0100/
F
FF
FF to

                                    equation 2.3 
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where Ft is mean intensity of fluorescence at time t, F0 is mean intensity of 
fluorescence at `baseline` level calculated by averaging mean intensity of 20-50 
consecutive images in the absence of transient and ΔF/F0 (%) is a relative measure of 
free intracellular calcium as described previously (Williams and Sims, 2007). An 
increase in fluorescence was considered to be a transient when ΔF/F0 ≥ 50 %. Cells 
were accepted as “oscillating” when at least three transients were recorded under 
control conditions within 10 min recording. 
 
2.12 Data analyses 
All quantitative data were presented as means ± standard errors of the mean (SEMs). 
Data analysis were performed using Excel 2003 (Microsoft), Origin 6.1 (Origin Lab) 
and SigmaStat 2.0 (Systat Software Inc.). Pairewise statistical significance were 
determined using paired or unpaired Student‟s t-test, or Mann-Whitney rank sum 
test, as appropriate (Krawetz, 2009). For comparisons involving more than two 
groups, statistical significance were determined using analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc analysis, or  Kruskal-Wallis analysis of 
variance as appropriate (Krawetz, 2009). Comparisons of linear regression slopes 
were performed using the following equation: 
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PP
t


                               equation 2.4 
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where P1 and P2 are parameters (slopes) being compared. Real-time PCR data were 
analyzed using the 2
-ΔΔCт
 method (Livak and Schmittgen, 2001). Results were 
considered significant at P < 0.05 (*) and highly significant at P < 0.001 (**). 
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Chapter  3 
 
EFFECTS OF CHRONIC HYPOXIA ON VOLTAGE-
GATED Na
+
 CHANNEL EXPRESSION AND 
METASTATIC CELL BEHAVIOURS OF DUNNING 
PROSTATE CANCER
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3.1  Introduction 
Hypoxia, reduced tissue oxygen level, has been detected in various human cancers, 
including cancers of prostate, breast, lung, pancreas, rectum, cervix, vulva, head and 
neck, brain, skin, liver and kidney (Vaupel et al., 2007; Harrison and Blackwell, 
2004). Accordingly, oxygen measurements from prostate tissue of patients showed 
that cancerous tissue has significantly lower O2 level (9.9 mmHg / ~1.5 % O2) 
compared to the normal muscle tissue (28.6 mmHg / ~4 % O2; Movsas et al.,2000). 
In addition, hypoxia is a natural characteristics of aging organs (Tanaka et al., 2006; 
Aalami et al., 2003). Tissue hypoxia is caused by poor/altered vascularisation, 
deterioration of diffusion geometry or anaemia (Vaupel et al., 2007). In carcinomas 
of cervix, head and neck, and soft tissue sarcomas, primary tumour hypoxia has been 
associated with increase incidence of metastases (Cairns et al., 2001). In prostate 
cancer, significant positive correlations between hypoxia level and clinical stage and 
patient age were reported (Movsas et al., 2000).  Hypoxia is considered to be a 
crucial event promoting invasion and metastasis of many human cancer cells, 
including MDA-MB-231, MDA-MB-468, MCF7 and 4T1 (breast cancer), HCT116 
and HT-29 (colon carcinoma), HepG2 (hepatoblastoma) and PANC-1 (pancreatic 
carcinoma) (Cronin et al., 2010; Lester et al., 2007; Graham et al., 1999, 
Krishnamachary et al., 2003). Although hypoxia can contribute to death of some 
tumour cells, it selects mainly for dedifferentiation, apoptosis resistance, cells with 
mutated p53 and increased metastatic capacity (Alqawi et al., 2007; Watson et al., 
2009; Salnikow et al., 2000; Ghafar et al., 2003; Butterworth et al., 2008; Harris 
2002; Graeber et al., 1996; Yu et al., 2002; Subarsky and Hill 2003). 
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 Hypoxia can regulate gene expression and regulate many signalling 
pathways, including those involving: 3`-5` adenosine monophosphate (cAMP) / 
protein kinase A (PKA), Ca
2+
-calmodulin, mitogen-activated protein kinase 
(MAPK), stress-activated protein kinase (SAPK) and phosphatidylinositol 3-kinase 
(PI3K) - Akt (Seta et al., 2002). Genome-wide DNA methylation and histone 
acetylation caused by hypoxia was documented in human prostate cancer cells 
(Watson et al., 2009). 
 As reviewed in the General Introduction (Chapter 1, Section 1.3.3), 
functional voltage-gated Na
+
 channel (VGSC) expression has been associated with 
several metastatic carcinomas (Grimes et al., 1995; Laniado et al., 1997; Grimes and 
Djamgoz, 1998; Abdul and Hoosein, 2002; Brackenbury and Djamgoz, 2006; 
Nakajima et al., 2009; Fraser et al., 2005; Roger et al., 2003; Gao et al., 2009; Fraser 
et al., 2004; Blandino et al., 1995; Onganer and Djamgoz 2005; Onganer et al., 
2005; Roger et al., 2007; Fulgenzi et al., 2006; Ou et al., 2005; Allen et al., 1997; 
Diaz et al., 2007; Gao et al., 2010; House et al., 2010). The sodium current generated 
by VGSC activity has two components: transient current (INaT) and inactivation-
resistant persistent current (INaP). Amplitude of INaP is generally 0.1 - 1 % of INaT; 
however, much greater amounts of Na
+
 can be carried by INaP since it persists for 
longer time (Saint, 2008).  It was previously reported that hypoxia increases INaP 
amplitude in neurons and cardiac cells (Hammarström and Gage 1998; Ju et al., 
1996; Wang et al., 2007). In contrast, hypoxia-induced small decrease of INaT was 
reported for neurons and myocytes (Hammarström and Gage 1998; Wang et al., 
2007). Importantly, increase in internal Na
+
 concentration was reported as a result of 
hypoxia (Haigney et al., 1994; Xiao and Allen, 1999). It was proposed that hypoxia 
could affect channel gating by formation or disruption of intermolecular disulfides 
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which causes conformational changes in VGSC protein (Hammarström and Gage 
2002). 
Therefore, in this chapter, we hypothesised that hypoxia would enhance 
MCBs of PCa cells by increasing the activity of VGSC, mainly through INaP. 
 
 
3.1.1 Aims and scope of the present study 
The main aim of this study was to investigate VGSC α- and β- subunit regulation by 
chronic hypoxia in strongly metastatic (Mat-LyLu) and weakly metastatic (AT2) rat 
prostate cancer cell lines. The specific aims were as follows: 
1. To test if hypoxia was involved in regulation of VGSC α- and β- subunit 
mRNA and protein levels; 
2. To test if hypoxia regulates metastatic cell behaviours (MCBs) - lateral 
motility, migration and invasion; and 
3. To test if possible effects of hypoxia on MCBs could involve VGSC 
expression / activity. 
 
3.2 Results 
 
3.2.1 Some initial observations: Effects of chronic hypoxia on cell morphology  
No change in the basic appearance or distribution of Mat-LyLu and AT2 cells in 
culture was observed under hypoxic (2 % O2) condition over 24 h or 48 h (Figures 
3.1A,C and  3.2A,C). Also, 24 h or 48 h treatment of Mat-LyLu and AT2 cells with 1 
µM TTX under either normoxic or hypoxic conditions did not effect the cells‟ two- 
dimensional distribution (Figures 3.1B, D and 3.2B, D).  On the other hand, the 
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Figure 3.1 Phase-contrast light-photomicrography of Mat-LyLu cells. 
Mat-LyLu cells were grown for 24 h (A & B) and 48 h (C & D) with (B & D) or 
without (A & C) 1µM TTX treatment in normoxia (left-hand pictures) or hypoxia 
(2 % O2; right-hand pictures). Micrographs are typical of 3 experiments. 
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Figure 3.2 Phase-contrast light-photomicrography of AT2 cells. 
AT2 cells were grown for 24 h (A & B) and 48 h (C & D) with (B & D) or without 
(A & C) 1µM TTX treatment in normoxia (left-hand pictures) or hypoxia (2 % O2; 
right-hand pictures). Micrographs are typical of 3 experiments. 
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number of Mat-LyLu cells in each field of view appeared less while no change was 
observed in AT2 cells when incubated under hypoxia for 48 h (Figures 3.1C, D and 
3.2C, D).  
Both Mat-LyLu and AT2 cells have extensive morphological heterogeneity. 
At the plating densities used, AT2 cells tended to form clusters, which dramatically 
reduced the number of single cells that could be used for morphological analysis 
(Figure 3.2). Therefore, morphological study of AT2 cells was not carried out. 
Morphological heterogeneity of Mat-LyLu cells were studied by subdividing cells 
into four groups: non-process bearing, monopolar, bipolar, multipolar, according to 
number of process possessed by the cells. Compared with normoxia, hypoxia did not 
change the percentage of non-process bearing cells (Figure 3.4A) both at 24 h (27.8 
± 7.3 % vs.  36.8 ± 6 %, respectively; p > 0.05; n = 3; Figures 3.3A and 3.4B; Table 
3.1) and 48 h (18.0 ± 1.0 % vs. 11.4 ± 2.5 %, respectively; p > 0.05; n = 3; Figures 
3.3C and 3.4C; Table 3.1). Treatment with 1 µM TTX  for 24 h or 48 h also had no 
effect on percentage of non-process bearing cell in normoxia (26.2 ± 2.1 % vs. 6.4 ± 
3.3 %, respectively; p > 0.05; n = 3; Figures 3.3 & 3.4B,C; Table 3.1) and hypoxia 
(30.5 ± 3.2 % vs. 16.8 ± 6.9 %, respectively; p > 0.05; n = 3; Figures 3.3 and 3.4B,C; 
Table 3.1). The percentage of monopolar cells (Figure 3.5A) also was not effected by 
24 h incubation in normoxic condition with TTX (1 µM) and hypoxic conditions 
with or without 1µM TTX (29.8 ± 5.2 %, 26.6 ± 3.3 %, 26.2 ± 3.4 % and 25.3 ± 3.2 
%, respectively; p > 0.05; n = 3; Figures 3.3A,B and 3.5B; Table 3.1). When the 
incubation period was increased to 48 h, 1 µM TTX or hypoxia again did not affect 
the proportion of monopolar cells (p > 0.05; n = 3; Figures 3.3C,D and 3.5C; Table 
3.1). However, when hypoxia and TTX (1 µM) were co-applied for 24 h, monopolar 
cells decreased significantly from 17.8 ± 3.0 % to 9.8 ± 1.3 % (p < 0.05; n = 3;  
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Figure 3.3 Phase-contrast light-photomicrography of Mat-LyLu cells in high 
magnification.  
Mat-LyLu cells were grown for 24 h (A & B) and 48 h (C & D) with (B & D) or 
without (A & C) 1µM TTX treatment in normoxia (left-hand pictures) or hypoxia 
(2 % O2; right-hand pictures). Micrographs are typical of 3 experiments. 
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Normoxia Hypoxia 
Control TTX Control TTX 
Non-process bearing cells 
24h 27.8±7.3 % 26.28±2.1 % - 36.8±6.0 % - 30.5±3.2 % - 
48h 18.0±1.0 % 6.4±3.3 % - 11.4±2.5 % - 16.8±6.9 % - 
Monopolar cells 
24h 29.8±5.2 % 26.6±3.3 % - 26.2±3.4 % - 25.3±3.27 % - 
48h 17.7±3.0 % 20.5±2.7 % - 19.6±1.6 % - 9.8±1.3 % ↓ 
Bipolar cells 
24h 37.6±5.7 % 39.0±3.3 % - 30.6±5.6 % - 39.5±6.0 % - 
48h 49.1±7.2 % 56.4±3.0 % - 47.1±4.2 % - 45.6±3.1 % - 
Multipolar cells 
24h 4.6±2.3 % 7.9±0.9 % - 6.3±3.0 % - 4.5±0.2 % - 
48h 14.9±6.3 % 16.5±3.2 % - 21.8±3.6 % - 27.6±4.0 % - 
Cell body diameter 
24h 15.0±0.2 µm 14.9±0.2 µm - 16.3±0.2 µm ↑ 15.8±0.3 µm ↑ 
48h 14.4±0.2 µm 13.7±0.3 µm - 15.7±0.3 µm ↑ 15.6±0.3 µm ↑ 
Cell area 
24h 4.8±0.1 x10
3
 µm
2
 4.8±0.1 x10
3
 µm
2
 - 5.2±0.2 x10
3
 µm
2
 - 5.3±0.2 x10
3
 µm
2
 - 
48h 5.4±0.1 x10
3
 µm
2
 6.2±0.2 x10
3
 µm
2
 ↑ 6.5±0.3 x103 µm2 ↑ 6.6±0.2 x103 µm2 ↑ 
Process thickness 
24h 5.5±0.2 µm 5.1±0.2 µm - 5.2±0.2 µm - 6.1±0.3 µm - 
48h 5.6±0.3 µm 6.3±0.3 µm - 5.6±0.3 µm - 5.8±0.3 µm - 
Process length 
24h 37.9±1.5 µm 38.8±1.4 µm - 41.9±1.7 µm - 38.3±1.3 µm - 
48h 37.8±1.1 µm 39.5±1.2 µm - 41.9±1.5 µm - 42.7±1.3 µm - 
Table 3.1 Summary of effect of hypoxia on Mat-LyLu cell morphology and morphological heterogeneity.  (↑) 
increase; (↓) decrease; (-) no change. 
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 1 vs 2 No 
1 vs 3 No 
1 vs 4 No 
2 vs 3 No 
2 vs 4 No 
3 vs 4 No 
Comparison p<0.05 
1 vs 2 No 
1 vs 3 No 
1 vs 4 No 
2 vs 3 No 
2 vs 4 No 
3 vs 4 No 
Cont TTX Cont TTX
0
10
20
30
40
50
60
HypoxiaNormoxia
n
o
n
-p
ro
c
e
s
s
 b
e
a
ri
n
g
 c
e
lls
 (
%
)
  24h
1 
2 
3 
4 
Cont TTX Cont TTX
0
10
20
30
40
50
60
HypoxiaNormoxia
n
o
n
-p
ro
c
e
s
s
 b
e
a
ri
n
g
 c
e
lls
 (
%
)
  48h
1 
2 
3 
4 
A 
Non-process 
bearing 
20 µm 
 
B 
C 
Figure 3.4 Studies effects of hypoxia on number of non-process bearing Mat-
LyLu cells. 
(A) Shows example phase-contrast light microscopy image of non-process 
bearing cells. Bar diagram show percentages of non-process bearing cells treated 
24 h (B) or 48 h (C) ± TTX (1 µM) in normoxia or hypoxia (2 % O2). Inset: table 
of multiple comparisons between treatments for statistical significance. Data are 
presented as means ± SEM and collected from ≥ 109 randomly selected 
individual cells (n = 3). Data were analysed by ANOVA followed by Newman-
Keuls post hoc analysis. 
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Figure 3.5 Studies effects of hypoxia on number of monopolar Mat-LyLu cells. 
(A) Shows example phase-contrast light microscopy image of monopolar cells. Bar 
diagram show percentages of monopolar cells treated 24 h (B) or 48 h (C) ± TTX 
(1 µM) in normoxia or hypoxia (2 % O2). Inset: table of multiple comparisons 
between treatments for statistical significance. Data are presented as means ± SEM 
and collected from ≥ 109 randomly selected individual cells (n = 3). Data were 
analysed by ANOVA followed by Newman-Keuls post hoc analysis. 
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Figures 3.3C,D and 3.5C; Table 3.1). The proportion of bipolar Mat-LyLu cells 
(Figure 3.6A) was not effected when incubated for 24 h or 48 h in normoxia with 
TTX (1 µM) or hypoxia with or without TTX (1 µM) (p > 0.05; n = 3; Figures 3.3 & 
3.6B,C; Table 3.1).  Under the same conditions, the percentage of multipolar cells 
(Figure 3.7A) remained unchanged (n = 3; Figures 3.3 and 3.7B,C; Table 3.1). 
In addition to the analysis of the morphological diversity of MatLyLu cells, 
possible effects of the treatments on cell body diameter, cell-surface area, process 
length and process thickness were studied. When Mat-LyLu cells were treated for 24 
h or 48 h with 1 µM TTX, there was no change in cell body diameter (Figure 3.8; 
Table 3.1). On the other hand, 24 h and 48 h incubation under hypoxic conditions 
increased Mat-LyLu cell body diameter from 15.0 ± 0.2 µm to 16.3 ± 0.2 µm and 
from 14.4 ± 0.2 µm to 15.7 ± 0.3 µm, respectively (p < 0.05; n ≥ 109; Figure 3.8; 
Table3.1). Similarly, 24 h and 48 h incubation of MatLyLu cells in the presence of 
TTX (1 µM) under hypoxic conditions increased cell body diameter to 15.8 ± 0.3 µm 
and 15.6 ± 0.3 µm, respectively (p < 0.05; n ≥ 114; Figure 3.8; Table 3.1).  Mat-
LyLu cell area (Figure 3.9A) did not change under both normoxic and hypoxic 
conditions with or without TTX (1 µM) over 24 h (p > 0.05; n ≥ 127; Figure 3.9; 
Table 3.1). On the other hand, incubating Mat-LyLu cells under hypoxic conditions 
for 48 h increased their surface area from 5.4 ± 0.1 x10
3
 µm
2
 to 6.5 ± 0.3 x10
3
 µm
2
 
(p < 0.05; n ≥ 109; Figure 3.9; Table 3.1). In addition, 48 h treatment with TTX in 
normoxia and hypoxia increased cell-surface area to 6.2 ± 0.2 x10
3
 and 6.6 ± 0.2 
x10
3
, respectively (p < 0.05; n ≥ 113; Figure 3.9; Table 3.1). However, cell process 
thickness (Figure 3.10A) and process length (Figure 3.11A) were not affected by 
TTX (1µM) or hypoxia with or without TTX (1 µM) treatment (p > 0.05; n ≥ 84; 
Figures 3.10 and 3.11; Table 3.1). 
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Figure 3.6 Studies effects of hypoxia on number of bipolar Mat-LyLu cells. 
(A) Shows example phase-contrast light microscopy image of bipolar cells. Bar 
diagram show percentages of bipolar cells treated 24 h (B) or 48 h (C) ± TTX (1 
µM) in normoxia or hypoxia (2 % O2). Inset: table of multiple comparisons 
between treatments for statistical significance. Data are presented as means ± SEM 
and collected from ≥109 randomly selected individual cells (n = 3). Data were 
analysed by ANOVA followed by Newman-Keuls post hoc analysis. 
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Figure 3.7 Studies effects of hypoxia on number of multipolar Mat-LyLu cells. 
(A) Shows example phase-contrast light microscopy image of multipolar cells. Bar 
diagram show percentages of multipolar cells treated 24 h (B) or 48 h (C) ± TTX (1 
µM) in normoxia or hypoxia (2 % O2). Inset: table of multiple comparisons 
between treatments for statistical significance. Data are presented as means ± SEM 
and collected from ≥109 randomly selected individual cells (n = 3). Data were 
analysed by ANOVA followed by Newman-Keuls post hoc analysis. 
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Figure 3.8 Bar diagram showing quantitative effect of hypoxia on cell body 
diameter.  
(A)Image of a Mat-LyLu cells illustrating cell body diameter measurement. 
Histogram shows quantitative measurement of cell body diameter (µm) of Mat-
LyLu cells which were treated 24h (B) or 48h (C) ± TTX (1 µM) in normoxia or 
hypoxia (2 % O2). Inset: table of multiple comparisons between treatments for 
statistical significance. Data are presented as means ± SEM (n ≥109). Data were 
analysed by ANOVA followed by Newman-Keuls post hoc analysis. 
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Figure 3.9 Bar diagram showing quantitative effect of hypoxia on cell area.  
(A)Image of a Mat-LyLu cells illustrating cell area measurement. Histogram shows 
quantitative measurement of cell area (µm
2
) of Mat-LyLu cells which were treated 
24h (B) or 48h (C) ± TTX (1 µM) in normoxia or hypoxia (2 % O2). Inset: table of 
multiple comparisons between treatments for statistical significance. Data are 
presented as means ± SEM (n ≥109). Data were analysed by ANOVA followed by 
Newman-Keuls post hoc analysis. 
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Figure 3.10 Histograms showing quantitative effect of hypoxia on process 
thickness.  
(A)Image of a Mat-LyLu cells illustrating process thickness measurement. Bar 
diagram shows quantitative measurement of process thickness (µm) of Mat-LyLu 
cells which were treated 24h (B) or 48h (C) ± TTX (1 µM) in normoxia or hypoxia 
(2 % O2). Inset: table of multiple comparisons between treatments for statistical 
significance. Data are presented as means ± SEM (n ≥84). Data were analysed by 
ANOVA followed by Newman-Keuls post hoc analysis. 
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Figure 3.11 Histograms showing quantitative effect of hypoxia on process 
length.  
(A)Image of a Mat-LyLu cells illustrating process length measurement. Bar 
diagram shows quantitative measurement of process length (µm) of Mat-LyLu cells 
which were treated 24h (B) or 48h (C) ± TTX (1 µM) in normoxia or hypoxia (2 % 
O2). Inset: table of multiple comparisons between treatments for statistical 
significance. Data are presented as means ± SEM (n ≥84). Data were analysed by 
ANOVA followed by Newman-Keuls post hoc analysis. 
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3.2.2 Effects of chronic hypoxia  
 
3.2.2.1 Cell viability 
Hypoxia was not toxic to Mat-LyLu and AT2 cells over 24 h and 48 h periods 
(Figure 3.12A&B). In addition, 24 and 48h treatment with TTX (1 µM) did not affect 
the viability of Mat-LyLu and AT2 cells under both normoxic and hypoxic 
conditions.   
 
3.2.2.2 Cellular proliferation 
Incubating Mat-LyLu cells for 24 h under hypoxic condition did not affect the cell 
number, compared with normoxia (Figure 3.13A). However, 48 and 72 h of hypoxia 
decreased number of Mat-LyLu cells significantly by 30 % and 59 %, respectively (p 
< 0.05 and p < 0.001, respectively; n = 4; Figure 3.13A). In contrast, hypoxia up to 
72 h did not affect the number of AT2 cells (p > 0.05; n = 3; Figure 3.13B).  Treating 
Mat-LyLu and AT2 cells with TTX (1 µM) up to 3 days did not affect cell numbers 
under both normoxic and hypoxic conditions (p > 0.05; n ≥ 3; Figure 3.13C, D, 
E&F). 
 
3.2.2.3 Nav1.7 mRNA expression 
Expression of Nav1.7 and VGSCβ subunit mRNAs was studied using real-time PCR 
technique. Mat-LyLu and AT2 cells were incubated for 24 h under normoxic or 
hypoxic conditions. Agarose gel electrophoresis of Mat-LyLu cells confirmed 
specific single bands at the expected sizes for Nav1.7 and β-actin (414 nt and 362 nt 
respectively; Figure 3.14A). No Nav1.7 mRNA could be detected in AT2 cells, 
grown in normoxic or hypoxic conditions (Figure 3.14B). In both cells, no-template  
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Figure 3.12 Bar diagram showing treatments had no toxic effect.  
Possible toxic effects of 24h (light grey columns) or 48h  (dark grey columns) 
treatment with or without TTX (1 µM) in normoxia or hypoxia (2 % O2) was 
studied in Mat-LyLu (A) and AT2 (B) cells. Data are represented as means ± SEM 
(n=3). Data were analysed by ANOVA followed by Newman-Keuls post hoc 
analysis. (X) p > 0.05. 
X 
X 
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Figure 3.13 Time dependent effect of hypoxia (2 % O2) on Mat-LyLu (A) 
and AT-2 (B) cell number.  
TTX (1µM) do no effect cell number of Mat-LyLu (C & E) and AT-2 (D & F) in 
both normoxia (C & D) and hypoxia (E & F).Data are presented as means ± 
SEM (n ≥ 3). Significance: (*) p < 0.05; (**) p < 0.001. 
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Figure 3.14 Effect of hypoxia (2 % O2) on Mat-LyLu and AT-2 Nav1.7 mRNA 
expression. 
 Agarose gel electrophoresis picture showing typical PCR product of Nav1.7 (414 bp) and 
normalising/control gene β-actin (362 bp) mRNA in Mat-LyLu (A) and AT2 (B) cells that 
was incubated under normoxic or hypoxic (2% O2) conditions for 24 h. Lane (1) normoxia; 
(2) hypoxia; (3) no-template control. (C) Bar diagram showing result of real-time PCR 
experiment which effect of hypoxia on Nav1.7 mRNA expression was studied. The data 
were normalized to Cytb5R (light grey column) or β-actin (dark grey column) using the 2-
ΔΔCт
 method and described as relative to normoxic mRNA expression. Inset: bar diagram 
showing that both control/normalising genes Cт values was not affected by hypoxic 
treatment. Un-paired student t-test was used for statistic analysis. Data are presented as 
means ± SEM (n  ≥ 3). Significance: (**) p < 0.001; (X) p > 0.05. 
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controls did not give any signal (Figures 3.14 A&B).  Hypoxia (24 h) significantly 
increased Nav1.7 mRNA expression by 309 ± 38.7 % (normalized to Cytb5R) / 336 
± 45.5 % (normalized to β-actin) (p < 0.001; n = 12; Figure 3.14C).  Possible 
changes in the expression levels of the normalising/control genes, Cytb5R and β-
actin (which should not be affect by treatments), were studied by plotting 
amplification threshold (Cт) values. Hypoxia did not have any significant effect on 
the Mat-LyLu normalising/control genes Cт values (p > 0.05; n = 4; Figure 3.14C 
inset). 
 
3.2.2.4 VGSCβ subunit mRNA expression 
 
3.2.2.4.1 Normoxia 
Mat-LyLu and AT2 cells were incubated 24 h under normoxic conditions, and 
VGSCβ subunit mRNA expression was assessed by real-time PCR. Agarose gel 
electrophoresis of the PCR products of Mat-LyLu cells, grown in normoxic 
conditions, confirmed a specific single bands at the expected sizes for VGSCβ1, 
VGSCβ2, VGSCβ4, β-actin and Cytb5R (258 nt, 295 nt, 215 nt, 362 nt and 362 nt 
respectively; Figure 3.15A). However, no band was detected for VGSCβ3 (233 nt). 
On the other hand, a specific single band at the expected size for VGSCβ1, VGSCβ2, 
VGSCβ3, VGSCβ4, β-actin and Cytb5R (258 nt, 295 nt, 233 nt, 215 nt, 362 nt and 
425 nt respectively) was detected for the PCR product of AT2 cells (Figure 3.15A). 
In both cells, no-template controls did not give any signal. VGSCβ1 was the 
predominant VGSCβ subunit that was expressed in both Mat-LyLu and AT2 cells. 
However, in Mat-LyLu cells, VGSCβ1 mRNA level was 30-fold and 5-fold higher 
than VGSCβ2 and VGSCβ4 mRNA levels, respectively; VGSCβ4 was ~6-fold 
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Figure 3.15 Basal mRNA expression profiles of VGSCβ subunits in Mat-LyLu 
and AT-2 cells. 
(A)Agarose gel electrophoresis pictures showing typical PCR product of VGSCβ1 
(258 bp), VGSCβ2 (295 bp), VGSCβ3 (233 bp), VGSCβ4 (215 bp) and 
normalising/control genes β-actin (362 bp) and Cytb5R (425 bp) mRNA in Mat-
LyLu and AT2 cells that was incubated under normoxic conditions for 24 h. (B) Bar 
diagram showing result of real-time PCR experiment which basal mRNA expression 
of VGSCβ subunits were studied in Mat-LyLu cells. Inset: table of multiple 
comparisons between treatments for statistical significance. (C) Bar diagram 
showing result of real-time PCR experiment which basal mRNA expression of 
VGSCβ subunits were studied in AT2 cells. Inset: table of multiple comparisons 
between treatments for statistical significance. The data were normalized to Cytb5R 
(light grey column) or β-actin (dark grey column) using the 2-ΔΔCт method and 
described as relative to VGSCβ1 mRNA expression. Data were analysed by 
ANOVA followed by Newman-Keuls post hoc analysis. Data are presented as 
means ± SEM (n ≥ 3).  
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higher than VGSCβ2 (p < 0.05; n = 6; Figure 3.15B). Again, no VGSCβ3 expression 
was detected in Mat-LyLu cells (Figure 3.15B).  In AT2 cells, the VGSCβ1 mRNA 
level was 411-fold, 384-fold and 2599-fold higher than the mRNA levels of 
VGSCβ2, VGSCβ3 and VGSCβ4, respectively (p < 0.05; n = 3; Figure 3.15C). 
VGSCβ2 and VGSCβ3 mRNA levels were same in AT2 cells while the VGSCβ4 
mRNA level was significantly less (15-fold and 14-fold, respectively; p < 0.05; n = 
3; Figure 3.15C). 
AT2 cells had 9-fold higher VGSCβ1 mRNA than Mat-LyLu cells (p < 0.05; 
n = 3; Figure 3.16A&B). VGSCβ2 mRNA levels were not different in both cell lines 
(p > 0.05; n = 3; Figure 3.16A&C). VGSCβ3 was expressed in AT2 cells but not in 
Mat-LyLu cells (p < 0.001; n = 3; Figure 3.16A&D). Mat-LyLu cells had 39-fold 
higher VGSCβ4 mRNA than AT2 cells (p < 0.05; n = 3; Figure 3.16A&E). 
Essentially identical results were obtained when β-actin was used as the 
normalizing/control gene instead of Cytb5R (Figure 3.17). 
 
3.2.2.4.2 Hypoxia 
Agarose gel electrophoresis of the real-time PCR products from Mat-LyLu cells, 
grown in normoxic and hypoxic conditions, confirmed specific single bands at the 
expected size for VGSCβ1, VGSCβ2, VGSCβ4, β-actin and Cytb5R (258 nt, 295 nt, 
215 nt, 362 nt and 425 nt, respectively; Figure 3.18A). However, no band was 
detected for VGSCβ3 (233 nt) in both conditions. No-template control experiment 
did not give any signal. When Mat-LyLu cells were incubated under hypoxic 
conditions, VGSCβ1 mRNA levels increased 1.9- and 2.1-fold when Cytb5R and β-
actin were used as the control/normalising gene, respectively (p < 0.05; n = 12; 
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Figure 3.16 Comparison of VGSCβ subunits mRNA expression, using Cytb5R 
as normalising/control gene, between Mat-LyLu and AT-2 cells. 
(A) Bar diagram showing result of real-time PCR experiment which basal mRNA 
expression of VGSCβ subunits in Mat-LyLu (light grey column) and AT2 (dark grey 
column) cells, incubated under control conditions for 24 h, were compared. 
Individual comparison of VGSCβ1 (B), VGSCβ2 (C), VGSCβ3 (D) and VGSCβ4 
(E) mRNA between Mat-LyLu and AT2 cells. The data were normalized to Cytb5R 
using the 2
-ΔΔCт
 method and described as relative to VGSCβ1 mRNA expression of 
AT2 cells. Un-paired student t-test was used for statistic analysis. Data are presented 
as means ± SEM (n ≥ 3). Significance: (*) p < 0.05; (**) p < 0.001; (X) p > 0.05. 
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Figure 3.17 Comparison of VGSCβ subunits mRNA expression, using β-actin as 
normalising/control gene, between Mat-LyLu and AT-2 cells. 
(A) Bar diagram showing result of real-time PCR experiment which basal mRNA 
expression of VGSCβ subunits in Mat-LyLu (light grey column) and AT2 (dark grey 
column) cells, incubated under control conditions for 24 h, were compared. 
Individual comparison of VGSCβ1 (B), VGSCβ2 (C), VGSCβ3 (D) and VGSCβ4 
(E) mRNA between Mat-LyLu and AT2 cells. The data were normalized to β-actin 
using the 2
-ΔΔCт
 method and described as relative to VGSCβ1 mRNA expression of 
AT2 cells. Un-paired student t-test was used for statistic analysis. Data are presented 
as means ± SEM (n ≥ 3). Significance: (*) p < 0.05; (**) p < 0.001; (X) p > 0.05. 
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Figure 3.18 Effect of hypoxia (2 % O2) on VGSCβ subunits mRNA expression 
in Mat-LyLu cells. 
(A)Agarose gel electrophoresis pictures showing typical PCR product of VGSCβ1 
(258 bp), VGSCβ2 (295 bp), VGSCβ3 (233 bp), VGSCβ4 (215 bp) and 
normalising/control genes β-actin (362 bp) and Cytb5R (425 bp) mRNA in Mat-
LyLu cells that was incubated under normoxic or hypoxic conditions for 24 h. 
Lanes (N): normoxia; (H): hypoxia; -: no template control. Bar diagram showing 
result of real-time PCR experiment which effect of hypoxia on mRNA expression 
of VGSCβ1 (B), VGSCβ2 (C), VGSCβ3 (D), VGSCβ4 (E) subunits was studied in 
Mat-LyLu cells. The data were normalized to Cytb5R (light grey column) or β-
actin (dark grey column) using the 2
-ΔΔCт
 method and described as relative to 
normoxic expression. Un-paired student t-test was used for statistic analysis. Data 
are presented as means ± SEM (n ≥ 3). Significance: (**) p < 0.05; (X) p > 0.05. 
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Figure 3.18B). No change in VGSCβ2, VGSCβ3 and VGSCβ4 mRNA expression 
was detected following the hypoxic treatment (p > 0.05; n = 6; Figures 3.18A,C&D). 
Agarose gel electrophoresis of the real-time PCR products from AT2 cells, grown in 
normoxic and hypoxic conditions, confirmed specific single bands at the expected 
sizes for VGSCβ1, VGSCβ2, VGSCβ3, VGSCβ4, β-actin and Cytb5R (258 nt, 295 
nt, 233 nt, 215 nt, 362 nt and 425 nt, respectively; Figure 3.19A). No-template 
control experiment did not give any signal. Hypoxia significantly increased VGSCβ1 
mRNA levels by 199 ± 32 % (normalised to Cytb5R) / 311 ± 32 % (normalised to β-
actin) (p < 0.05; n = 3; Figure 3.19B). VGSCβ2 mRNA levels increased by 123 ± 13 
% (normalised to Cytb5R) / 195 ± 21 % (normalised to β-actin); the latter was 
statistically significant (p < 0.05; n = 3; Figure 3.19C). The VGSCβ3 mRNA level 
was unchanged by the hypoxic treatment (p > 0.05; n = 3; Figure 3.19D). In addition, 
VGSCβ4 mRNA levels increased significantly by ~4-fold (normalised to Cytb5R) / 
6-fold (normalised to β-actin) (p < 0.05; n = 3; Figure 3.19E). Hypoxia did not have 
any effect on the Cт values of normalising/control genes, Cytb5R and β-actin, in 
Mat-LyLu cells (p > 0.05; n = 3; Figure 3.19F). 
 
3.2.2.5 Expression of VGSCα protein  
In preliminary Western blot experiments, expression of VGSC protein with a 
molecular weight of 220 kD was confirmed (Figure 3.20). However, the antibody 
proved difficult to handle in Western blots, so in the studies of hypoxia (2 % O2) on 
subcellular distribution of VGSCα protein in Mat-LyLu cells quantitative data were 
obtained by immunocytochemistry and confocal image analyses, as follows (Figures 
3.21-3.25). 
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Figure 3.19 Effect of hypoxia (2 % O2) on VGSCβ subunits mRNA expression in AT2 
cells. 
(A)Agarose gel electrophoresis pictures showing typical PCR product of VGSCβ1 (258 bp), 
VGSCβ2 (295 bp), VGSCβ3 (233 bp), VGSCβ4 (215 bp) and normalising/control genes β-
actin (362 bp) and Cytb5R (425 bp) mRNA in AT2 cells that was incubated under normoxic 
or hypoxic conditions for 24 h. Lanes (N): normoxia; (H): hypoxia; -: no template control. 
Bar diagram showing result of real-time PCR experiment which effect of hypoxia on mRNA 
expression of VGSCβ1 (B), VGSCβ2 (C), VGSCβ3 (D), VGSCβ4 (E) subunits was studied 
in AT2. The data were normalized to Cytb5R (light grey column) or β-actin (dark grey 
column) using the 2
-ΔΔCт
 method and described as relative to normoxic expression. Man-
Witney rank sum test was used for statistic analysis.(F) Histogram showing that both 
control/normalising genes Cт values was not affected by hypoxic treatment. Un-paired 
student t-test was used for statistic analysis. Data are presented as means ± SEM (n ≥ 3). 
Significance: (*) p < 0.05; (X) p > 0.05. 
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Figure 3.20 Effect of hypoxia (2 % O2) on VGSCα protein expression in Mat-
LyLu cells. 
(A) Western blot of 50 µg of total protein per lane from Mat-LyLu cells. Lanes (N): 
normoxia; (H): hypoxia; (P): pre-absorbed with immunizing peptide; (-) no primary 
antibody. Bloats were immunostained with pan-VGSCα and anti-actinin antibodies. 
(B) Histogram showing relative VGSCα protein expression in normoxic and hypoxic 
conditions.  The signal from pan-VGSC antibody was normalised to the respective 
anti-actinin signal. All data were represented as relative to normoxic VGSCα protein 
level. Un-paired student t-test was used for statistic analysis. Data are presented as means ± 
SEM (n = 4). Significance: (X) p > 0.05.  
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3.2.2.5.1 Control experiments 
VGSCα protein expression was observed in intracellular and plasma membranes but 
not in nucleus of Mat-LyLu cells under control conditions (Figures 3.21A and 3.22). 
A number of control experiments were carried out for the immunocytochemical 
staining of Mat-LyLu cells with the pan-VGSC antibody (Figure 3.21B-D). No 
staining of Mat-LyLu cells was seen with the following treatments: i) a non-specific 
IgG used at the same concentration as the primary pan-VGSC antibody antibody 
(Figure 3.21B);  ii) application of only the secondary antibody (Figure 3.21C); and 
iii) application of the pan-VGSC antibody pre-absorbed with the immunizing 
peptide, at x5 the antibody concentration (Figure 3.21D). These controls confirmed 
the specificity of the pan-VGSC antibody and the procedure used.   
 
3.2.2.5.2 Plasma membrane VGSCα protein level 
Quantification of VGSCα immunocytochemical staining in the cell periphery by 
“free form line profile” analysis of XYZ scans of Mat-LyLu cells revealed a decrease 
of plasma membrane VGSCα level, by ~15 %, from 208.7 ± 7.1 AU/µm to 176.7 ± 
7.1 AU/µm by 24 h hypoxic (2 % O2) treatment (p < 0.05; n = 105; Figure 3.23). 
 
3.2.2.5.3 Intracellular VGSCα protein level 
Quantification of VGSCα protein level by “area histogram” analysis of XYZ scans of 
Mat-LyLu cells revealed a decrease of internal VGSCα level by ~16 %  from 22978 
± 587 AU to 19173 ± 389 AU by 24 h hypoxic (2 % O2) treatment (p < 0.001; n ≥ 
77; Figure 3.24). 
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Figure 3.21 Controls for Immunocytochemistry with Mat-LyLu cells. 
Typical confocal image of Mat-LyLu cells immunostained (A) pan-VGSC primary antibody, (B) instead of Pan-VGSC primary 
antibody equal amount of non-specific IgG, (C) instead of primary antibody equal amount of 5% BSA/PBS, (D) pan-VGSC antibody 
that was pre-absorbed with the immunizing peptide.  Alexa-568 conjugated secondary antibody (red) was used in all samples. Slides 
were co-stained with FITCY conjugated Concanavalin A (Con A) plasma membrane marker (green). Scale bar (40 µm) applicable to 
all panels. 
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Figure 3.22 Confocal images from immunochemistry of Mat-LyLu cells incubated in 
normoxia and hypoxia (2 % O2) with pan-VGSC antibody.  
Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions. Signal from concanavalin A plasma membrane marker (green), pan-
VGSC antibody (red) and overlay of both (merged image) are shown in addition to bright 
field image. Scale bar (40 µm) applicable to all panels. 
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Figure 3.23 Effect of hypoxia (2 % O2) on VGSCα protein levels in plasma membrane 
of Mat-LyLu cells. 
(A) Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions. White lines indicate typical freeform line guided by Con A staining to 
measure cell surface protein level. Scale bar (5µm) applicable to all panels. (B) 
Representative trace showing signal intensity of Con A plasma membrane marker (green) 
and VGSCα  (red) immunofluorescence along plasma membrane from typical cells 
incubated (24 h) in normoxic conditions (Figure 3.23A). (C) Representative trace showing 
signal intensity of Con A plasma membrane marker and VGSCα immunofluorescence along 
plasma membrane from typical cells incubated (24 h) in hypoxic conditions (Figure 3.23A). 
Dotted gray lines indicate mean pan-VGSC fluorescence. (D) Bar diagram showing level of 
VGSCα protein immunoreactivity along plasma membrane as a immunoreactivity (AU) per 
µm. Un-paired student t-test was used for statistic analysis. Data are presented as means ± 
SEM (n = 105). Significance: (*) p < 0.05. 
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Figure 3.24 Effect of hypoxia (2 % O2) on internal VGSCα protein levels of Mat-LyLu 
cells. 
(A) Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions. White box indicates typical area covering 16 µm
2
 square section of 
cytoplasm avoiding nucleus to measure internal protein level. Scale bar (5µm) applicable to 
all panels. (B) Representative histogram showing distribution of pixels (0.0625 µm
2
) with 
signal intensity of Con A plasma membrane marker (green) and VGSCα  (red) 
immunofluorescence in cytoplasm from typical cells incubated (24 h) in normoxic 
conditions (Figure 3.24A). (C) Representative histogram showing distribution of signal 
intensity of Con A plasma membrane marker (green) and VGSCα  (red) 
immunofluorescence in cytoplasm from typicals cell incubated (24 h) in hypoxic conditions 
(Figure 3.24A). Dotted gray lines indicate mean pan-VGSC fluorescence. (D) Bar diagramt 
showing internal VGSCα protein immunoreactivity (AU). Un-paired student t-test was used 
for statistic analysis. Data are presented as means ± SEM (n ≥ 77). Significance: (**) p < 
0.001. 
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3.2.2.5.4 Subcellular distribution 
The subcellular distribution of the VGSCα protein in Mat-LyLu cells was studied by 
“straight-line cross-sectional profile” analysis. This analysis revealed that the relative 
levels of plasma membrane and intracellular VGSCα protein were not affected by 24 
h hypoxic (2 % O2) treatment (10.5 ± 0.5 % and 11.2 ± 0.5 %, respectively; p > 0.05; 
n = 61; Figure 3.25). This result was consistent with the outcome of the “free form 
line profile” and “area histogram” analyses. 
 
3.2.2.6 VGSCβ1 protein expression 
Confocal immunocytochemistry with VGSCβ1 antibody was used to test possible 
effect of hypoxia (2 % O2) on distribution of VGSCβ1 protein in Mat-LyLu cells 
(Figure 3.26-3.29). VGSCβ1 expression was observed in intracellular and plasma 
membrane but not in nucleus of Mat-LyLu cells under control conditions (Figure 
3.26). 
 
3.2.2.6.1 Plasma membrane VGSCβ1 protein level 
Quantification of VGSCβ1 protein level by “free form line profile” analysis of XYZ 
scans of Mat-LyLu cells revealed no change in plasma membrane VGSCβ1 protein 
level after 24 h hypoxia (2 % O2) treatment (245.8 ± 12.5 AU/µm and 245.5 ± 19.4 
AU/µm, respectively; p > 0.05; n = 86; Figure 3.27). 
 
3.2.2.6.2 Intracellular VGSCβ1 protein level 
Quantification of VGSCβ1 protein level by “area histogram” analysis of XYZ scans 
of Mat-LyLu cells revealed no change of internal VGSCβ1 level by 24 h hypoxic (2 
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Figure 3.25 Effect of hypoxia (2 % O2) on VGSCα protein distribution along typical 
cellular cross-section in Mat-LyLu cells. 
(A) Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions. White line indicates typical cross-section. Scale bar (5µm) applicable to 
all panels. (B) Representative trace showing signal intensity of Con A plasma membrane 
marker (green) and VGSCα immunofluorescence (red) along cross-section from typical cells 
incubated (24 h) in normoxic conditions (Figure 3.22A). (C) Representative trace showing 
signal intensity of Con A plasma membrane marker and VGSCα immunofluorescence along 
cross-section from typical cells incubated (24 h) in hypoxic conditions (Figure 3.22A). (D) 
Bar diagram showing distribution of VGSCα protein immunoreactivity along subcellular 
cross-sections as a percentage of total (%). For plasma membrane (PM) immunoreactivity, 
1.5 µm sections was measured inward from the edge of Con A staining. For internal (INT) 
immunoreactivity, middle 30 % of the cross-section was measured. Un-paired student t-test 
was used for statistic analysis. Data are presented as means ± SEM (n = 61). Significance: 
(X) p > 0.05. 
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Figure 3.26 Confocal images from immunochemistry of Mat-LyLu cells incubated in 
normoxia and hypoxia (2 % O2) with VGSCβ1 antibody.  
Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions. Signal from concanavalin A plasma membrane marker (green), 
VGSCβ1 antibody (red) and overlay of both (merged image) are shown in addition to bright 
field image. Scale bar (40 µm) applicable to all panels. 
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Figure 3.27 Effect of hypoxia (2 % O2) on VGSCβ1 protein levels in plasma membrane 
of Mat-LyLu cells. 
(A) Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions. White line indicates typical freeform line guided by Con A staining to 
measure cell surface protein level. Scale bar (5µm) applicable to all panels. (B) 
Representative trace showing signal intensity of Con A plasma membrane marker (green) 
and VGSCβ1  (red) immunofluorescence along plasma membrane from typical cells 
incubated (24 h) in normoxic conditions (Figure 3.27A). (C) Representative trace showing 
signal intensity of Con A plasma membrane marker and VGSCβ1 immunofluorescence 
along plasma membrane from typical cells incubated (24 h) in hypoxic conditions (Figure 
3.27A). Dotted gray lines indicate mean VGSCβ1 fluorescence. (D) Bar diagram showing 
level of VGSCβ1 protein immunoreactivity along plasma membrane as a immunoreactivity 
(AU) per µm. Un-paired student t-test was used for statistic analysis. Data are presented as 
means ± SEM (n = 86). Significance: (x) p > 0.05. 
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% O2) treatment (15562 ± 645 AU and 14197 ± 1203 AU, respectively; p > 0.05; n = 
92; Figure 3.28). 
 
3.2.2.6.3 Subcellular distribution 
Quantification of VGSCβ1 protein distribution by „straight line profile‟ analysis of 
XYZ scans of Mat-LyLu cells revealed that relative plasma membrane and 
intracellular VGSCβ1 distribution was not affected by 24 h hypoxic (2 % O2) 
treatment (13.5 ± 0.5 % and 14.0 ± 0.7 % respectively; p > 0.05; n = 63; Figure 
3.29). This result was consistent with the outcome of the “free form line profile” and 
“area histogram” analyses. 
 
3.2.2.7 Studies on metastatic cell behaviours 
 
3.2.2.7.1 Lateral motility 
Effect of hypoxia on lateral motility of Mat-LyLu cells was studied using wound-
heal assay. Chronic treatment (24 h) with hypoxia did not change Mat-LyLu motility 
index (MoI: 0.74 ± 0.11 and 0.75 ± 0.10, respectively; p > 0.05; n = 5; Figures 
3.30A&B). In addition, 1 µM TTX treatment did not have effect on motility of Mat-
LyLu cells under both normoxic and hypoxic conditions (MoI: 0.74 ± 0.11 and 0.68 
± 0.09, respectively; p > 0.05; n = 5; Figure 3.30A&B).  In order to control for 
consistency of wound size, initial wound width were measured and plotted in Figure 
3.30C. All wounds were 0.5 to 0.8 mm wide; there was no significant difference in 
the initial wound widths in all conditions tested (Figure 3.30C). 
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Figure 3.28 Effect of hypoxia (2 % O2) on internal VGSCβ1 protein levels of Mat-
LyLu cells. 
(A) Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions. White box indicates typical area covering 16 µm
2
 square section of 
cytoplasm avoiding nucleus to measure internal protein level. Scale bar (5µm) applicable to 
all panels. (B) Representative histogram showing distribution of pixels (0.0625 µm
2
) with 
signal intensity of Con A plasma membrane marker (green) and VGSCβ1 (red) 
immunofluorescence in cytoplasm from typical cells incubated (24 h) in normoxic 
conditions (Figure 3.28A). (C) Representative histogram showing distribution of signal 
intensity of Con A plasma membrane marker (green) and VGSCβ1 (red) 
immunofluorescence in cytoplasm from typical cells incubated (24 h) in hypoxic conditions 
(Figure 3.28A). Dotted gray lines indicate mean pan-VGSC fluorescence. (D) Chart 
showing internal VGSCβ1 protein immunoreactivity (AU). Un-paired student t-test was 
used for statistic analysis. Data are presented as means ± SEM (n = 92). Significance: (x) p 
> 0.05. 
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Figure 3.29 Effect of hypoxia (2 % O2) on VGSCβ1 protein distribution along typical cellular 
cross-section in Mat-LyLu cells. 
(A) Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and hypoxic 
conditions. White line indicates typical cross-section. Scale bar (5µm) applicable to all panels. (B) 
Representative trace showing signal intensity of Con A plasma membrane marker (green) and 
VGSCβ1 immunofluorescence (red) along cross-section from typical cells incubated (24 h) in 
normoxic conditions (Figure 3.26A). (C) Representative trace showing signal intensity of Con A 
plasma membrane marker and VGSCβ1 immunofluorescence along cross-section from typical cells 
incubated (24 h) in hypoxic conditions (Figure 3.26A). (D) Bar diagram showing distribution of 
VGSCβ1 protein immunoreactivity along subcellular cross-sections as a percentage of total (%). For 
plasma membrane (PM) immunoreactivity, 1.5 µm sections was measured inward from the edge of 
Con A staining. For internal (INT) immunoreactivity, middle 30 % of the cross-section was 
measured. Un-paired student t-test was used for statistic analysis. Data are presented as means ± SEM 
(n = 63). Significance: (X) p > 0.05. 
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Figure 3.30 Effect of hypoxia (2 % O2) on lateral motility of Mat-LyLu cells. 
(A) Typical phase-contrast light-microscopy images obtained from wound-heal assay of 
Mat-LyLu cells incubated 24 h under normoxic and hypoxic conditions ± TTX (1 µM). 
Scale bar (0.5 mm) applicable to all panels. (B) Bar diagram showing motility index of Mat-
LyLu cells, incubated in normoxia and hypoxia ± TTX (1 µM) for 24 h. (C) Bar diagram 
showing width of the wounds at 0 h of wound-heal assay. Data were analysed by analysis 
of variance followed by Newman-Keuls post hoc analysis. Data are presented as 
means ± SEM (n = 5). Significance: (x) p > 0.05. 
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3.2.2.7.2 Transwell migration 
Transwell assays were used to study the effect of hypoxia on Mat-LyLu cell 
migration. Long-term treatment (24 h) with hypoxia significantly increased 
migration by 45 % (p < 0.05; n = 9; Figures 3.31). TTX (1 µM) treatment (24 h) did 
not change number of migrated Mat-LyLu cells under normoxic conditions (p > 0.05; 
n = 9; Figures 3.31). On the other hand, TTX (1 µM) treatment significantly 
decreased migrated cell number from 145 ± 17 % to 97 ± 12 % under hypoxic 
conditions (p < 0.05; n = 9; Figures 3.31). Interestingly, there was no difference 
between the migrated cell numbers for TTX treatment under hypoxic condition and 
the control condition in normoxia (p > 0.05; n = 9; Figures 3.31). Under hypoxic 
conditions TTX reduced migrated cell numbers to normoxic control levels (p > 0.05; 
n = 9; Figures 3.31). 
 
3.2.2.7.3 Matrigel
тм
 invasion 
Matrigel
тм
 invasion assay was used to study effect of hypoxia on invasion of the 
Mat-LyLu cells. TTX (1 µM) significantly decreased invasion of Mat-LyLu cells 
under normoxic conditions to 47 ± 13 % of control (p < 0.05; n ≥ 4; Figures 3.32). 
When Mat-LyLu cells were incubated under hypoxic conditions, the number of 
invaded cells was not changed (100 % and 104 ± 18 %, respectively; p > 0.05; n = 8; 
Figures 3.32). However, invasion of Mat-LyLu cells incubated under hypoxic 
conditions significantly decreased when treated with 1 µM TTX (104 ± 18 % and 38 
± 6 % respectively; p > 0.05; n ≥ 4; Figures 3.32).   
 
 - 161 - 
 
 
 
Comparison p<0.05 
1 vs 2 No 
1 vs 3 Yes 
1 vs 4 No 
2 vs 3 Yes 
2 vs 4 No 
3 vs 4 Yes 
Control TTX 
Hypoxia 
Normoxia 
200 µm 
Figure 3.31 Effect of hypoxia (2 % O2) on migration of Mat-LyLu cells. 
(A) Typical phase-contrast light-microscopy images of migrated cells obtained from 
transwell migration assay of Mat-LyLu cells incubated 24 h under normoxic and hypoxic 
conditions ± TTX (1 µM). Migrated cells were fixed and stained with crystal violet (purple). 
Scale bar (200 µm) applicable to all panels. (B) Histogram showing number of migrated 
Mat-LyLu cells, incubated in normoxia and hypoxia ± TTX (1 µM) for 24 h. Data were 
expressed as % relative to the control and presented as means ± SEM (n = 9). Data were 
analysed by ANOVA followed by Newman-Keuls post hoc analysis. Inset: table of multiple 
comparisons between treatments for statistical significance. 
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Figure 3.32 Effect of hypoxia (2 % O2) on invasion of Mat-LyLu cells. 
(A) Typical phase-contrast light-microscopy images of invaded cells obtained from 
Matrigel
тм
 invasion assays of Mat-LyLu cells incubated 24 h under normoxic and hypoxic 
conditions ± TTX (1 µM). Invaded cells were fixed and stained with crystal violet (purple). 
Scale bar (200 µm) applicable to all panels. (B) Bar diagram showing number of invaded 
Mat-LyLu cells, incubated in normoxia and hypoxia ± TTX (1 µM) for 24 h. Data were 
expressed as % relative to the control and presented as means ± SEM (n ≥ 4). Data were 
analysed by ANOVA followed by Newman-Keuls post hoc analysis. Inset: table of multiple 
comparisons between treatments for statistical significance. 
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3.3 Discussion 
 
The main findings of this study are as follows:  (1) 24 h hypoxia or blocking VGSC 
activity with TTX (1 µM) did not affect the relative proportions of morphological 
subtypes (non-process bearing, monopolar, bipolar and multipolar) of Mat-LyLu 
cells. (2) Chronic hypoxia increased cell body diameter, whilst TTX had no effect. 
(3) Hypoxia decreased Mat-LyLu cell number when incubated for 48 - 72 h. (4) No 
effect of hypoxia was observed on proliferation of AT2 cells up to 72 h. (5) TTX had 
no effect on proliferation of both Mat-LyLu and AT2 cells. (6) Nav1.7 mRNA 
expression was increased after 24 h hypoxic treatment. (7) VGSCβ1 was the 
predominant subunit expressed in both AT2 and Mat-LyLu cells. (8) Hypoxia 
increased VGSCβ1 mRNA expression in both Mat-LyLu and AT2 cells. (9) Hypoxia 
decreased both internal and plasma membrane VGSCα protein level. (10) Hypoxia 
(24 h) had no effect on VGSCβ1 protein level. (11) Both hypoxia and TTX (1 µM) 
had no effect on lateral motility. (12) TTX (1 µM) had no effect on transverse 
migration under normoxic conditions. (13) Hypoxia increased Mat-LyLu cell 
transverse migration and TTX (1 µM) decreased it to normoxic levels. (14) Hypoxia 
had no effect on Mat-LyLu cell invasion but TTX (1 µM) decreased invasion under 
both normoxic and hypoxic conditions. 
 
3.3.1 Effect of hypoxia on morphological development 
Previously, it was reported that 72 h of hypoxia (3 % O2) caused „loosening‟ of cell 
contact and scattering from cell clusters of human hepatoblastoma, pancreatic cancer, 
colon cancer and breast cancer cells (Cannito et al., 2008). However, no obvious 
such change in two dimensional distribution of Mat-LyLu and AT2 cells was 
   
 - 164 - 
 
observed when treated with hypoxia (2 % O2) for 24 h and 48 h. In addition, TTX 
had no effect on distribution of these cells both in hypoxia and normoxia.  
Both Mat-LyLu and AT2 cells have extensive morphological heterogeneity. 
This heterogeneity was assessed by sub-dividing cells according their process 
number. No change in percentage of non-process bearing, monopolar, bipolar and 
multipolar cells was detected up to 48 h hypoxic treatment. In addition, blocking 
VGSC activity with TTX under hypoxic and normoxic conditions for 24 h had no 
effect on the morphological heterogeneity. However 48 hypoxia + TTX (1 µM) 
treatment significantly decreased percentage of monopolar cells. This was probably 
caused by the decrease in cell number with 48 h hypoxic treatment, which will be 
discussed in section 3.3.2.   
 It has been proposed that morphological change from epithelial to a spindle-
shaped and fibroblast like morphology can be correlated with aggressiveness of 
cancer (Thiery, 2002). Furthermore, hypoxic transition to fibroblast like morphology 
was observed in various cancer cells such as human hepatoblastoma, pancreatic 
cancer, colon cancer and breast cancer cells (Cannito et al., 2008; Lester et al., 
2007).  A small, but significant increase in cell body diameter of Mat-LyLu cells 
treated with 24 h and 48 h hypoxia (2 % O 2) was detected.  In addition, 48 h, but not 
24 h, hypoxia increased Mat-LyLu cell size. Process length and process thickness 
were not affected by hypoxia (24 h and 48 h). Therefore, we can speculate that Mat-
LyLu rat prostate cancer cell morphology did not change to fibroblast-like 
morphology with hypoxic treatment as was observed in other cancer cells. TTX (1 
µM) had no effect on cell morphology in both hypoxic and normoxic conditions. The 
only exception was process thickness where 24 h hypoxia + TTX treatment increased 
process thickness slightly but significantly. On the other hand, a role for VGSC in 
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morphological development was established for Mat-LyLu cells by Fraser et al. 
(1999). It was shown that blocking VGSC with 6 µM TTX decreased cell process 
length and increased cell body diameter and process thickness (Fraser et al., 1999). 
TTX (6 µM) used in Fraser et al. (1999) experiment was well above the necessary 
dose required to obtain complete blockage of Nav1.7. Therefore, we can speculate 
that morphologic effect seen by Fraser et al. (1999) can be caused by the high 
concentration of TTX used. In the same experiment, the cells were fixed by 
paraformaldehyde and stained by toluidine blue; on the other hand, in the current 
study morphological analyses were carried on images taken from live cells. 
 
3.3.2 Effect of hypoxia on proliferation  
Weakly metastatic rat prostate cancer AT2 cells were not affected by hypoxia up to 
72 h. Incubation of Mat-LyLu cells in hypoxia for 24 h did not change the cell 
number. However, 48 h and 72 h hypoxia decreased Mat-LyLu cell number 
significantly compared to normoxia. Consistently, Alqawi et al. (2007) showed that 
only 5 % of Mat-LyLu cells survive after 3 weeks of hypoxia (1 % O2).  In addition, 
a decrease in human prostate cancer cell number after 72 h hypoxia (1 % O2) was 
reported by Ackerstaff et al. (2007). Similarly, no change in tongue squamous 
carcinoma cell proliferation was observed at 24 h hypoxia but a decrease of 
proliferation was reported after 48 h and 72 h (Song et al., 2009). On the other hand, 
no significant change in human hepatoblastoma, pancreatic cancer, colon cancer and 
breast cancer cell number was reported when treated with 72 h hypoxia (3 % O2) 
(Cannito et al., 2008). In the case of human prostate cancer, PC3 cells, Ackerstaff et 
al. (2007) proposed that hypoxia mediated down regulation of genes responsible for 
formation of the “pre-replicative complex”. 
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 We then investigated the possible involvement of VGSC activity in control of 
cell number. No change in AT2 and Mat-LyLu cell numbers was measured when 
VGSC was blocked by TTX (1 µM) under both hypoxic and normoxic conditions. 
Similarly, Fraser et al. (2000) documented that VGSC had no effect on the 
proliferation of either cell line. In other cancers also, VGSC activity was found not to 
affect cellular proliferation, e.g. breast cancer (Fraser et al., 2005). Therefore, we can 
conclude that decrease in cell number by prolonged hypoxia was not controlled by 
VGSC activity.  
 Since hypoxia treatments longer than 24 h reduced cell number, subsequent 
experiments were restricted to 24h hypoxia, in order not to „contaminate‟ any effect 
e.g. on cell motility. However, we should note that 24 h is still a nominal duration 
employed under „model‟ experimental conditions. In reality, the clinical course of 
hypoxic (metastatic) tumours would run over months. 
 
3.3.3 Regulation of VGSCα subunit expression by hypoxia 
 
3.3.3.1 Nav1.7 mRNA expression 
Nav1.7, the predominant VGSC functionally expressed in rat and human prostate 
cancer (Mat-LyLu and PC3) cells, was shown to enhance the cells‟ metastatic 
potential (Diss et al., 2001; Grimes et al., 1995; Nakajima et al., 2009).  The present 
study confirmed the previous work that strongly metastatic Mat-LyLu, but not the 
weakly metastatic AT2 cells, express Nav1.7 mRNA (Diss et al., 2001). In Mat-
LyLu cells, chronic hypoxia (24 h, 2 % O2) significantly increased Nav1.7 mRNA 
levels. Consistently, prolong hypoxia induced increase in VGSCα mRNA level in 
developing rat cortex tissue (Zhang et al., 2001). In addition, hypoxic regulation of 
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various ion channel mRNA expression was reported such as: voltage-gated 
potassium channel α-subunits (Kv1.1, Kv1.2, Kv1.5, Kv2.1, Kv4.3 and Kv9.3) and 
α1H voltage-gated T type calcium channel (Platoshyn et al., 2001; Conforti and 
Millhorn, 1997; Del Toro et al., 2003). The mechanism of hypoxic upregulation of 
Nav1.7 mRNA expression is not known. However, there are several candidate 
pathways that can regulate gene expression by hypoxia, including:  3`-5` adenosine 
monophosphate (cAMP) / protein kinase A (PKA), Ca
2+
-calmodulin, mitogen-
activated protein kinase (MAPK) and hypoxia-inducible factors (HIF) pathway. 
There is evidence to suggest that the cAMP-PKA pathway could be involved in 
hypoxia mediated increase in Nav1.7 mRNA expression. Accordingly, hypoxia 
induced increase in PKA activity was reported in bone cells and endothelial cells 
(Zhang et al., 2010). Offord and Catterall (1989) reported that 8-Br-cAMP, a 
membrane-permeant analogue of cAMP which activates PKA, increased the VGSC 
α-subunit mRNA expression in developing rat muscle cells. Conversely, treatment of 
Mat-LyLu cells with KT5720, a PKA inhibitor, for 48 h decreased Nav1.7 mRNA 
level (Brackenbury and Djamgoz, 2006). On the other hand, hypoxia induced HIF1α 
independent changes in genome-wide DNA methylation and histone acetylation, also 
known to regulate gene expression, was documented in human prostate cells (Watson 
et al., 2009).  Such genome-wide change in DNA methylation and histone 
acetylation may affect expression of a large number of genes, including those for ion 
channels.  
 
3.3.3.2 VGSCα protein expression 
Interestingly, increase in Nav1.7 mRNA expression by hypoxia was not reflected in 
VGSCα protein level. In fact, hypoxia decreased both internal and plasma membrane 
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VGSC α-subunit levels by ~ 15 %.  There is evidence to suggest that mRNA 
regulation and protein levels can be controlled separately and independently 
(Orphanides and Reinberg, 2002). Discrepancy between VGSCα mRNA and protein 
expression in Mat-LyLu cells was also documented previously where TTX-induced 
decrease in Nav1.7 mRNA expression was not observed in total protein level   
(Brackenbury and Djamgoz, 2006). Similarly, difference in mRNA and protein 
expression was reported in a range of other pathophysiological conditions such as 
rheumatoid arthritis, psoriasis, B-chronic lymphoproliferative disorders (Sola et al., 
1999; Schedel et al., 2004; Sano et al., 2005 Gu et al., 2006). It was speculated that 
this difference in mRNA and protein expression may be because of post-
transcriptional disregulation or alterations in protein conformation (Sola et al., 1999; 
Schedel et al, 2004). 
Cellular mechanism underlying the decrease in VGSCα protein level is not 
known. This decrease in VGSCα protein level indicates change in protein turnover 
which can be because of decrease in protein synthesis and/or increase in protein 
degradation. Hypoxic reduction of VGSCα level is also reported in turtle brain 
(Pérez-Pinzón et al., 1992). O‟Reilly et al., (1997) proposed that decreased VGSCα 
activity in hypoxic neuron cells is an adaptive mechanism to increase neuronal 
tolerance to hypoxia because it would reduce Na
+
 influx and this would result in 
reduction in energy demand when energy supply is diminished during hypoxia.  
 
3.3.3.3 Relative subcellular distribution of VGSC protein 
In immunocytochemistry experiments, the relative percentages of intracellular and 
plasma membrane VGSCα protein levels did not change after 24 h of hypoxic 
treatment. This is consistent with the results obtained from the absolute 
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quantifications of intracellular and plasma membrane proteins, i.e. intracellular and 
plasma membrane VGSCα protein levels decreased similarly by ~ 15 %. These 
results suggest that the VGSCα protein cytoplasm-plasma membrane recycling, 
which has a turnover period of some 24 h, was not affected by hypoxia (2 % O2). 
 
3.3.4 VGSCβ subunit expression in Mat-LyLu and AT2 cells 
All of the four known VGSC β-subunits mRNA expression was detected in the 
weakly metastatic rat prostate cancer cell line, AT2 where VGSCβ1 was the highest 
expressed subunit followed by VGSCβ3, VGSCβ2 and VGSCβ4. On the other hand, 
all but VGSCβ3 subunits mRNA expression was detected in strongly metastatic rat 
prostate cancer cell line, Mat-LyLu; VGSCβ1 was the highest expressed subunit 
followed by VGSCβ4 and VGSCβ2. High levels of VGSCβ1 mRNA expression in 
both AT2 and Mat-LyLu cell lines was consistent with previous finding on human 
prostate cancer cells, human breast cancer cells and human prostate tissue (Diss et 
al., 2008; Chioni et al., 2009; Candenas et al., 2006). Similar to human prostate 
tissue, human prostate cancer cells and human breast cancer cells VGSCβ2 
expression was low (Diss et al., 2008; Chioni et al., 2009; Candenas et al., 2006).  
Interestingly, human breast cancer cells frequently express very low levels or no 
VGSCβ3 mRNA (Chioni et al., 2009; Candenas et al., 2006). VGSCβ4 mRNA 
expression in both AT2 and Mat-LyLu cell lines was consistent with previous 
finding on human prostate cancer cells, human breast cancer cells and human 
prostate tissue (Diss et al., 2008; Chioni et al., 2009; Candenas et al., 2006).  
AT2 cells expressed higher VGSCβ subunit mRNA than Mat-LyLu mainly 
due to higher VGSCβ1 expression. Similar result was documented in human breast 
cancer cells where weakly metastatic cells have higher VGSCβ expression (Chioni et 
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al., 2009). However, strongly metastatic human prostate cancer cells have higher 
VGSCβ expression than weakly metastatic cells (Diss et al., 2008). On the other 
hand, no significance difference was observed between prostate cancer and non-
cancerous human prostate tissues (Diss et al., 2008). It is well documented that 
VGSCβ1 can interact with extracellular matrix proteins, cell adhesion molecules 
(CAM), cytoskeleton, and functions as CAMs (Isom and Catterall, 1996; Isom, 2002; 
Undrovinas et al., 1995; Faissner 1997; Srinivasan et al., 1998; Xiao et al., 1999; 
Peles et al., 1995; Malhotra et al., 2000; Ratcliffe et al., 2000; Isom, 2001; McEwen 
and Isom, 2004). Reduced adhesiveness in rat prostate cancer, in addition to human 
prostate and breast cancer cells was associated with higher metastatic potential, i.e. 
single-cell adhesion of weakly metastatic AT2 cells was lower than adhesion of 
strongly metastatic Mat-LyLu cells (Palmer et al., 2008).  Down regulation of 
VGSCβ1 with siRNA in weakly metastatic MCF-7 breast cancer cells decreased 
single-cell adhesion and increased Transwell migration (Chioni et al., 2009). Over 
expression of VGSCβ1 in strongly metastatic MDA-MB-231 cells increased cell-cell 
adhesion and decreased lateral motility (Chioni et al., 2009). Therefore, we can 
speculate, similar to human breast cells, that higher VGSCβ1 expression might be 
responsible for the higher adhesiveness of AT2 cells. On the other hand, it was 
shown that down regulation of VGSCβ1 cause increase in VGSCα mRNA 
expression (Chioni et al., 2009). So, the lower VGSCβ1 expression in Mat-LyLu 
cells might take part in increased Nav1.7 mRNA expression. In fact, the cytoplasmic 
domain of  VGSCβ1, when cleaved, can regulate gene expression (Brackenbury and 
Isom, 2008) 
Low levels of VGSCβ2 expression were detected in both AT2 and Mat-LyLu 
cells. Expression of this subunit was not different between these strongly and weakly 
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metastatic cell lines. This result is consistent with previous finding on human 
prostate cell lines, where there was no difference in VGSCβ2 mRNA expression 
between strongly and weakly metastatic human prostate cancer cells, PNT2-C2, 
LnCaP, PC3 and PC3M (Diss et al., 2008). Furthermore, a similar result was 
obtained in in vivo experiments on human tissues by Diss et al., (2008). However, 
strongly metastatic MDA-MB-231 breast cancer cells have higher VGSCβ2 mRNA 
than weakly metastatic MCF-7 breast cancer cell line (Chioni et al., 2009). VGSCβ2 
was reported to regulate functional expression of VGSC α-subunit, channel gating, 
channel conductance and translocation of the channel (Isom et al., 1995; Cruz et al., 
1999; Chen et al., 2002; Pertin et al., 2005). Therefore, VGSCβ2 expression in Mat-
LyLu cells might be involved in regulation of VGSC expression / functioning.  
VGSCβ3 mRNA expression was detected in AT2 cells but not in Mat-LyLu 
cells. A low level mRNA expression of this subunit was reported in human prostate 
cell lines, PNT2-C2, LnCaP, PC3 and PC-3M where no difference in expression 
between strongly and weakly metastatic cells was observed (Diss et al., 2008). In the 
same study, no difference in VGSCβ3 mRNA expression was detected between 
prostate cancer and non-cancerous prostate tissue. However, Candenas et al., (2006) 
did not find VGSCβ3 mRNA expression in human prostate tissue. In addition, 
similar to Mat-LyLu cells, no expression of VGSCβ3 was detected in human breast 
cancer cells.  Interestingly, VGSCβ3 expression was correlated with p53 oncogene 
expression (Adachi et al., 2004). VGSCβ3 gene contains two p53-response elements 
and was upregulated by overexpression of p53 (Adachi et al., 2004). Thus, VGSCβ3 
is a target gene for p53 and its minimised expression may give metastatic cancer 
cells an advantage against apoptosis, i.e. it is possible that diminishing VGSCβ3 
expression may contribute to metastatic transformation. 
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A low level of VGSCβ4 mRNA expression was detected in both AT2 and 
Mat-LyLu cells, latter having higher expression. Studies on human prostate and 
breast cancer cell lines showed higher VGSCβ4 mRNA expression in weakly 
metastatic cell lines compared to strongly metastatic cell lines (Chioni et al., 2009; 
Diss et al., 2008). On the other hand, no difference in VGSCβ4 mRNA expression 
was detected between human prostate cancer and non-cancerous tissues (Diss et al., 
2008). VGSCβ4 was associated with changing activation voltage of Nav1.2 and 
Nav1.4 and was predicted to associate with extracellular matrix and CAMs (Yu et 
al., 2003).  
Further functiona studies are required to determine the possible 
pathophysiological role of VGSCβ expression in cancer and metastatic disease. 
 
3.3.5 Regulation of VGSCβ expression by hypoxia 
 
3.3.5.1 VGSCβ mRNA expression 
Long-term hypoxia (24 h, 2 % O2) increased VGSCβ1 mRNA expression of both 
weakly and strongly metastatic rat prostate cancer cell lines, AT2 and Mat-LyLu, 
respectively. The mechanism(s) underlying VGSCβ1 mRNA regulation in rat 
prostate cancer is not known. As discussed earlier, hypoxia may affect a number of 
signalling pathways in addition to genome-wide changes in methylation and 
acetilation (Seta et al., 2002; Watson et al., 2009). In addition, increase in VGSCβ1 
mRNA expression in both strongly and weakly metastatic cell lines indicate that 
hypoxia influences similar mechanisms in these cell lines. 
 VGSCβ2 expression of Mat-LyLu cells was not affected by 24 h hypoxic 
treatment.   On the other hand, VGSCβ2 mRNA level was elevated by 24 h hypoxic 
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treatment in AT2 cells. Hypoxia had no effect on VGSCβ3 mRNA expression of 
AT2 cells. No change in VGSCβ3 expression was observed in Mat-LyLu cells. 
VGSCβ4 subunit mRNA level of Mat-LyLu cells was not affected by chronic 
hypoxia. However, increase in VGSCβ4 was documented in AT2 cells in this study.  
It is evident from this result that VGSC β2, β3 and β4 subunit mRNA expressions 
were controlled differentially in weakly and strongly metastatic rat prostate cells and 
could result in different functional components, assuming that the mRNA changes 
were reflected at protein level. 
 
3.3.5.2 VGSCβ1 protein expression 
In this study,  VGSCβ1 subunit protein expression was studied since this was found 
to be the predominant VGSCβ subunit expressed in rat prostate cancer, human 
prostate cancer and human breast cancer cell lines was VGSCβ1 (Chioni et al., 2009; 
Diss et al., 2008). Unfortunately, antibodies for VGSCβ2, VGSCβ3 and VGSCβ4 
were not readily available. Interestingly, increase in VGSCβ1 mRNA expression by 
hypoxia was not reflected in VGSCβ1 protein level in Mat-LyLu cells. Hypoxia had 
no effect on both intracellular and plasma membrane levels of VGSCβ1 protein. As 
discussed previously, mRNA and protein levels can be controlled separately and 
independently (e.g. Orphanides and Reinberg, 2002). 
 
3.3.5.3 Relative subcellular distribution of VGSCβ1 protein 
The relative percentages of intracellular and plasma membrane VGSCβ1 protein 
levels did not change after 24 h hypoxic treatment. This is consistent with results 
obtained from „absolute‟ quantification of intracellular and plasma membrane protein 
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levels, which also did not show any change. These results suggested that VGSCβ1 
cytoplasm-plasma membrane protein cycling was not affected by hypoxia (2 % O2). 
 
 
3.3.6 Hypoxic regulation of metastatic activity of Mat-LyLu cells and possible 
involvement of VGSC activity 
 
3.3.6.1 Lateral motility 
It was reported that hypoxia (48 h) changed expression of various genes related to 
cellular motility in human prostate cancer PC3 cells (Ackerstaff et al., 2007).  In that 
study, upregulation of 8 genes and down regulation of 10 genes related to motility 
were detected. However, we found that lateral motility of Mat-LyLu cells was 
unchanged with 24 h hypoxia. In addition, no report on effect of hypoxia on lateral 
motility was found. Blocking VGSC for 24 h had no effect on lateral motility of Mat-
LyLu cells in both hypoxic and normoxic conditions. On the other hand, previously, 
Fraser et al. (2003) suggested that functional VGSC expression enhances lateral 
motility. However, their results were based on assays lasting 48 h and no data was 
reported for 24 h TTX treatment. Taken together, these results would suggest that 
regulation of lateral motility by VGSC activity and the effect of hypoxia are time-
dependent process. 
 
3.3.6.2 Transverse migration 
Increase in migration by hypoxia was reported previously for MDA-MB-231, MDA-
MB-468, MCF7 and 4T1 breast cancer model cells (Cronin et al., 2010, Lester et al., 
2007). In the present study, we also found that 24 h hypoxic treatment of Mat-LyLu 
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cells enhanced migration. This increase in migration was reduced to normoxic 
control levels when VGSC activity was blocked by TTX. However, blocking VGSC 
activity had no effect on migration in normoxic conditions. In contrast, Brackenbury 
and Djamgoz (2006) reported decrease of migration with TTX treatment in normoxic 
conditions. These contradicting results were probably caused by experimental 
conditions. Brackenbury and Djamgoz (2006) used 12 µm-pore Transwell filters in 
migration assay but 8 µm-pores Transwell filters were used in this study since former 
was no longer commercially available. It was also shown that serum factors may be 
required for VGSC dependent potentiation of migration where in presence of 0 % 
FBS TTX had no effect on Mat-LyLu cell migration (Brackenbury and Djamgoz 
2007). Clearly, the increase in migration by hypoxia depended on VGSC activity. 
Accordingly, Onkal (2010) showed that hypoxia (2 % O2, 24 h) significantly 
increased Na
+
 peak current density in Mat-LyLu cells, so a follow-on increase in INaT 
may be expected (Appendix 1). In addition, it was previously reported that hypoxia 
increased INaP amplitude in neurons and cardiac cells (Hammarström and Gage 1998; 
Ju et al., 1996). Although a small decrease in VGSC protein level was detected, 
hypoxic increase in INaP or INAT could be the reason for the VGSC-dependent 
increase in migration.  
 
3.3.6.3 Matrigel
тм
 invasion 
Hypoxic treatment for 24 h did not have any affect on the invasion of Mat-LyLu 
cells. Consistently, Alqawi et al. (2007) reported that 5 h hypoxia (1 % O2) did not 
effect invasion of Mat-LyLu cells. However in that study, increased invasion was 
reported for a hypoxia-resistant sub-clone of Mat-LyLu, surviving 8 weeks of 
hypoxia (1 % O2). Watson et al. (2009) also reported increased invasiveness of a 
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hypoxia-resistant sub-clone of PwR-1E benign prostate epithelial cells maintained 
for 14 weeks in hypoxia. In contrast, Ackerstaff et al. (2007) reported decreased 
invasiveness of PC3 human prostate cancer cells after 72 h of hypoxia (1 % O2). 
However, in the same study the cell number was found to decrease with hypoxia, 
which could explain the decrease in invasion capability. In addition to prostate 
cancer, many other studies on various type of cancer cell showed change in invasion 
by hypoxia. However, there is no general consensus on the direction of this effect. 
Increase of invasion with hypoxia was reported for MDA-MB-231, MDA-MB-468, 
MCF7 and 4T1 breast cancer cells, HCT116 and HT-29 human colon carcinoma, 
HepG2 human hepatoblastoma and PANC-1 pancreatic carcinoma cells (Cronin et 
al., 2010; Lester et al., 2007; Graham et al., 1999, Krishnamachary et al., 2003). On 
the other hand, no affect of hypoxia on invasion was reported for SiHa human 
cervical cancer, U2-OS human osteosarcoma cells, OW-1, SAU and SKA ovarian 
cancer cells (Pennacchietti et al., 2003; Krtolica and Ludlow 1996). Decrease of 
invasion with hypoxic treatment was documented for choriocarcinoma cells (Sato et 
al., 2002). Taking into account all these results, we can conclude that hypoxic 
regulation of invasion can change from one cancer type to another and may be time 
dependent. 
 Blocking VGSC with TTX decreased invasion of MatLyLu cells both in 
normoxic and hypoxic conditions. Similarly, role of VGSC on invasion of prostate 
cancer was extensively studied previously under normoxic conditions (Grimes et al., 
1995; Laniado et al., 1997; Smith et al., 1998; Bennett et al., 2004; Nakajima et 
al.,2009).  Bennett and colleagues (2004) proposed that functional expression of 
VGSC is “necessary and sufficient” for prostate cancer cell invasion. In the case of 
human strongly metastatic breast cancer cells, VGSC activity dependent increase in 
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invasiveness was proposed to be due to control of pH-dependent activation of 
cysteine cathepsins (Gillet et al., 2009). Such an effect could explain why a role of 
VGSC activity in lateral motility and transverse migration was not always seen. 
 
 
3.4 Concluding remarks 
In the present study, we found differential regulation of mRNA and protein 
expression of VGSC α- and β1- subunit of Mat-LyLu cells when incubated in 
hypoxic conditions (24 h; 2 % O2). Hypoxia increased both VGSC α- and β1- subunit 
mRNA expression but decreased or not effected the protein expression, respectively. 
No major effect of hypoxia on cell morphology was observed. In addition, hypoxia 
did not affect lateral motility and matrigel invasion of Mat-LyLu cells. On the other 
hand, VGSC activity-dependent enhancement of transverse migration was 
documented by chronic hypoxia (24 h; 2 % O2).  In overall conclusion, therefore, 
hypoxia mediated increase in transverse migration of Mat-LyLu cells was caused, at 
least in part, by increased VGSC activity which was probably regulated at a post-
transcriptional level. 
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  Chapter 4 
 
EFFECTS OF PHARMACOLOGICAL BLOCKERS ON 
VOLTAGE-GATED Na
+
 CHANNEL EXPRESSION AND 
METASTATIC CELL BEHAVIOURS OF  
DUNNING PROSTATE CANCER
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4.1 Introduction 
Functional expression of VGSCs has been associated with metastatic carcinomas as 
reviewed in Chapter 1 - General Introduction (also, Grimes et al., 1995; Blandino et 
al., 1995; Laniado et al., 1997; Allen et al., 1997; Grimes and Djamgoz, 1998; Abdul 
and Hoosein, 2002; Roger et al., 2003; Fraser et al., 2004; Ou et al., 2005; Fraser et 
al., 2005; Onganer and Djamgoz, 2005; Onganer et al., 2005; Brackenbury and 
Djamgoz, 2006; Fulgenzi et al., 2006; Roger et al., 2007; Diaz et al., 2007; Nakajima 
et al., 2009; Gao et al., 2009; Gao et al., 2010; House et al., 2010). It was reported 
that VGSC activity in rat strongly metastatic prostate cancer (PCa) Mat-LyLu cells 
can auto-regulate mRNA expression and protein trafficking via a positive feedback 
mechanism (Brackenbury and Djamgoz, 2006). In addition, VGSC activity was 
reported to contribute positively metastatic cell behaviours (MCBs), such as 
galvanotaxis, lateral motility, endocytotic membrane activity, transverse migration 
and invasion (Brackenbury and Djamgoz, 2006; Gillet et al., 2009; Nakajima et al., 
2009; Fraser et al., 2003; Mycielska et al., 2003; Djamgoz et al., 2001; Krasowska et 
al., 2004; Grimes et al., 1995; Laniado et al., 1997; Smith et al., 1998; Bennett et al., 
2004). Indeed, it was proposed that functional expression of VGSC is “necessary and 
sufficient” for cellular invasiveness in PCa (Bennett et al., 2004). Finally, House et 
al. (2010) recently showed that functional VGSCs (Nav1.5) are a key regulator of 
invasiveness in colon cancer.  
Because of their VGSC blocking activity, various pharmacological agents, 
including ranolazine, riluzole, procaine and lidocaine, have been used to treat a 
variety of pathological conditions, such as chronic angina, amyotropic lateral 
sclerosis, painful diabetic polyneuropathies, neuralgic pain and traumatic peripheral 
nerve injuries (Maier, 2009; Bensimon et al., 1994; Lacomblez et al., 2996). The 
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antianginal effect of ranolazine is thought to be through blockage of INaP 
(Antzelevitch et al., 2004; Fredj et al., 2006). Similarly, the neuroprotective property 
of riluzole was attributed to its ability to block INaP (Urbani and Belluzi, 2000; Zona 
et al., 1998). It was also proposed that INaP is more sensitive to VGSC blockers 
lidocaine and TTX than INaT in neurons (Hammarström and Gage, 1998). There is 
also some evidence that lidocaine and procaine may block embryonic VGSCs more 
than adult (Ribeiro and Costa, 2003). Ranolazine was proposed as a therapeutical 
agent in treatment of haematological malignancies and riluzole was suggested as a 
drug for advanced melanoma treatment (Samudio et al., 2010; Le et al., 2010).  In 
addition, procaine was suggested as potential candidate for breast cancer therapy 
because of its reported anti-proliferative effects (Villar-Garea et al., 2003). Procaine 
was also shown to enhance anti-tumoral activities of drugs used in cancer therapy 
(Chlebowski et al., 1982; Esposito et al., 1990; Viale et al., 1998; Mizuno and 
Ishida, 1982). Furthermore, procaine and lidocaine were reported to radiosensitize 
hypoxic murine L5178Y cells (Yau and Kim, 1980). These findings would further 
suggest that clinical VGSC blockers could ultimately be useful as anti-cancer drugs.  
Hypoxia occurs in many human solid cancers, including PCa, as tumours 
grow (Vaupel et al., 2007; Harrison and Blackwell, 2004). Significant correlation 
with tissue hypoxia and clinical stage was reported in PCa (Movsas et al., 2000). 
Development of hypoxia in growing tumours is crucial for inducing „global‟ changes 
in gene expression, metabolic phenotype, ion haemostasis and, finally, angiogenesis 
(Higgins et al., 2009; Ackerstaff et al., 2007; Watson et al., 2009, Haigney et al., 
1994; Xiao and Allen, 1999). 
 Interestingly, hypoxia can modulate VGSC activity by affecting channel 
gating by conformational changes caused by formation or disruption of 
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intermolecular disulfides (Hammarström and Gage, 2002). Accordingly, hypoxia 
induced increase in “persistent Na+ current” (INaP) was reported in neurons and 
cardiac cells (Ju et al., 1996; Hammarström and Gage, 2002; Wang et al., 2007). On 
the other hand, hypoxia reduced “transient Na+ current” (INaT) in neurons and 
myocytes (Hammarström and Gage, 2002; Wang et al., 2007). It was also reported 
that intracellular Na
+
 concentration increased by hypoxia (Haigney et al., 1994; Xiao 
and Allen, 1999). 
In the light of these findings, it was hypothesised that targeting VGSC could 
be a novel and effective strategy to reduce metastatic potential of PCa. Therefore, in 
this chapter we proposed that pharmacological VGSC blockers, that are currently 
being used as „safe‟ clinical drugs, could be used to decrease MCBs of PCa. In 
addition, tissue O2 level could modify the effect of these drugs, since tissue O2 level 
would affect VGSC activity. 
 
4.1.1 Aims and scope of the present study 
The main aim of this study was to evaluate possible effects of key pharmacological 
blockers on VGSCα expression and involvement in MCBs in the strongly metastatic 
rat PCa model, Mat-LyLu cells. The specific aims were as follows: 
1. To test if ranolazine, riluzole (blockers of INaP) , procaine and lidocaine 
(general VGSC blockers) could regulate VGSCα mRNA and protein 
levels in normoxic and hypoxic conditions; and 
2. To determine the possible effects of these pharmacological blockers on 
Matrigel
тм
 invasion in normoxic and hypoxic conditions. 
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4.2 Results 
Hypoxia treatments longer than 24 h reduced cell number, therefore all experiments 
were restricted to 24 h treatment, in order not to „contaminate‟ any effect on Matrigel 
invasion. In addition, many previous experiments have been carried out using 24 h 
hypoxia (Ghafer et al., 2003; Franovic et al., 2007; Chen et al., 2010; Dai et al., 
2011). 
 
4.2.1 Effects of ranolazine 
Ranolazine has been used extensively as an inhibitor of VGSC persistent currents, 
although it has a range of actions, depending on concentration (Chen et al., 2009; 
Samudio et al., 2010; Rajamani et al., 2008; Antzelevitch et al., 2004; Clarke et al., 
1996). In the present study, it was used in the concentration range 20 to 300 µM, 
since in this concentration range, ranolazine was shown to block INaP more 
effectively than INaT (Antzelevitch et al., 2004). 
 
4.2.1.1 Some initial observations: Cell morphology 
No change in the basic appearance or distribution of Mat-LyLu cells in culture was 
observed when cultures were treated (24 h) with 20 µM and 50 µM ranolazine under 
both normoxic and hypoxic (2 % O2) conditions (Figures 4.1A-C). On the other 
hand, after 300 µM ranolazine treatment, Mat-LyLu cells, maintained in either 
condition, appeared generally „loose‟ and scattered (Figure 4.1D). Studying the cells 
under high magnification revealed that following 300 µM ranolazine treatment, cells 
lost their spindle-shaped / fibroblast-like morphology in both normoxic and hypoxic 
conditions (Figure 4.2D).  
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Figure 4.1 Phase-contrast light-photomicrography of Mat-LyLu cells treated 
with ranolazine. 
Mat-LyLu cells were grown for 24 h  under (A) control conditions, and in (B) 
20µM ranolazine, (C) 50µM ranolazine, and (D) 300µM ranolazine treatment in 
normoxia (left hand pictures) and hypoxia (2 % O2; right hand pictures). 
Micrographs are typical of 3 experiments. 
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Figure 4.2 Phase-contrast light-photomicrography of Mat-LyLu cells, treated 
with ranolazine in high magnification.  
Mat-LyLu cells were grown for 24 h  under (A) control conditions, and in (B) 
20µM ranolazine, (C) 50µM ranolazine, (D) 300µM ranolazine treatment in 
normoxia (left hand pictures) and hypoxia (2 % O2; right hand pictures). 
Micrographs are typical of 3 experiments. 
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4.2.1.2 Cell viability 
Treatment with concentrations of ranolazine up to 300 µM for 24 h had no effect on 
the viability of Mat-LyLu cells maintained in normoxic or hypoxic conditions 
(Figure 4.3).  
 
4.2.1.3 Cellular proliferation 
There was no change in Mat-LyLu cell number after treatment with ranolazine (20, 
50 and 300 µM) over 24 h in normoxic conditions (Figure 4.4). Similarly, the cell 
number was not affected by 20 and 50 µM ranolazine treatment (24 h) in hypoxia 
(Figure 4.4). There was no effect when cell numbers were compared to the respective 
control. However, comparison of the cell number for 300 µM ranolazine in hypoxia 
with the normoxic control (~21 % O2) suggested a statistically significant effect (p < 
0.05; n = 3 each; Figure 4.4). Hypoxia by itself had no effect on cell number.   
 
4.2.1.4 Nav1.7 mRNA expression 
Expression of Nav1.7 mRNA was studied by real-time PCR. cDNAs were prepared 
from Mat-LyLu cells  treated with 20 - 300 µM ranolazine for 24 h under normoxic 
or hypoxic conditions. Agarose gel electrophoresis confirmed specific single bands at 
the expected sizes for Nav1.7 and Cytb5R (414 nt and 425 nt, respectively; n = 3; 
Figure 4.5A). The “no-template control” did not give any signal (n = 3; Figure 4.5A). 
Significant decreases of Nav1.7 mRNA expression by 17 %, 20 % and 17 % were 
found to result from the treatment of the cells with 20, 50 and 300 µM ranolazine, 
respectively, under normoxic conditions (p < 0.05; n = 3 each; Figure 4.5B). 
Hypoxia (24 h) alone significantly increased Nav1.7 mRNA expression by 407 % (p 
< 0.05; n = 3; Figure 4.5B). Treatment of Mat-LyLu cells (24 h) with 20, 50 and 300 
   
 - 186 - 
 
0
1
2
98
99
100
101
102
Ranolazine
(M)
Ranolazine
(M)
30050Cont 2030020 50Cont
V
ia
b
le
 c
e
lls
 (
%
)
  Normoxia
  Hypoxia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Bar diagram showing ranolazine treatments had no toxic effect.  
A possible effect of 20, 50 and 300 µM ranolazine on Mat-LyLu cell viability 
under normoxia (light grey columns) or hypoxia (2 % O2; dark grey columns). Data 
are represented as means ± SEM (n = 3). 
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Figure 4.4 Dose dependent effect of ranolazine on Mat-LyLu cell number. 
Bar diagram showing the effect of 20, 50 and 300 µM ranolazine on cell number 
of normoxic (light grey columns) or hypoxic (dark grey columns) Mat-LyLu 
cells. Data are presented as means ± SEM (n ≥ 3). Data were analysed by 
ANOVA followed by Newman-Keuls post hoc analysis. Table of multiple 
comparisons between different treatments for statistical significance are shown 
underneath the bar diagram. 
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Figure 4.5 Effect of ranolazine on Mat-LyLu Nav1.7 mRNA expression. 
(A) Typical PCR products of Nav1.7 (414 bp) and normalising/control gene Cytb5R 
(425 bp) mRNA in Mat-LyLu cells that was incubated with 20, 50 and 300 µM 
ranolazine under normoxic or hypoxic (2 % O2) conditions for 24 h. (B) Bar diagram 
showing the result of real-time PCR experiment in which the effect of ranolazine on 
Nav1.7 mRNA expression was studied under normoxic (light grey column) or 
hypoxic (dark grey column) conditions. The data were normalized to Cytb5R using 
the 2
-ΔΔCт
 method and expressed relative to normoxic control Nav1.7 level. The table 
of multiple comparisons between different treatments for statistical significance are 
shown underneath the bar diagram. Kruskal-Wallis method was used for statistic 
analysis. Data are presented as means ± SEM (n = 3).  (-): no template control 
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µM ranolazine reduced Nav1.7 mRNA expression levels significantly by 30 %, 43 % 
and 44 %, respectively, under hypoxic conditions (p < 0.05; n = 3; Figure 4.5B).  
 
4.2.1.5 Subcellular VGSCα protein expression 
 
4.2.1.5.1 Relative distribution 
Confocal immunocytochemistry with a pan-VGSC antibody was used to test the 
possible effect of ranolazine (50 µM) on subcellular distribution of VGSCα protein 
in Mat-LyLu cells under normoxic or hypoxic (2 % O2/ 24 h) conditions (Figure 4.6). 
VGSCα protein expression was detected in cytoplasm and plasma membrane but not 
in nucleus of Mat-LyLu cells (Figure 4.6). The subcellular distribution of the VGSCα 
protein was studied by „straight line cross-sectional profile‟ analysis (Figure 4.7). In 
normoxia, relative to the total immunoreactivity (across the cell), plasma membrane 
VGSCα protein levels were 9.7 ± 0.4 % (control) and, 9.1 ± 0.3 % (ranolazine). In 
hypoxia, the corresponding values were 9.5 ± 0.5 % (hypoxia control) and 10.0 ± 0.5 
% (ranolazine). Similar data were obtained for the internal VGSCα protein level: 
35.2 ± 0.5 % (normoxia control), 35.6 ± 0.5 % (normoxia ranolazine), 35.6 ± 0.5 % 
(hypoxia control) and 34.7 ± 0.5 % (hypoxia ranolazine). There was no difference in 
the data for ranolazine vs corresponding control (for both: p > 0.05; n ≥ 63; Figure 
4.8A&B). It was concluded that ranolazine did not affect the relative subcellular 
distribution of VGSCα protein in normoxia or hypoxia. 
 
4.2.1.5.2 Plasma membrane VGSCα protein level 
Digital quantification of the peripheral VGSCα immunoreactivity (IRpm) by „free-
form line profile‟ analysis of XYZ scans of Mat-LyLu cells treated (24 h) with
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Figure 4.6 Confocal immunocytochemistry study of Mat-LyLu cells incubated with ranolazine.  
Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and hypoxic (2 % O2) conditions with or without ranolazine (50 
µM). Signal from concanavalin A plasma membrane marker (green), pan-VGSC antibody (red) and overlay of both (merged image) are shown in 
addition to bright field image. Scale bar (40 µm) applicable to all panels. 
 
40 µm 
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Figure 4.7 Typical image showing effect of ranolazine on VGSCα protein distribution 
along typical cellular cross-section in Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without ranolazine (50 µM). White lines indicate typical cross-
sections. Scale bar (5µm) applicable to all panels.  
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Figure 4.8 Effect of ranolazine on VGSCα protein distribution along typical cellular 
cross-section in Mat-LyLu cells. 
(A) Representative traces showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα immunofluorescence (red) along cross-section from typical cells  
(Figure 4.7) incubated (24 h) in normoxic or hypoxic conditions with or without ranolazine 
(50 µM). (B) Bar diagram showing distribution of VGSCα protein immunoreactivity along 
subcellular cross-sections as a percentage of total (%). For plasma membrane (PM) 
immunoreactivity, 1.5 µm sections was measured inward from the edge of Con A staining. 
For internal (INT) immunoreactivity, middle 30 % of the cross-section was measured. Data 
were analysed by ANOVA followed by Newman-Keuls post hoc analysis. Data are 
presented as means±SEM (n =63). Significance: (X) p > 0.05. 
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ranolazine (50 µM) revealed no change in plasma membrane VGSCα protein level 
under normoxic conditions (IRpm = 155 ± 5 AU/µm and 144 ± 3 AU/µm, 
respectively; p > 0.05; n ≥ 63; Figures 4.9 and 4.10A&B). Similarly, in Mat-LyLu 
cells treated with ranolazine and maintained in hypoxia, plasma membrane level of 
VGSCα protein did not change compared to hypoxia control (IRpm = 121 ± 3 AU/µm 
and 131 ± 4 AU/µm, respectively; p > 0.05; n ≥ 63; Figures 4.9 and 4.10A&B). On 
the other hand, hypoxia by itself caused a significant 22 % decrease in plasma 
membrane VGSCα protein level (p < 0.05; n ≥ 63; Figures 4.9 and 4.10A&B) with 
no further effect of the ranolazine treatment.  
 
4.2.1.5.3 Internal VGSCα protein level 
Digital quantification of the „internal‟ VGSCα immunoreactivity (IRint) by the „area 
histogram‟ analysis of XYZ scans of Mat-LyLu cells treated (24 h) with ranolazine 
(50 µM) under normoxic conditions revealed a significant (~ 9 %) decrease of 
internal VGSCα protein level, from 22978 ± 587 AU to 20934 ± 704 AU (p < 0.05; n 
≥ 77; Figures 4.11 and 4.12A&B). Hypoxia by itself caused a significant 16.5 % 
decrease in VGSCα immunoreactivity to 10173 ± 389 AU (p < 0.05; n ≥ 77; Figures 
4.11 and 4.12A&B). There was no further effect of the treatment with ranolazine 
under hypoxia (IRint =18501 ± 682; p < 0.05; n ≥ 77; Figures 4.11 and 4.12A&B).  
 
4.2.1.6 Matrigelтм invasion 
Matrigel
тм
 invasion assays were used to assess the possible effect of ranolazine 
treatment on the invasiveness of Mat-LyLu cells maintained in normoxic and 
hypoxic conditions. Treatment with 20, 50 and 300 µM ranolazine significantly 
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Figure 4.9 Typical image showing effect of ranolazine on VGSCα protein levels in 
plasma membrane of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without ranolazine (50 µM). White lines indicate typical 
freeform line guided by Con A staining to measure cell surface protein level. Scale bar 
(5µm) applicable to all panels.  
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Figure 4.10 Effect of ranolazine on VGSCα protein levels in plasma membrane of Mat-
LyLu cells. 
(A) Representative trace showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα  (red) immunofluorescence along plasma membrane from a typical cells  
(Figure 4.9) incubated (24 h) in normoxic or hypoxic conditions with or without ranolazine 
(50 µM). Dotted gray lines indicate mean pan-VGSC fluorescence. (B) Bar diagram 
showing level of VGSCα protein immunoreactivity along plasma membrane as 
immunoreactivity (AU) per µm. Inset: table of multiple comparisons between 
treatments for statistical significance. Data were analysed by ANOVA followed by 
Newman-Keuls post hoc analysis. Data are presented as means ± SEM (n = 71).  
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Figure 4.11 Typical image showing effect of ranolazine on internal VGSCα protein 
levels of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without ranolazine (50 µM). White box indicates typical area 
covering 16 µm
2
 square section of cytoplasm avoiding nucleus to measure internal protein 
level. Scale bar (5µm) applicable to all panels.  
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Figure 4.12 Effect of ranolazine on internal VGSCα protein levels of Mat-LyLu cells. 
(A) Representative histograms showing distribution of pixels (0.0625 µm
2
) with signal 
intensity of Con A plasma membrane marker (green) and VGSCα  (red) 
immunofluorescence in cytoplasm from typical cells  (Figure 4.11) incubated (24 h) in 
normoxic or hypoxic conditions with or without ranolazine (50 µM). Dotted gray lines 
indicate mean pan-VGSC fluorescence. (B) Bar diagram showing internal VGSCα protein 
immunoreactivity (AU). Inset: table of multiple comparisons between treatments for 
statistical significance. Data were analysed by ANOVA followed by Newman-Keuls 
post hoc analysis. Data are presented as means ± SEM (n = 77).  
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decreased invaded cell number by 59 %, 55 %, 74 %, respectively (p < 0.05; n ≥ 4 
each; Figures 4.13 and 4.14) under normoxic conditions. Similarly, 24 h treatment of 
cells in hypoxic conditions with 20, 50 and 300 µM ranolazine significantly 
decreased invaded cell number by 63 %, 73 %, 87 %, respectively (p < 0.05; n ≥ 4 
each; Figures 4.13 and 4.14). Hypoxia alone had no effect on cellular invasion (p > 
0.05; n = 8; Figures 4.13 and 4.14). 
 
4.2.1.7 Summary of the effects of ranolazine 
Hypoxia increased Nav1.7 mRNA expression whilst decreasing plasma membrane 
and intracellular VGSCα protein levels. The effects of ranolazine on Mat-LyLu cells 
were as follows: i) decreased Nav1.7 mRNA expression (both conditions); (ii) 
decreased intracellular VGSCα protein; and (iii) decreased invasion (both 
conditions). Some of these effects were concentration dependent. There was no effect 
on any of the other characteristics measured, including cell viability and number 
(proliferation) (Table 4.1). 
 
4.2.2 Effects of riluzole 
Riluzole has also been used as an inhibitor of VGSC persistent currents, although it 
too can have a range of actions, depending on concentration (Weiss et al., 2010; Le 
et al., 2010; Parihar et al., 2003; Doble, 1996; Zona et al., 1998; Frizzo et al., 2004; 
Xu et al., 2001). In the present study, riluzole (dissolved in DMSO) was used in the 
concentration range 1 to 100 µM. This concentration range was shown previously to 
block INaP more effectively than INaT (Weiss et al., 2010; Urbani and Belluzi, 2000).  
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Figure 4.13 Typical images of invaded cells showing the effect of ranolazine on 
invasion of Mat-LyLu invesiveness. 
Typical phase-contrast light-microscopy images of invaded cells obtained from Matrigel
тм
 
invasion assays of Mat-LyLu cells incubated 24 h under normoxic and hypoxic conditions 
with or without ranolazine (20, 50 and 300 µM). Invaded cells were fixed and stained with 
crystal violet (purple). Scale bar (200 µm) applicable to all panels.  
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Figure 4.14 Effect of ranolazine on invasion of Mat-LyLu cells. 
Bar diagram showing number of invaded Mat-LyLu cells, incubated 24 h under normoxic 
and hypoxic conditions with or without ranolazine (20, 50 and 300 µM). Data were 
expressed relative to the control (%) and presented as means ± SEM (n ≥ 4). Data were 
analysed by Kruskal-Wallis analysis of variance. Inset: table of multiple comparisons 
between treatments for statistical significance. 
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STUDIES HYPOXIA 
RANOLAZINE RILUZOLE PROCAINE LIDOCAINE 
Nor Hyp Nor Hyp Nor Hyp Nor Hyp 
MORPHOLOGY 0 0 / + 0 / + 0 0 0 0 / + 0 / + 0 / + 
VIABILITY 0 0 0 0 0 0 0 0 0 
PROLIFERATION 0 0 0 0 / - 0 / - 0 0 0 0 / - 
Nav1.7 mRNA + - 0 / - 0 / - 0 / - 0 / - 0 0 / - 0 / - 
VGSCα PROTEIN          
(i) Subcellular 0 0 0 0 0 0 0 0 0 
(ii) PM - 0 0 0 + - 0 - 0 
(iii) Internal - - 0 - - - 0 - - 
INVASION 0 - - 0 0 - - - - 
Table 4.1 Summary of results 
(Nor) normoxia; (Hyp) hypoxia; (PM) plasma membrane; (/) concentration dependent; (+) increase; (-) decrease; (0) no change 
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4.2.2.1 Some initial observations: Cell morphology 
Treatment of Mat-LyLu cells in culture with 0.015 % DMSO, 10 µM and 30 µM 
riluzole for 24 h revealed no obvious change in the basic appearance or distribution 
of the cells under both normoxic and hypoxic (2 % O2) conditions (Figures 4.15 A-
D). A similar conclusion was reached after studying the cells under high 
magnification (Figures 4.16A-D).  
 
4.2.2.2 Cell viability 
Treatment with riluzole (up to 100 µM) or 0.05 % DMSO (corresponding 
concentration of solvent) for 24 h was not toxic to Mat-LyLu cells that were 
maintained in normoxic or hypoxic conditions (Figure 4.17).  
 
4.2.2.3 Cellular proliferation 
No significant change was recorded in Mat-LyLu cell number after treatments (24 h) 
with 0.015 % DMSO, 3 µM and 5 µM riluzole in normoxic and hypoxic conditions 
(n ≥ 3 each; Figure 4.18). Also, DMSO by itself had no effect on cell number in 
either condition. However, some statistical variations were noted. For example, 10 
µM and 30 µM riluzole treatments had no effect on cell number when compared to 
the respective DMSO control but cell numbers were significantly lower by 29 % and 
48 %, respectively, when compared to the non-treated controls under normoxic 
conditions (n ≥ 3 each; Figure 4.18). Under hypoxia, 10 µM riluzole treatment (24 h) 
decreased cell number by 26 % and 24 % when compared to non-treated and DMSO 
controls, respectively, the former change being significant (p < 0.05; n ≥ 3 each; 
Figure 4.18). The highest concentration of riluzole tested (30 µM) significantly 
decreased cell number by 44 % and 41 % when compared to both non-treated and 
DMSO controls, respectively (p < 0.05; n ≥ 3 each; Figure 4.18). 
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Figure 4.15 Phase-contrast light-photomicrography of Mat-LyLu cells, treated 
with riluzole. 
Mat-LyLu cells were grown for 24 h  under (A) control conditions, and in (B) 
0.015 % DMSO, (C) 10 µM riluzole, and (D) 30 µM riluzole treatment in 
normoxia (left hand pictures) and hypoxia (2 % O2; right hand pictures). 
Micrographs are typical of 3 experiments. 
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Figure 4.16 Phase-contrast light-photomicrography of Mat-LyLu cells, treated 
with riluzole, in high magnification.  
Mat-LyLu cells were grown for 24 h  under (A) control conditions, and in (B) 
0.015 % DMSO, (C) 10 µM riluzole, and (D) 30 µM riluzole treatment in 
normoxia (left hand pictures) and hypoxia (2 % O2; right hand pictures). 
Micrographs are typical of 3 experiments. 
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Figure 4.17 Bar diagram showing riluzole treatments had no toxic effect.  
A possible effect of 0.05 % DMSO and 10, 30 and 100 µM ranolazine on Mat-
LyLu cell viability under normoxia (light grey columns) or hypoxia (2 % O2; dark 
grey columns). Data are represented as means ± SEM (n = 3). 
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Figure 4.18 Dose dependent effect of riluzole on Mat-LyLu cell number. 
Bar diagram showing the effect of 3, 5, 10 and 30 µM riluzole on cell number of 
normoxic (light grey columns) or hypoxic (dark grey columns) Mat-LyLu cells. 
Data are presented as means ± SEM (n ≥ 3). Data were analysed by ANOVA 
followed by Newman-Keuls post hoc analysis. Table of multiple comparisons 
between different treatments for statistical significance are shown underneath the 
bar diagram. (D) 0.015 % DMSO. 
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Because 24 h treatments with 10 µM riluzole consistently reduced cell 
number, subsequent experiments were restricted to 1 to 5 µM range, in order not to 
„contaminate‟ any effect on Matrigel invasion. 
 
4.2.2.4 Nav1.7 mRNA expression 
Mat-LyLu cells were treated for 24 h with 1, 2.5 and 5 µM riluzole or 0.0025 % 
DMSO (highest concentration involved) under normoxic or hypoxic conditions and 
cDNAs were prepared for real-time PCRs. Agarose gel electrophoresis confirmed 
specific single bands at the expected sizes for Nav1.7 and Cytb5R (414 nt and 425 nt, 
respectively; n = 3 each; Figure 4.19A). The “no-template control” did not give any 
signal (n = 3; Figure 4.19A).  No significant change in Nav1.7 mRNA expression 
was recorded when Mat-LyLu cells were treated (24 h) with 1 µM and 5 µM riluzole 
and 0.015 % DMSO (p > 0.05; n = 3 each; Figure 4.19B). On the other hand, 24 h 
treatment of Mat-LyLu cells, incubated with 2.5 µM riluzole under normoxic 
conditions, decreased Nav1.7 mRNA expression by 32 % and 22 %  when compared 
to no treatment control (NTC)  and DMSO controls, respectively, the former being 
statistically significant (n = 3 each; Figure 4.19B). Hypoxia itself readily increased 
Nav1.7 mRNA expression. Treatment with 1 µM riluzole for 24 h under hypoxic 
conditions had no significant effect on Nav1.7 mRNA level (p > 0.05; n = 3; Figure 
4.19B). In contrast, under hypoxic conditions, 2.5 µM riluzole treatment (24 h) 
significantly decreased Nav1.7 mRNA level by 40 % and 43 % when compared to 
the NTC and DMSO controls, respectively (p < 0.05; n = 3 each; Figure 4.19B). 
Similarly, 5 µM riluzole treatment (24 h) in hypoxia significantly decreased Nav1.7 
mRNA level by 41 % and 43 % when compared to the NTC and DMSO controls.  
  - 208 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Comparison p<0.05 
1 vs 2 No 
1 vs 3 No 
1 vs 4 Yes 
1 vs 5 No 
1 vs 6 Yes 
1 vs 7 Yes 
1 vs 8 Yes 
1 vs 9 Yes 
1 vs 10 Yes 
2 vs 3 No 
2 vs 4 No 
2 vs 5 No 
2 vs 6 Yes 
2 vs 7 Yes 
2 vs 8 Yes 
Comparison p<0.05 
2 vs 9 Yes 
2 vs 10 Yes 
3 vs 4 No 
3 vs 5 No 
3 vs 6 Yes 
3 vs 7 Yes 
3 vs 8 Yes 
3 vs 9 Yes 
3 vs 10 Yes 
4 vs 5 No 
4 vs 6 Yes 
4 vs 7 Yes 
4 vs 8 Yes 
4 vs 9 Yes 
4 vs 10 Yes 
Comparison p<0.05 
5 vs 6 Yes 
5 vs 7 Yes 
5 vs 8 Yes 
5 vs 9 Yes 
5 vs 10 Yes 
6 vs 7 No 
6 vs 8 No 
6 vs 9 Yes 
6 vs 10 Yes 
7 vs 8 No 
7 vs 9 Yes 
7 vs 10 Yes 
8 vs 9 No 
8 vs 10 No 
9 vs 10 No 
0
1
2
3
4
5
6
7
Riluzole
(M)
Riluzole
(M)
52.51DCont52.51DCont
m
R
N
A
 e
x
p
re
s
s
io
n
  Normoxia
  Hypoxia
1 2 3 4 
5 
6 
7 
8 
9 10 
Cont 1 2.5 5 Cont 1 2.5 5 D 
Riluzole (µM) Riluzole (µM) 
Normoxia Hypoxia 
Nav1.7 
Cytb5R 
414 bp 
425 bp 
Figure 4.19 Effect of riluzole on Mat-LyLu Nav1.7 mRNA expression. 
(A) Typical PCR products of Nav1.7 (414 bp) and normalising/control gene Cytb5R (425 
bp) mRNA in Mat-LyLu cells that was incubated with 1, 2.5 and 5 µM riluzole under 
normoxic or hypoxic (2 % O2) conditions for 24 h. (B) Bar diagram showing the result of 
real-time PCR experiment in which the effect of riluzole on Nav1.7 mRNA expression was 
studied under normoxic (light grey column) or hypoxic (dark grey column) conditions. The 
data were normalized to Cytb5R using the 2
-ΔΔCт
 method and expressed relative to normoxic 
control Nav1.7 level. The table of multiple comparisons between different treatments for 
statistical significance are shown underneath the bar diagram. Kruskal-Wallis method was 
used for statistic analysis. Data are presented as means ± SEM (n = 3). (D) 0.0025 % 
DMSO. 
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4.2.2.5 Subcellular VGSCα protein expression 
 
4.2.2.5.1 Relative distribution 
Confocal immunocytochemistry with the pan-VGSC antibody was used to test the 
possible effect of riluzole (2.5 µM) on subcellular distribution of VGSCα protein in 
Mat-LyLu cells under normoxic or hypoxic (2 % O2) conditions (Figure 4.20). The 
relative subcellular distribution of the VGSCα protein was studied by „straight line 
cross-sectional profile‟ analysis of Mat-LyLu cells (Figure 4.21). This analysis 
revealed that the relative level of plasma membrane and intracellular VGSCα protein 
was not affected by 24 h treatment with riluzole (2.5 µM) under both normoxic and 
hypoxic conditions (p > 0.05; n ≥ 63; Figure 4.22). The relative plasma membrane 
VGSCα protein levels were as follows: 9.7 ± 0.4 % (normoxia control), 10.4 ± 0.4 % 
(normoxia + riluzole), 9.5 ± 0.5 % (hypoxia control), 10.6 ± 0.5 % (hypoxia + 
riluzole). Similarly, the relative intracellular VGSCα protein levels were as follows: 
35.2 ± 0.5 % (normoxia control), 36.6 ± 0.4 % (normoxia + riluzole), 35.6 ± 0.5 % 
(hypoxic control) and 35.8 ± 0.5 % (hypoxia + riluzole). Thus, riluzole had no effect 
on relative levels of VGSCα protein in either cellular compartment. 
 
4.2.2.5.2 Plasma membrane VGSCα protein level 
Digital quantification of peripheral VGSCα immunoreactivity by „free-form line 
profile‟ analysis of XYZ scans of Mat-LyLu cells, treated (24 h) with riluzole (2.5 
µM), revealed no change in plasma membrane VGSCα level under normoxic 
conditions (IRpm = 155 ± 5 AU/µm and 148 ± 3 AU/µm, respectively; p > 0.05; n ≥ 
63 each; Figures 4.23 and 4.24A&B). However, when Mat-LyLu cells were treated  
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Figure 4.20 Confocal immunocytochemistry study of Mat-LyLu cells incubated with riluzole.  
Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and hypoxic (2 % O2) conditions with or without riluzole (2.5 
µM). Signal from concanavalin A plasma membrane marker (green), pan-VGSC antibody (red) and overlay of both (merged image) are shown in 
addition to bright field image. Scale bar (40 µm) applicable to all panels. 
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Figure 4.21 Typical image showing effect of riluzole on VGSCα protein distribution 
along typical cellular cross-section in Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without riluzole (2.5 µM). White lines indicate typical cross-
section. Scale bar (5µm) applicable to all panels.  
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Figure 4.22 Effect of riluzole on VGSCα protein distribution along typical cellular 
cross-section in Mat-LyLu cells. 
(A) Representative traces showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα immunofluorescence (red) along cross-section from typical cells  
(Figure 4.21) incubated (24 h) in normoxic or hypoxic conditions with or without riluzole 
(2.5 µM). (B) Bar diagram showing distribution of VGSCα protein immunoreactivity along 
subcellular cross-sections as a percentage of total (%). For plasma membrane (PM) 
immunoreactivity, 1.5 µm sections was measured inward from the edge of Con A staining. 
For internal (INT) immunoreactivity, middle 30 % of the cross-section was measured. Data 
were analysed by ANOVA followed by Newman-Keuls post hoc analysis. Data are 
presented as means ± SEM (n = 63). Significance: (X) p > 0.05. 
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Figure 4.23 Typical image showing effect of riluzole on VGSCα protein levels in 
plasma membrane of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without riluzole (2.5 µM). White lines indicate typical freeform 
line guided by Con A staining to measure cell surface protein level. Scale bar (5µm) 
applicable to all panels.  
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Figure 4.24 Effect of riluzole on VGSCα protein levels in plasma membrane of Mat-
LyLu cells. 
(A) Representative trace showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα  (red) immunofluorescence along plasma membrane from typical cells  
(Figure 4.23) incubated (24 h) in normoxic or hypoxic conditions with or without riluzole 
(2.5 µM). Dotted gray lines indicate mean pan-VGSC fluorescence. (B) Bar diagram 
showing level of VGSCα protein immunoreactivity along plasma membrane as an 
immunoreactivity (AU) per µm. Inset: table of multiple comparisons between 
treatments for statistical significance. Data were ANOVA of variance followed by 
Newman-Keuls post hoc analysis. Data are presented as means ± SEM (n = 74).  
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with riluzole (2.5 µM) under hypoxic conditions, plasma membrane level of VGSCα 
protein increased significantly: IRpm = 121 ± 3 AU/µm (hypoxia control) vs 143 ± 4 
AU/µm (hypoxia + riluzole) (p < 0.05; n ≥ 63; Figures 4.23 and 4.24A&B). Hypoxia 
itself, again, reduced VGSCα protein level in plasma membrane: IRpm = 121 ± 3 
AU/µm (normoxia) vs 155 ± 5 AU/µm (hypoxia) (p < 0.05; n ≥ 63 each; Figures 
4.23 and 4.24A&B).  
 
4.2.2.5.3 Internal VGSCα protein level 
Quantification of „internal‟ VGSCα immunoreactivity by „area histogram‟ analysis 
of XYZ scans of Mat-LyLu cells revealed a significant decrease of internal VGSCα 
level (relative to normoxic control) by 9 %, 16 % and 17 % when incubated in (i) 
normoxic condition with riluzole (2.5 µM), (ii) hypoxic control condition and (iii) 
hypoxic condition with riluzole (2.5 µM), respectively (p < 0.05; n ≥ 77 each; 
Figures 4.25 and 4.26A&B). On the other hand, internal VGSCα protein levels of 
cells maintained in hypoxia with or without riluzole (2.5 µM) for 24 h were not 
different  (p > 0.05; n ≥ 77 each; Figures 4.25 and 4.26A&B).   
 
4.2.2.6 Matrigelтм invasion 
Matrigel
тм
 invasion assays were used to study the possible effects of riluzole 
treatment on invasiveness of Mat-LyLu cells maintained in normoxic and hypoxic 
conditions.  Under normaxic conditions, 0.0025 % DMSO (control) and 1 µM and 
2.5 µM riluzole treatments had no significant effect on invaded Mat-LyLu cell 
number (p > 0.05; n ≥ 4 each; Figures 4.27 and 4.28). On the other hand, 5 µM 
riluzole treatment significantly reduced invaded cell number by 50 % when 
compared to the „non-treated control‟ under normoxia (p < 0.05; n ≥ 4; Figures 4.27   
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Figure 4.25 Typical image showing effect of riluzole on internal VGSCα protein levels 
of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without riluzole (2.5 µM). White box indicates typical area 
covering 16 µm
2
 square section of cytoplasm avoiding nucleus to measure internal protein 
level. Scale bar (5µm) applicable to all panels.  
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Figure 4.26 Effect of riluzole on internal VGSCα protein levels of Mat-LyLu cells. 
(A) Representative histograms showing distribution of pixels (0.0625 µm
2
) with signal 
intensity of Con A plasma membrane marker (green) and VGSCα  (red) 
immunofluorescence in cytoplasm from typical cells  (Figure 4.25) incubated (24 h) in 
normoxic or hypoxic conditions with or without riluzole (2.5 µM). Dotted gray lines 
indicate mean pan-VGSC fluorescence. (B) Bar diagram showing internal VGSCα protein 
immunoreactivity (AU). Inset: table of multiple comparisons between treatments for 
statistical significance. Data were analysed by ANOVA followed by Newman-Keuls 
post hoc analysis. Data are presented as means ± SEM (n = 77).  
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Figure 4.27 Typical images of invaded cells showing the effect of riluzole on invasion of 
Mat-LyLu invasiveness. 
Typical phase-contrast light-microscopy images of invaded cells obtained from Matrigel
тм
 
invasion assays of Mat-LyLu cells incubated 24 h under normoxic and hypoxic conditions 
with or without riluzole (1, 2.5 and 5 µM). Invaded cells were fixed and stained with crystal 
violet (purple). Scale bar (200 µm) applicable to all panels. DMSO (0.0025 %). 
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Figure 4.28 Effect of riluzole on invasion of Mat-LyLu cells. 
Histogram showing number of invaded Mat-LyLu cells, incubated 24 h under normoxic and 
hypoxic conditions with or without riluzole (1, 2.5 and 5 µM). Data were expressed relative 
to the control (%) and presented as means ± SEM (n ≥ 4). Data were analysed by Kruskal-
Wallis analysis of variance. The table of multiple comparisons between treatments for 
statistical significance shown underneath. D: DMSO (0.0025 %). 
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and 4.28). However, riluzole (1, 2.5 and 5 µM) had no significant effect on invasion 
when compared to DMSO controls under normoxic conditions (p > 0.05; n ≥ 4; 
Figures 4.27 and 4.28). Treatment of Mat-LyLu cells for 24 h in hypoxic conditions 
with 1 , 2.5  and 5 µM riluzole significantly decreased invaded cell number by 66 %, 
63 % and 66 %, respectively (p < 0.05; n ≥ 4; Figures 4.27 and 4.28). Invaded cell 
number under hypoxia decreased by 41 % by 0.0025 % DMSO treatment; this 
change was not significant (p > 0.05; n ≥ 4 each; Figures 4.27 and 4.28). Riluzole (1, 
2.5 and 5 µM) had no significant effect on invasion when compared to the respective 
DMSO controls under hypoxic conditions (p > 0.05; n ≥ 4 each; Figures 4.27 and 
4.28). Again, hypoxia by itself had no effect on invasiveness. 
 
4.2.2.7 Summary of effects of riluzole 
Under normoxic conditions, riluzole had some inhibitory effect on cell proliferation 
and decreased intracellular VGSCα level and invasiveness. Hypoxia had no effect on 
invasion. DMSO introduced considerable variability in the invasion assays and under 
hypoxia, again, riluzole, had no effect on invasion (Table 4.1).   
 
4.2.3 Effects of procaine 
Procaine is a local anaesthetic that has been used as a non-selectively blocker of 
VGSCs. In the present study, it was used in the concentration range 1 to 1000 µM, 
since this concentration range was shown previously to block VGSC (Bräu et al., 
1998; Vlachová et al., 1999). 
 
4.2.3.1 Some initial observations: Cell morphology 
No change in the basic appearance or distribution of Mat-LyLu cells in culture was 
observed when cultures were treated (24 h) with 100 µM and 500 µM procaine under 
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both normoxic and hypoxic (2 % O2) conditions (Figures 4.29A-C). At the higher 
concentration of 1000 µM, also, procaine treatment in normoxia did not change the 
basic appearance or distribution of the cells. On the other hand, Mat-LyLu cells 
maintained in hypoxic conditions and treated similarly acquired generally to lose 
inter-cellular contacts and appear scattered (Figure 4.29D). Studying the effect of 
procaine treatment on Mat-LyLu cells under  high magnification revealed that 1000 
µM treatment caused loss of spindle-shaped fibroblast like morphology in hypoxic 
but not in normoxic conditions (Figure 4.30D). Thus, procaine treatment (24 h) of up 
to 500 µM had no obvious effect on cell morphology in normoxia or hypoxia (Figure 
4.30A-C).  
 
4.2.3.2 Cell viability 
Procaine treatment (24 h) up to 1000 µM was not toxic to Mat-LyLu cells maintained 
in normoxic or hypoxic conditions (Figure 4.31).  
 
4.2.3.3 Cellular proliferation 
No significant change was recorded in Mat-LyLu cell number after 24 h procaine 
treatment (10, 100, 500, 700 and 1000 µM) in normoxic conditions (p > 0.05; n ≥ 3 
each; Figure 4.32). Hypoxia by itself had no effect, as before, and all concentrations 
of procaine used did not affect Mat-LyLu cell number (24 h) (p > 0.05; n ≥ 3 each; 
Figure 4.32). However, when compared to the normoxic control, 700 and 1000 µM 
procaine in hypoxia appeared to reduce cell numbers by 32 % and 31 %, respectively 
(p < 0.05; n ≥ 3 each; Figure 4.32).  
Because 24 h treatments with 700 µM procaine under hypoxia reduced cell 
number, subsequent experiments were restricted to 1 to 500 µM range, in order not to 
„contaminate‟ any effect on Matrigel invasion. 
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Figure 4.29 Phase-contrast light-photomicrography of Mat-LyLu cells, treated 
with procaine. 
Mat-LyLu cells were grown for 24 h under (A) control conditions, and in (B) 100 
µM procaine, (C) 500 µM procaine, (D) 1000 µM procaine treatment in normoxia 
(left hand pictures) and hypoxia (2 % O2; right hand pictures). Micrographs are 
typical of 3 experiments. 
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Figure 4.30 Phase-contrast light-photomicrography of Mat-LyLu cells, treated 
with procaine, in high magnification.  
Mat-LyLu cells were grown for 24 h under (A) control conditions, and in (B) 100 
µM procaine, (C) 500 µM procaine, (D) 1000 µM procaine treatment in normoxia 
(left hand pictures) and hypoxia (2 % O2; right hand pictures). Micrographs are 
typical of 3 experiments. 
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Figure 4.31 Bar diagram showing procaine treatments had no toxic effect.  
A possible effect of 100, 500 and 1000 µM procaine on Mat-LyLu cell viability 
under normoxia (light grey columns) or hypoxia (2 % O2; dark grey columns). Data 
are represented as means ± SEM (n = 3). 
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Figure 4.32 Dose dependent effect of procaine on Mat-LyLu cell number. 
Bar diagram showing the effect of 10, 100, 500 and 700 µM procaine on cell 
number of normoxic (light grey columns) or hypoxic (dark grey columns) Mat-
LyLu cells. Data are presented as means ± SEM (n ≥ 3). Data were analysed by 
ANOVA followed by Newman-Keuls post hoc analysis. Table of multiple 
comparisons between different treatments for statistical significance are shown 
underneath the bar diagram. 
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4.2.3.4 Nav1.7 mRNA expression 
Mat-LyLu cells were treated for 24 h with 1, 10, 100 and 500 µM procaine under 
normoxic or hypoxic conditions, and cDNAs were prepared for real-time PCR 
analyses. Agarose gel electrophoresis confirmed specific single bands at the expected 
sizes for Nav1.7 and Cytb5R (414 nt and 425 nt, respectively; n = 3 each; Figure 
4.33A). The “no-template control” did not give any signal (n = 3 each; Figure 
4.33A). There was a dose dependent effect of procaine on Nav1.7 mRNA expression 
in normoxia. For 1, 100 or 500 µM procaine, there was no change in Nav1.7 mRNA 
expression in Mat-LyLu cells treated in normoxia for 24 h (p > 0.05; n = 3 each; 
Figure 4.33B). On the other hand, 10 µM procaine significantly decreased Nav1.7 
mRNA by 35 % under normoxic conditions (p < 0.05; n ≥ 3; Figure 4.33B). Hypoxia 
itself significantly increased Nav1.7 mRNA expression. On the other hand, in 
hypoxia, 24 h treatment with procaine (up to 500 µM) had no effect on the Nav1.7 
mRNA level (p > 0.05; n ≥ 3 each; Figure 4.33B). 
 
4.2.3.5 Subcellular VGSCα protein expression 
4.2.3.5.1 Relative distribution 
Confocal immunocytochemistry and digital imaging of Mat-LyLu cells stained with 
the pan-VGSC antibody was used to test the possible effect of procaine (100 µM) on 
subcellular distribution of VGSCα protein under normoxic or hypoxic (2 % O2) 
conditions (Figure 4.34). The subcellular distribution of the VGSCα protein was 
studied by „straight line cross-sectional profile‟ analysis (Figure 4.35). The relative 
plasma membrane VGSCα protein levels were as follows: 9.7 ± 0.4 % (normoxia 
control), 10.6 ± 0.4 % (normoxia + procaine), 9.5 ± 0.5 % (hypoxia control), 9.0 ± 
0.5 % (hypoxia + procaine). The corresponding internal VGSCα protein levels were
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Figure 4.33 Effect of procaine on Mat-LyLu Nav1.7 mRNA expression. 
(A) Typical PCR products of Nav1.7 (414 bp) and normalising/control gene Cytb5R 
(425 bp) mRNA in Mat-LyLu cells that was incubated with 1, 10, 100 and 500 µM 
procaine under normoxic or hypoxic (2 % O2) conditions for 24 h. (B) Bar diagram 
showing the result of real-time PCR experiment in which the effect of procaine on 
Nav1.7 mRNA expression was studied under normoxic (light grey column) or 
hypoxic (dark grey column) conditions. The data were normalized to Cytb5R using 
the 2
-ΔΔCт
 method and expressed relative to normoxic control Nav1.7 level. The table 
of multiple comparisons between different treatments for statistical significance are 
shown underneath the bar diagram. Kruskal-Wallis method was used for statistic 
analysis. Data are presented as means ± SEM (n = 3). (-): no template control. 
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Figure 4.34 Confocal immunocytochemistry study of Mat-LyLu cells incubated with procaine.  
Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and hypoxic (2 % O2) conditions with or without procaine (100 
µM). Signal from concanavalin A plasma membrane marker (green), pan-VGSC antibody (red) and overlay of both (merged image) are shown in 
addition to bright field image. Scale bar (40 µm) applicable to all panels. 
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Figure 4.35 Typical image showing effect of procaine on VGSCα protein distribution 
along typical cellular cross-section in Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without procaine (100 µM). White lines indicate typical cross-
section. Scale bar (5µm) applicable to all panels.  
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as follows: 35.2 ± 0.5 % (normoxia control), 35.0 ± 0.4 % (normoxia + procaine), 
35.6 ± 0.5 % (hypoxia) and 35.7 ± 0.5 % (hypoxia + procaine). This analysis 
revealed that the relative levels of plasma membrane and intracellular VGSCα 
protein were not affected by 24 h procaine (100 µM) treatment in both normoxic and 
hypoxic conditions (for both: p > 0.05; n ≥ 63; Figure 4.36A&B).  
 
4.2.3.5.2 Plasma membrane VGSCα protein level 
Digital quantification of VGSCα peripheral immunostaining by „free-form line 
profile‟ analysis of XYZ scans of Mat-LyLu cells, treated (24 h) with procaine (100 
µM), revealed a significantly lower level of plasma membrane VGSCα level under 
normoxic conditions: IRpm = 155 ± 5 AU/µm vs 129 ± 4 AU/µm (p < 0.05; n ≥ 74 
each; Figures 4.37 and 4.38A&B).  Hypoxia by itself significantly reduced the 
plasma membrane VGSCα level. On the other hand, 100 µM procaine treatment for 
24 h in hypoxia had no effect (p > 0.05; n ≥ 74 each; Figures 4.37 and 4.38A&B). 
 
4.2.3.5.3 Internal VGSCα protein level 
Digital quantification of intracellular VGSCα immunoreactivity by „area histogram‟ 
analysis of XYZ scans of Mat-LyLu cells revealed a significant decreases in IRint by 
19 %, 16 % and 24 % when the cells were incubated in (i) normoxic condition with 
procaine (100 µM), (ii) hypoxic control condition and (iii) hypoxia with procaine 
(100 µM), respectively (p < 0.05; n ≥ 77 each; Figures 4.39 and 4.40A&B). On the 
other hand, the internal VGSCα protein level of Mat-LyLu cells maintained in 
hypoxia with or without procaine (100 µM) treatment (24 h) remained unchanged (p 
> 0.05; n ≥ 77 each; Figures 4.39 and 4.40A&B).   
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Figure 4.36 Effect of procaine on VGSCα protein distribution along typical cellular 
cross-section in Mat-LyLu cells. 
(A) Representative traces showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα immunofluorescence (red) along cross-section from typical cells  
(Figure 4.35) incubated (24 h) in normoxic or hypoxic conditions with or without procaine 
(100 µM). (B) Bar diagram showing distribution of VGSCα protein immunoreactivity along 
subcellular cross-sections as a percentage of total (%). For plasma membrane (PM) 
immunoreactivity, 1.5 µm sections was measured inward from the edge of Con A staining. 
For internal (INT) immunoreactivity, middle 30 % of the cross-section was measured. Data 
were analysed by ANOVA followed by Newman-Keuls post hoc analysis. Data are 
presented as means ± SEM (n = 63). Significance: (X) p > 0.05. 
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Figure 4.37 Typical image showing effect of procaine on VGSCα protein levels in 
plasma membrane of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without procaine (100 µM). White lines indicate typical freeform 
line guided by Con A staining to measure cell surface protein level. Scale bar (5µm) 
applicable to all panels.  
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Figure 4.38 Effect of procaine on VGSCα protein levels in plasma membrane of Mat-
LyLu cells. 
(A) Representative trace showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα  (red) immunofluorescence along plasma membrane from typical cells  
(Figure 4.37) incubated (24 h) in normoxic or hypoxic conditions with or without procaine 
(100 µM). Dotted gray lines indicate mean pan-VGSC fluorescence. (B) Bar diagram 
showing level of VGSCα protein immunoreactivity along plasma membrane as 
immunoreactivity (AU) per µm. Inset: table of multiple comparisons between 
treatments for statistical significance. Data were analysed by ANOVA followed by 
Newman-Keuls post hoc analysis. Data are presented as means ± SEM (n = 74).  
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Figure 4.39 Typical image showing effect of procaine on internal VGSCα protein levels 
of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without procaine (100 µM). White box indicates typical area 
covering 16 µm
2
 square section of cytoplasm avoiding nucleus to measure internal protein 
level. Scale bar (5µm) applicable to all panels.  
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Figure 4.40 Effect of procaine on internal VGSCα protein levels of Mat-LyLu cells. 
(A) Representative histograms showing distribution of pixels (0.0625 µm
2
) with signal 
intensity of Con A plasma membrane marker (green) and VGSCα  (red) 
immunofluorescence in cytoplasm from typical cells  (Figure 4.39) incubated (24 h) in 
normoxic or hypoxic conditions with or without procaine (100 µM). Dotted gray lines 
indicate mean pan-VGSC fluorescence. (B) Bar diagram showing internal VGSCα protein 
immunoreactivity (AU). Inset: table of multiple comparisons between treatments for 
statistical significance. Data were analysed by ANOVA followed by Newman-Keuls 
post hoc analysis. Data are presented as means ± SEM (n = 77).  
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4.2.3.6 Matrigelтм invasion 
Matrigel
тм
 invasion assay was used to study effect of procaine treatment on the 
invasivenss of Mat-LyLu cells maintained in normoxic and hypoxic conditions. 
Treatment of 1, 10  and 100 µM procaine under normoxic conditions significantly 
decreased invaded cell number by 50 %, 57 %, 61 %, respectively (p < 0.05; n ≥ 4 
each; Figures 4.41 and 4.42). Hypoxia by itself had no effect. However, similar to 
normoxia, 24 h treatment of Mat-LyLu cells under hypoxia with 1, 10 and 100 µM 
procaine significantly decreased invaded cell number by 64 %, 69 %, 81 %, 
respectively (p < 0.05 each; n ≥ 4; Figures 4.41 and 4.42). There was no difference in 
the effects of given concentrations of procaine in normoxia vs hypoxia (Figure 4.42 
inset). 
 
4.2.3.7 Summary of effects of procaine 
Under normoxic (but not hypoxic) conditions, procaine inhibited Nav1.7 mRNA and 
protein expression in plasma membrane and cytoplasm. Invasion was inhibited by 
procaine under both normoxic and hypoxic conditions. Hypoxia itself had no effect 
on invasiveness (Table 4.1).  
 
4.2.4 Effects of lidocaine 
Lidocaine is another local anaesthetic that has been used extensively as a non-
selectively blocker of VGSCs. In the present study, it was used in the concentration 
range 1 to 1000 µM, since this concentration range was shown to block INaP more 
effectively than INaT (Bräu et al., 1998; Rajamani et al., 2008; Fraser et al., 2005; 
Hammarström and Gage, 1998). 
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Figure 4.41 Typical images of invaded cells showing the effect of procaine on invasion 
of Mat-LyLu invasiveness. 
Typical phase-contrast light-microscopy images of invaded cells obtained from Matrigel
тм
 
invasion assays of Mat-LyLu cells incubated 24 h under normoxic and hypoxic conditions 
with or without procaine (1, 10 and 100 µM). Invaded cells were fixed and stained with 
crystal violet (purple). Scale bar (200 µm) applicable to all panels.  
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Figure 4.42 Effect of procaine on invasion of Mat-LyLu cells. 
Bar diagram showing number of invaded Mat-LyLu cells incubated 24 h under normoxic 
and hypoxic conditions with or without procaine (1, 10 and 100 µM). Data were expressed 
relative to the control (%) and presented as means ± SEM (n ≥ 4). Data were analysed by 
Kruskal-Wallis analysis of variance. The table of multiple comparisons between 
treatments for statistical significance are shown underneath the bar diagram. 
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4.2.4.1 Some initial observations: Cell morphology 
No change in the basic appearance or distribution of Mat-LyLu cells was observed 
when the cultures were treated (24 h) with up to 500 µM lidocaine under both 
normoxic and hypoxic (2 % O2) conditions (Figures 4.43A-C). On the other hand, 
after 1000 µM lidocaine treatment, Mat-LyLu cells, maintained in normoxic or 
hypoxic conditions, appeared generally to „lose‟ cell contacts and become scattered 
(Figure 4.43D). Studying effect of lidocaine treatment on Mat-LyLu cells in high 
magnification revealed that 1000 µM treatment caused loss of spindle-shaped 
fibroblast like morphology in both normoxic and hypoxic conditions (Figure 4.44D). 
Examination under higher magnification still revealed no obvious effect on cell 
morphology by the lower doses of lidocaine (100 and 500 µM) (Figures 4.44A-C). 
 
4.2.4.2 Cell viability 
Treatment (24 h) with lidocaine at concentrations up to 1000 µM was not toxic to 
Mat-LyLu cells maintained in normoxic or hypoxic conditions (Figure 4.45).  
 
4.2.4.3 Cellular proliferation 
No significant change was recorded in Mat-LyLu cell number after 24 h lidocaine 
treatment (10, 100, 500, 700 and 1000 µM) in normoxic conditions (p > 0.05; n ≥ 3 
each; Figure 4.46). Similarly, Mat-LyLu cell number was not affected by 10, 100 and 
500 µM lidocaine treatment (24 h) in hypoxia (p > 0.05; n ≥ 3 each; Figure 4.46). On 
the other hand, under hypoxia, 700 and 1000 µM lidocaine treatment (24 h) 
significantly decreased Mat-LyLu cell number by 37 and 35 %, respectively, when  
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Figure 4.43 Phase-contrast light-photomicrography of Mat-LyLu cells treated 
with lidocaine. 
Mat-LyLu cells were grown for 24 h  under (A) control conditions, and in (B) 100 
µM lidocaine, (C) 500 µM lidocaine, (D) 1000 µM lidocaine treatment in normoxia 
(left hand pictures) and hypoxia (2 % O2; right hand pictures). Micrographs are 
typical of 3 experiments. 
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Figure 4.44 Phase-contrast light-photomicrography of Mat-LyLu cells, treated 
with lidocaine, in high magnification.  
Mat-LyLu cells were grown for 24 h  under (A) control conditions, and in (B) 100 
µM lidocaine, (C) 500 µM lidocaine, (D) 1000 µM lidocaine treatment in normoxia 
(left hand pictures) and hypoxia (2 % O2; right hand pictures). Micrographs are 
typical of 3 experiments. 
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Figure 4.45 Bar diagram showing lidocaine treatments had no toxic effect.  
A possible effect of 100, 500 and 1000 µM lidocaine on Mat-LyLu cell viability 
under normoxia (light grey columns) or hypoxia (2 % O2; dark grey columns). Data 
are represented as means ± SEM (n = 3). 
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Figure 4.46 Dose dependent effect of lidocaine on Mat-LyLu cell number. 
Bar diagram showing the effect of 10, 100, 500 and 700 µM lidocaine on cell 
number of normoxic (light grey columns) or hypoxic (dark grey columns) Mat-
LyLu cells. Data are presented as means ± SEM (n ≥ 3). Data were analysed by 
ANOVA followed by Newman-Keuls post hoc analysis. Table of multiple 
comparisons between different treatments for statistical significance are shown 
underneath the bar diagram. 
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compared to the corresponding hypoxic control (p < 0.05; n ≥ 3 each; Figure 4.46). 
Hypoxia by itself had no effect. 
Because 24 h treatments with 700 µM lidocaine under hypoxia reduced cell 
number, subsequent experiments were restricted to 1 to 500 µM range, in order not to 
„contaminate‟ any effect on Matrigel invasion. 
 
4.2.4.4 Nav1.7 mRNA expression 
Mat-LyLu cells were treated for 24 h with 1, 10, 100 and 500 µM lidocaine under 
normoxic or hypoxic conditions and cDNAs were prepared for realtime PCR 
analyses. Agarose gel electrophoresis confirmed specific single bands at the expected 
sizes for Nav1.7 and Cytb5R (414 nt and 425 nt, respectively; n = 3 each; Figure 
4.47A). The “no-template control” did not give any signal (n = 3 each; Figure 
4.47A). Lidocaine treatment (24 h) had a dose-dependent, biphasic effect on Nav1.7 
mRNA expression. No significant change was recorded for 1, 100 and 500 µM 
lidocaine under both normoxic and hypoxic conditions (p > 0.05; n = 3 each; Figure 
4.47B). On the other hand, 10 µM lidocaine significantly decreased Nav1.7 mRNA 
under both conditions, by 36 % (compared to normoxic control) and 30 % (compared 
to hypoxic control) (p < 0.05; n ≥ 3 each; Figure 4.47B). Hypoxia by itself increased 
Nav1.7 mRNA, as before. 
 
4.2.4.5 Subcellular VGSCα protein expression 
 
4.2.4.5.1 Relative distribution 
Digital confocal analyses of the immunostaining obtained with the pan-VGSC 
antibody was used to test the possible effect of lidocaine (100 µM) on the subcellular 
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Figure 4.47 Effect of lidocaine on Mat-LyLu Nav1.7 mRNA expression. 
(A) Typical PCR products of Nav1.7 (414 bp) and normalising/control gene Cytb5R 
(425 bp) mRNA in Mat-LyLu cells that was incubated with 1, 10, 100 and 500 µM 
lidocaine under normoxic or hypoxic (2 % O2) conditions for 24 h. (B) Bar diagram 
showing the result of real-time PCR experiment in which the effect of lidocaine on 
Nav1.7 mRNA expression was studied under normoxic (light grey column) or 
hypoxic (dark grey column) conditions. The data were normalized to Cytb5R using 
the 2
-ΔΔCт
 method and expressed relative to normoxic control Nav1.7 level. The table 
of multiple comparisons between different treatments for statistical significance are 
shown underneath the bar diagram. Kruskal-Wallis method was used for statistic 
analysis. Data are presented as means ± SEM (n = 3). (-): no template control. 
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distribution of VGSCα protein in Mat-LyLu cells under normoxic or hypoxic (2 % 
O2) conditions (Figure 4.48). The subcellular distribution of the VGSCα protein was 
studied by „straight line cross-sectional profile‟ analysis (Figure 4.49). The relative 
plasma membrane VGSCα protein levels were as follows: 9.7 ± 0.4 % (normoxia 
control), 10.1 ± 0.5 % (normoxia + lidocaine),  = 9.5 ± 0.5 % (hypoxic control) and  
9.9 ± 0.4 % (hypoxia + lidocaine); the corresponding internal VGSCα protein levels 
were as follows: 35.2 ± 0.5 % (normoxia control),  =34.0 ± 0.5 % (normoxia + 
lidocaine),  35.6 ± 0.5 % (hypoxic control) and 35.2 ± 0.5 % (hypoxia + lidocaine) 
(for all: p > 0.05; n ≥ 63; Figure 4.50A&B). Thus, this method revealed that the 
relative level of plasma membrane and intracellular VGSCα protein was not affected 
by 24 h lidocaine (100 µM) treatment under both normoxic and hypoxic conditions. 
 
4.2.4.5.2 Plasma membrane VGSCα protein level 
Digital quantification of the VGSCα immunoreactivity protein level by „free-form 
line profile‟ analysis of XYZ scans of Mat-LyLu cells, treated (24 h) with lidocaine 
(100 µM), revealed a significant decrease of plasma membrane VGSCα protein 
level: IRpm = 155 ± 5 AU/µm (normoxic control) vs  129 ± 4 AU/µm (normoxic 
lidocaine) (p < 0.05; n ≥ 74 each; Figures 4.51 and 4.52A&B). On the other hand, 
100 µM lidocaine treatment for 24 h did not change plasma membrane VGSCα 
protein level when the Mat-LyLu cells were maintained in hypoxia (p > 0.05; n ≥ 74; 
Figures 4.51 and 4.52A&B). 
 
4.2.4.5.3 Internal VGSCα protein level 
Digital quantification of the intracellular VGSCα immunoreactivity by „area 
histogram‟ analysis of XYZ scans of Mat-LyLu cells revealed a significant decreases 
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Figure 4.48 Confocal immunocytochemistry study of Mat-LyLu cells incubated with lidocaine.  
Typical XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and hypoxic (2 % O2) conditions with or without lidocaine (100 
µM). Signal from concanavalin A plasma membrane marker (green), pan-VGSC antibody (red) and overlay of both (merged image) are shown in 
addition to bright field image. Scale bar (40 µm) applicable to all panels. 
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Figure 4.49 Typical image showing effect of lidocaine on VGSCα protein distribution 
along typical cellular cross-section in Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without lidocaine (100 µM). White lines indicate typical cross-
section. Scale bar (5µm) applicable to all panels.  
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Figure 4.50 Effect of lidocaine on VGSCα protein distribution along typical cellular 
cross-section in Mat-LyLu cells. 
(A) Representative traces showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα immunofluorescence (red) along cross-section from typical cells  
(Figure 4.49) incubated (24 h) in normoxic or hypoxic conditions with or without lidocaine 
(100 µM). (B) Bar diagram showing distribution of VGSCα protein immunoreactivity along 
subcellular cross-sections as a percentage of total (%). For plasma membrane (PM) 
immunoreactivity, 1.5 µm sections was measured inward from the edge of Con A staining. 
For internal (INT) immunoreactivity, middle 30 % of the cross-section was measured. Data 
were analysed by ANOVA followed by Newman-Keuls post hoc analysis. Data are 
presented as means ± SEM (n = 63). Significance: (X) p > 0.05. 
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Figure 4.51 Typical image showing effect of lidocaine on VGSCα protein levels in 
plasma membrane of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without lidocaine (100 µM). White lines indicate typical 
freeform line guided by Con A staining to measure cell surface protein level. Scale bar 
(5µm) applicable to all panels.  
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Figure 4.52 Effect of lidocaine on VGSCα protein levels in plasma membrane of Mat-
LyLu cells. 
(A) Representative trace showing signal intensity of Con A plasma membrane marker 
(green) and VGSCα  (red) immunofluorescence along plasma membrane from typical cells  
(Figure 4.51) incubated (24 h) in normoxic or hypoxic conditions with or without lidocaine 
(100 µM). Dotted gray lines indicate mean pan-VGSC fluorescence. (B) Bar diagram 
showing level of VGSCα protein immunoreactivity along plasma membrane as 
immunoreactivity (AU) per µm. Inset: table of multiple comparisons between 
treatments for statistical significance. Data were analysed by ANOVA followed by 
Newman-Keuls post hoc analysis. Data are presented as means ± SEM (n = 74).  
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of internal VGSCα protein level by 17 %, 16 % and 27 % when the cells were 
incubated in (i) normoxic condition with lidocaine (100 µM), (ii) hypoxic control 
condition and (iii) hypoxic condition with lidocaine (100 µM), respectively ( for all: 
p < 0.05; n ≥77 each; Figures 4.53 and 4.54A&B)  
 
4.2.4.6 Matrigelтм invasion 
Matrigel
тм
 invasion assays were used to study possible effects of lidocaine treatment 
on the invasiveness of Mat-LyLu cells maintained in normoxic or hypoxic 
conditions. There was some variability in the data obtained. Under normaxic 
conditions, although 1 µM lidocaine decreased the invaded cell number by 45 %, this 
change was not statistically significant (p > 0.05; n ≥ 4 each; Figures 4.55 and 4.56). 
Treatment of 10 µM and 100 µM lidocaine significantly decreased invaded cell 
numbers by 46 % and 76 %, respectively, under normoxic conditions (p < 0.05; n ≥ 
4; Figures 4.55 and 4.56). Similarly, 24 h treatment of Mat-LyLu cells in hypoxic 
conditions with 1 , 10  and 100 µM procaine significantly decreased invaded cell 
number by 69 %, 74 % and 58 %, respectively (p < 0.05; n ≥ 4 for all; Figures 4.55 
and 4.56). Hypoxia by itself was not effective, as in all other assay sets. 
 
4.3 Discussion 
 
The main findings of this study on Mat-LyLu cells are as follows (Table 4.1):  
1) Hypoxia, highly consistently, had no effect on cellular morphology, 
viability, proliferation or invasion. However, it increased Nav1.7 mRNA 
expression whilst decreasing VGSCα protein levels in plasma membrane 
and cytoplasm. 
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Figure 4.53 Typical image showing effect of lidocaine on internal VGSCα protein levels 
of Mat-LyLu cells. 
Representative XYZ confocal images of Mat-LyLu cells incubated 24 h under normoxic and 
hypoxic conditions with or without lidocaine (100 µM). White box indicates typical area 
covering 16 µm
2
 square section of cytoplasm avoiding nucleus to measure internal protein 
level. Scale bar (5µm) applicable to all panels.  
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Figure 4.54 Effect of lidocaine on internal VGSCα protein levels of Mat-LyLu cells. 
(A) Representative histograms showing distribution of pixels (0.0625 µm
2
) with signal 
intensity of Con A plasma membrane marker (green) and VGSCα  (red) 
immunofluorescence in cytoplasm from typical cells  (Figure 4.53) incubated (24 h) in 
normoxic or hypoxic conditions with or without lidocaine (100 µM). Dotted gray lines 
indicate mean pan-VGSC fluorescence. (B) Bar diagram showing internal VGSCα protein 
immunoreactivity (AU). Inset: table of multiple comparisons between treatments for 
statistical significance. Data were analysed by ANOVA followed by Newman-Keuls 
post hoc analysis. Data are presented as means ± SEM (n = 77).  
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Figure 4.55 Typical images of invaded cells showing the effect of lidocaine on Mat-
LyLu invasiveness. 
Typical phase-contrast light-microscopy images of invaded cells obtained from Matrigel
тм
 
invasion assays of Mat-LyLu cells incubated 24 h under normoxic and hypoxic conditions 
with or without lidocaine (1, 10 and 100 µM). Invaded cells were fixed and stained with 
crystal violet (purple). Scale bar (200 µm) applicable to all panels.  
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Figure 4.56 Effect of lidocaine on invasion of Mat-LyLu cells. 
Bar diagram showing number of invaded Mat-LyLu cells, incubated 24 h under normoxic 
and hypoxic conditions with or without lidocaine (1, 10 and 100 µM). Data were expressed 
relative to the control (%) and presented as means ± SEM (n ≥ 4). Data were analysed by 
Kruskal-Wallis analysis of variance. The table of multiple comparisons between 
treatments for statistical significance are shown underneath the bar diagram. 
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2) Ranolazine treatment (20-300 µM; 24 h) had no effect on cellular 
viability or proliferation under both normoxic and hypoxic conditions. 
Nav1.7 mRNA expression was reduced in both conditions. There was no 
effect on plasma membrane VGSCα protein levels in both conditions, 
whilst internal VGSCα protein expression was reduced under normoxia. 
Importantly, ranolazine decreased invasiveness under both conditions 
with some dose dependency. 
3) Riluzole treatment (1-5 µM; 24 h) had no effect on cellular morphology 
and viability; however, there was a tendency for reduction of cell number 
at high concentration (30 µM).  Use of DMSO as a solvent introduced 
considerable variability in the data. There was some reduction of Nav1.7 
mRNA and intracellular VGSC protein expression in normoxia. On the 
other hand, plasma membrane VGSCα protein level increased under 
hypoxia. Although there was a consistent trend in suppression of 
invasiveness by riluzole at concentrations that did not affect proliferation, 
the changes were not significant when compared to DMSO controls. 
4) Procaine treatment (10-1000 µM; 24 h) slightly altered Mat-LyLu cell 
morphology under hypoxia; cell viability and numbers were not affected 
in both normoxia and hypoxia. Procaine decreased Nav1.7 mRNA 
expression and both internal and plasma membrane VGSCα protein levels 
were reduced by procaine under normoxic conditions; there was no effect 
on protein expression or distribution under hypoxia. Procaine decreased 
Mat-LyLu cell invasion both under normoxic and hypoxic conditions. 
5)  Lidocaine treatment (10 - 1000 µM; 24 h) had no effect on cell viability 
or cell numbers in normoxia; high doses had an inhibitory effect under 
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hypoxia. There was some reduction in Nav1.7 mRNA and VGSCα 
protein expression by lidocaine in both normoxic and hypoxic conditions, 
but, in hypoxia, only cytoplasmic protein level was reduced by lidocaine. 
Lidocaine (10 and 100 µM) decreased Mat-LyLu cell invasion under both 
normoxic and hypoxic conditions. 
 
4.3.1 Effects of hypoxia alone 
The effects of hypoxia alone were highly consistent: Thus, no effect was seen 
cellular morphology, viability or cell number. Interestingly, Nav1.7 mRNA 
expression was increased whilst both cytoplasmic and plasma membrane VGSCα 
protein levels were decreased. There was no effect on invasiveness. 
 
4.3.2 Observations on cell morphology 
None of the four pharmacological treatments had an obvious effect on the 
morphologies or distribution of Mat-LyLu cells. This was somewhat surprising since 
VGSC blockers have previously been shown to induce changes in morphologies of 
cells, including neurones (Wilkemeyer and Angelides, 1996; Sretavan et al., 1988) 
and Mat-LyLu cells (Fraser et al., 1999). These changes have generally been in the 
direction of making the cellular architecture appear less developed, e.g. retracted 
dendrites in the case of neurones (Friedman and Shatz, 1990). It is not clear why the 
observations of Fraser et al. (1999) could not be replicated here. Possible reasons for 
this include lack of fixing and staining of the cells, in the present study, which could 
have precluded some changes being clearly observed. However, some effects 
(loosening of cell contacts and lost of spindle-shaped / fibroblast-like morphology) 
were observed with the following treatments: i) 300 µM ranolazine (normoxia and 
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hypoxia). This could be due to inhibition of sodium - calcium exchanger activity 
(Antzelevitch et al., 2004). (ii) 1000 µM procaine and lidocaine (normoxia and 
hypoxia). This could be due to changes in the physicochemical properties (e.g. 
membrane fluidity) of lipid membranes. Such effects of 7 mM procaine and 1000 
µM lidocaine were demonstrated on 1,2-dipalmitoylphosphatidylcholine membrane 
by Tsuchiya et al. (2007). 
 
4.3.3 Effects on cell number 
Here, the term “cell number” rather than “proliferation” has been used since it was 
not possible to study systematically possible effects on apoptosis. Nevertheless, since 
the working concentrations of the agents used did not affect cell viability (as 
determined by trypan blue staining), it can be assumed that the measurements made 
represent mainly proliferative activity. At the lower end of the concentration ranges 
of all 4 pharmacological agents used, there was no effect on cell number. Assuming 
that these low concentrations would affect/block mainly VGSC activity, the results 
agree with the established notion that VGSCs are not involved in cellular 
proliferation of cancer cells (Nakajima et al., 2009; Fulgenzi et al., 2006; Fraser et 
al., 1999, 2000, 2005). On the other hand, it was previously reported that 250 and 
500 µM ranolazine decreased leukemia cell proliferation via inhibition of fatty acid 
oxidation (Samudio et al., 2010). Riluzole (3-10 µM) had no effect on proliferation 
of Mat-LyLu cells under both normoxic and hypoxic conditions. 30 µM riluzole 
decreased the Mat-LyLu cell number under both conditions. This decrease in Mat-
LyLu cell number is not because of INaP block since riluzole concentration used was 
much higher than IC50 of INaP (IC50=2 µM). It was also suggested that 25 µM riluzole 
treatment inhibits proliferation of melanoma cells via inhibition of glutamate release 
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(Le et al., 2010).  In addition, it was documented that riluzole (10-50 µM) decrease 
viable LNCaP and C4-2 prostate cancer cell number by inhibition of DNA synthesis 
and apoptotic cell death via ER stress (Akamatsu et al., 2009). Therefore, following 
experiments were carried out at riluzole concentrations between 1 and 5 µM. 
 
4.3.4 mRNA versus protein expression 
It was clear from the results (and as summarised in Table 1) that the various 
treatments had differential effects on Nav1.7 and VGSCα protein expression in Mat-
LyLu cells. In fact, it can be assumed that the VGSCα studied represented mainly 
Nav1.7 protein in these cells, since this is the main VGSC species expressed in rat 
(and human) PCa cells (Diss et al., 2001,, 2005; Nakajima et al., 2009). It is now 
generally accepted that mRNA and protein expression can be regulated differentially 
and independently in cells, such that (i) mRNA can be produced and „docked‟ 
without being translated and (ii) protein synthesis can occur from such stored mRNA 
without any transcription (Sola et al., 1999; Ropponen et al., 2001; Orphanides and 
Reinberg, 2002; Schedel et al., 2004; Gu et al., 2006; Martin and Zukin, 2006; 
Pfeiffer and Huber, 2006). Such differential regulation presumably is functionally 
expedient and depends on intracellular factors such as mRNA stability and protein 
lifetime (Brackenbury et al., 2007; Brackenbury and Djamgoz, 2006; Ben Fredj et 
al., 2004; St Johnston, 2005). This could be particulary important 
pathophysiologically in cancer cells exposed dynamically to a wide variety of micro-
environmental conditions. Previously also, Brackenbury and Djamgoz (2006) 
showed in Mat-LyLu cells that nerve growth factor upregulated VGSC protein 
expression without any change in Nav1.7 mRNA expression.  
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In the following, we discuss further the effects of the pharmacological agent 
used, one by one, on VGSC expression and cellular invasiveness. 
  
4.3.5 Effects of ranolazine 
Ranolazine, (±)-4-[2-hydroxy-3-(ο-methoxyphenoxy)propyl]-l-piperazineaceto-2',6'-
xylidide, is a antianginal drug that does not affect heart rate or blood pressure (Maier, 
2009). It is commercially available under the brand name of “Ranexa” and clinical 
usage was approved in the United States and European Union (Maier, 2009). Its main 
mode of action is thought to be blockage of persistent (late) Na
+
 current (INaP) of 
VGSCs (Antzelevitch et al., 2004; Fredj et al., 2006). Therapeutic plasma 
concentrations during treatment of patients with ischemic heart disease have been 
estimated to be in the range 2-8 µM (Rajamani et al., 2008). Depending on 
concentration, ranolazine can block both INaP and INaT but lower, clinical doses 
preferentially block INaP (Chen et al., 2009; Wang et al., 2008; Antzelevitch et al., 
2004; Fredj et al., 2006). It was shown earlier that ranolazine thus blocks INaP of 
mouse myocytes and HEK-293 cells expressing long-QT syndrome 3 mutant VGSC 
with a half-maximum inhibitory concentration (IC50) of ~15 µM (Fredj et al., 2006). 
In the same study, the value of IC50 for block of INaT with ranolazine was 135 µM 
(Fredj et al., 2006). In addition, Antzelevitch et al. (2004) found that ranolazine 
blocked INaP more effective than INaT of isolated canine ventricular myocytes (IC50s = 
5.9 and 296 µM, respectively). A similar effect of ranolazine was observed on human 
embryonic kidney 293T cells expressing inactivation-deficient rat Nav1.4, the values 
of IC50s being 2.4 µM (INaP) and 225.4 µM (INaT) (Wang et al., 2008). Block of Na
+
 
current by ranolazine was also documented for human Nav1.7 and rat Nav1.8 
channels (Rajamani et al., 2008; Wang et al., 2008). Rajamani et al. (2008) also 
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documented that ranolazine blocked Na
+
 current with IC50 value of 10.3 µM, when 
Nav1.7 was co-expressed with VGSCβ1 subunit in human embryonic kidney 293 
cells. Various site-directed mutagenesis studies showed that ranolazine blocks 
VGSCs by binding to a conserved local anaesthetic site (D1/D3/D4:S6) on the inside 
of the membrane (Wang et al., 2008; Fredj et al., 2006). In addition to VGSC 
currents, however, ranolazine found to block the following ionic mechanisms: human 
Kv11.1 / human ether-a-go-go related gene, hERG (IC50=11.5 µM), sodium-calcium 
exchanger (IC50=91 µM), peak and late L-type voltage-gated Ca
+
 channel (VGCC) 
currents (IC50 = 50 and 296 µM, respectively) in canine myocytes (Antzelevitch et 
al., 2004). Kv11.1 was shown to be expressed in various cancer cell lines (Bianchi et 
al., 1998; Wang et al., 2002). However, there is no evidence of Kv11.1 expression in 
prostate cancer. Also, Ding et al. (2006) showed absence of VGCCs in Mat-LyLu 
cells. Initially, it was proposed that the antianginal effect of ranolazine occurred via 
inhibition of fatty acid oxidation (McCormack et al., 1996; Clarke et al., 1996). 
However, subsequently, it has been shown that ranolazine at therapeutical doses does 
not inhibit fatty acid oxidation (Hale et al., 2008). Therefore, we can assume that the 
primary effect of ranolazine seen in this study is via blockage of VGSC. 
As already noted, the predominant VGSC functionally expressed in rat and 
human prostate cancer cells, Nav1.7, was reported to increase the metastatic potential 
(Diss et al., 2001; Grimes et al., 1995; Nakajima et al., 2009).  Brackenbury and 
Djamgoz (2006) proposed that Nav1.7 mRNA is up-regulated at steady-state via 
positive feedback in Mat-LyLu cells. It was reported that blockage of VGSC activity 
with TTX reduced Nav1.7 mRNA expression in Mat-LyLu cells (Brackenbury and 
Djamgoz, 2006). Similarly, Mat-LyLu cell Nav1.7 mRNA expression decreased by 
24 h ranolazine treatment (20-300 µM) under both hypoxic and normoxic conditions. 
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This indicates involvement of ranolazine on Nav1.7 mRNA regulation via inhibition 
of VGSC activity. Although ranolazine (50 µM) had no effect on plasma membrane 
VGSCα protein level, invasiveness was reduced significantly.  
Previously, involvement of VGSC activity on invasive capacity of prostate 
cancer cells was studied extensively (Grimes et al., 1995; Laniado et al., 1997; Smith 
et al., 1998; Bennett et al., 2004; Nakajima et al., 2009). It was also suggested that, 
functional expression of VGSC is “necessary and sufficient” for prostate cancer cell 
invasion (Bennett et al., 2004). In addition, previously we showed that TTX 
decreased Mat-LyLu cell invasion under both normoxic and hypoxic conditions 
(Sections 3.2.2.7.3 and 3.3.6.3). Similarly, ranolazine (20-300 µM) decreased 
invasion of Mat-LyLu cells under both normoxic and hypoxic conditions probably 
via inhibition of VGSC / INaP activity.  
These results raise the possibility that ranolazine may be useful as an anti-
metastatic drug, especially as it is already in clinical use against angina (Maier, 
2009). Interestingly, in the only in vivo study reported to date, ranolazine (30 mg/kg, 
twice daily), in fact, increased the number of tumours in APC
(Min/+)
 mice and tumours 
become more invasive, thought to occur via inhibition of fatty acid oxidation 
(Suckow et al., 2004). However, ranolazine used in that study was more than the 
maximum recommended dose for human: 500-1000 mg, twice daily (Chaitman, 
2006).  
 
4.3.6 Effects of riluzole   
Riluzole (2-amino-6-trifluoromethoxy benzothiazole) is an anti-excitatory and 
neuroprotective agent. Its use, under the brand name “Rilutex”, was approved for 
treatment of the fatal neurodegenerative disease Amyotrophic Lateral Sclerosis 
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(ALS) in USA and Europe (Bensimon et al., 1994; Lacomblez et al., 1996). Riluzole 
was shown to be not harmful in humans at concentrations up to 10 µM (Weiss et al., 
2010; Le Liboux et al., 1999). It was proposed that the neuroprotective property of 
riluzole was via inhibition of INaP (Urbani and Belluzi, 2000; Zona et al., 1998). 
Indeed, riluzole was shown to protect against cardiac ischemia by inhibiting INaP 
(Weiss et al., 2010). Riluzole would bind to VGSCα subunit (binding site is not 
known) and stabilize the channel in its inactivated formation (Doble, 1999; Hebert et 
al., 1994). 
Riluzole treatment had some inhibitory effect on Nav1.7 mRNA expression 
and intracellular VGSCα protein expression in both normoxia and hypoxia. Although 
riluzole caused some increase in VGSCα protein expression in plasma membrane 
under hypoxia, there was no effect on invasiveness. In fact, although there was a 
strong and consistent trend towards inhibition, riluzole had no effect on invasiveness  
at concentrations (1 – 5 µM) that did not affect cellular viability or proliferative 
activity. This is likely to be due the significant variability introduced by DMSO used 
as a solvent.    
Riluzole had no effect on Nav1.7 mRNA expression in normoxia but 
decreased it significantly under hypoxia. It was previously reported that hypoxia 
would increase INaP amplitude and therefore increase internal Na
+
 concentration in 
neurons and cardiac cells (Hammarström and Gage, 1998; Ju and Gage, 1996). As 
discussed earlier (Section 4.3.1.3), Nav1.7 mRNA was regulated by VGSC activity 
in Mat-LyLu cells (Brackenbury and Djamgoz, 2006). Therefore, we can speculate 
that the increase intracellular Na
+
 and the subsequent increase in PKA activity could 
be the reasons of increase in Nav1.7 mRNA expression in Mat-LyLu cells.   
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The effect on VGSCα protein expression was studied with 2.5 µM riluzole which 
nevertheless increased plasma membrane expression. This was surprising 
considering the activity-dependent positive feedback hypothesis, involving 
intracellular trafficking, proposed by Brackenbury and Djamgoz (2006) according 
which a reduction would be expected. One possibility is that 2.5 µM riluzole was not 
sufficient to block INaP completely, since regulation may occur in all-or-none fashion 
(Brackenbury and Djamgoz, 2006).  
 Previously, effects of riluzole on human prostate cancer cells were 
investigated in 3 separate studies, as follows: 
1. Abdul and Hoosein (2002) initially studied effects on four different cell 
lines, including the VGSC-expressing PC-3 cells and found that riluzole 
inhibited growth with an IC50 of 43-128 µM.  
2. Parihar et al. (2003) found that riluzole (EC50 = 2 µM) evoked 
concentration-dependent increases in proliferation of PC-3 (and LNCaP) 
cells. However, this effect was proposed to be through intermediate-
conductance Ca
2+
-activated K
+
 channels. 
3. Akamatsu et al. (2009) showed that riluzole (10-50 µM) induces 
inhibition of DNA synthesis and apoptotic cell death via endoplasmic 
reticulum stress in both LNCaP and C4-2 prostate cancer cell lines.  
In conclusion, riluzole is likely to have anti-PCa effects via a number of ionic 
and cellular mechanisms. Further work is required to determine the role of INaP in the 
effects of riluzole. In particular, anti-invasive/metastatic effects would be worthwhile 
investigating further.  
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4.3.7 Effects of procaine  
Procaine (4-aminobenzoic acid-2-diethylaminoethyl ester) is a clinically used local 
anaesthetic. It was documented that its main mode of action is via VGSC block by 
interacting with local anaesthetic binding site at D1/D3/D4:S6 of VGSCα subunit 
(Lilley and Robinson, 1998; Bräu et al., 1998; Ragsdale et al., 1994). However, 
procaine can also block voltage-dependent K
+
 current in peripheral nerves with IC50 
value of 6302 µM (Bräu et al., 1998).  
Procaine (1 mM but not 0.5 mM) inhibited growth of breast cancer MCF-7 
cells via DNA-demethylation (Villar-Garea et al., 2003). In the present study, 
procaine (1 µM – 1 mM) had no effect on Mat-LyLu cell number under normoxia or 
hypoxia. This result is consistent with VGSC activity having no role in Mat-LyLu 
cell proliferation (Fraser et al., 2000).  
Procaine reduced Mat-LyLu cell invasion dose dependent manner under both 
normoxic and hypoxic conditions, consistent with involvement of VGSC activity. 
Overall, this agrees with previous work showing enhancement of prostate cancer cell 
invasiveness by functional VGSC expression (e.g. Grimes et al., 1995; Laniado et 
al., 1997; Smith et al., 1998; Bennett et al., 2004; Nakajima et al., 2009). However, 
as well the presumed suppression of VGSC activity, procaine also had some 
inhibitory effects on Nav1.7 mRNA and VGSCα protein expression. Thus, procaine 
may have potential as an anti-metastatic drug. Interestingly, procaine was reported to 
enhance antitumoral activity of several drugs used in cancer therapy, such as 
cisplatin, mitomycine C, peplomycin and doxorubicin (Chlebowski et al., 1982; 
Esposito et al., 1990; Viale et al., 1998; Mizuno and Ishida, 1982).   
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4.3.8 Effects of lidocaine 
Lidocaine (2-diethylamino-N-(2,6-dimethylphenyl) acetamide), a structural analogue 
of ranolazine, is another clinically used local anaesthetic.  It is reported to be useful 
in therapy of painful diabetic polyneuropathies, neuralgic pain and traumatic 
peripheral nerve injuries (Klinger et al., 1997). Lidocaine achieves anaesthetic effect 
mainly by blocking VGSC activity by binding to local anaesthetic site located at 
D1/D3/D4:S6 region (Sheet et al., 2007; Chevrier et al., 2004; Lilley and Robinson, 
1998; Bräu et al., 1998; Ragsdale et al., 1994). Lidocaine was also shown to block 
VGSC in MDA-MB-231 breast cancer cell line (Fraser et al., 2005). It was also 
reported that lidocaine (200 µM) decrease endocytic membrane activity via VGSC 
channel blockage (Onganer and Djamgoz, 2005). In addition, similar to procaine, 
lidocaine can also block voltage-dependent K
+
 currents in peripheral nerves with an 
IC50 of ~1118 µM (Bräu et al., 1998).  In the present study, lidocaine (10 and 100 
µM) decreased invasion of Mat-LyLu cells under both normoxic and hypoxic 
conditions, thereby providing further evidence on involvement of VGSC in 
invasiveness of cancer cells. At these concentrations (in fact, up to 1 mM), lidocaine 
had no effect on Mat-LyLu cell number in normoxia. Only at high concentrations 
(700 and 1000 µM) was cell number reduced under hypoxic conditions.  
 At the concentrations used to suppress invasiveness, there was also a 
tendency to inhibit expression of Nav1.7 mRNA and VGSCα protein. These results 
agree generally with previous findings (i) that VGSC activity promotes cellular 
invasiveness without any involvement in proliferation and (ii) VGSC expression is 
under auto-controlling such that channel activity can have both transcriptional and 
post-translational effects (Brackenbury and Djamgoz, 2006). 
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 Overall, the effects of lidocaine reported elucidated here would support the 
notion that lidocaine can also have anti-cancer/metastatic effects. It was shown 
earlier that that 3.5 mM lidocaine caused growth inhibition of SHG human 
melanoma cells (Chlebowski et al., 1982). In another study, Mammoto et al. (2002) 
found that lidocaine inhibited the invasiveness of various human cancer cell lines but 
this was thought to be independent of any VGSC blockage. 
 
4.4 Concluding remarks 
In overall conclusion, 3 of the 4 VGSC blockers (ranolazine, procaine and lidocaine) 
employed in the present study produced inhibitory effects on metastatic cell 
behaviour (invasion) at concentrations that did not affect primary cell growth. These 
findings further support the following viewpoints. First, primary and secondary 
tumourigenesis are controlled differently, perhaps even independently (Hanahan and 
Weinberg, 2000; Welch et al., 2000; Welch, 2004; Welch, 2006). Second, VGSC 
blockers can be useful clinically as anti-metastatic drugs (Onkal and Djamgoz, 2009; 
Gillet et al., 2009; Roger et al., 2006; Prevarskaya et al., 2007; Brackenbury and 
Djamgoz, 2006). The only apparent exception was riluzole which did not produce 
statistically significant effects in spite of the strong inhibitory trends. This was likely 
to be due to the obligatory use of DMSO as a solvent. Nevertheless, with further 
experimentation and optimization, it is possible that riluzole can also produce 
significant effects. We should emphasise, however, that blocking VGSC activity was 
accompanied by changes in Nav1.7 mRNA and protein expression, and these 
secondary effects will need to be taken into account when considering the full 
clinical potential of VGSC blockers as anti-metastatic agents. 
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  Chapter 5 
 
STUDY OF INTRACELLULAR Ca
2+
 OSCILLATIONS IN 
HUMAN METASTATIC PROSTATE CANCER PC-3M 
CELLS 
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5.1 Introduction 
 
Ca
2+
 signalling is a key player in transmembrane activity and intracellular signal 
transmission. Ca
2+
 signalling regulates many cellular processes such as fertilization 
(Ozil and Swann, 1995), cell cycle (e.g. Ding et al., 2010), apoptosis (Norberg et al., 
2008), mitochondrial redox state (Hajnóczky et al., 1995), differential gene 
expression (Wang et al., 2010; Liao et al., 2006; Dolmetsch et al., 1998;  Li et al., 
1998; Haisenleder et al., 2001; Buonanno and Fields, 1999; Olson and Williams, 
2000), motility / invasion (Amuthan et al., 2002; Wei et al., 2009; Huang et al., 
2004; Komuro and Rakic, 1996), muscle contraction, pacemaker activity, growth-
cone turning / migration (Gomez et al., 1995; Gomez et al., 2001), axonal growth 
(Tang et al., 2003), development of neurotransmitter phenotype (Ciccolini et al., 
2003), formation of nodules in plant root hairs (Ehrhardt et al., 1996), development 
of muscle (Ferrari et al., 1998), release of cytokines (Uhlén et al., 2000), exocytosis 
(Tse et al., 1993), adhesion (Giannone et al., 2002; Liao et al., 2006), chemotaxis, 
and synaptic plasticity (Parkash and Asotra, 2010; Mycielska et al., 2004 Berridge, 
1998; Berridge, 2009). Ca
2+
 signalling has also been implicated in modulation of 
metastatic cell behaviours (MCBs) in various cancers, including  prostate cancer 
(PCa), breast cancer, head and neck squamous cell carcinoma, pulmonary 
adenocarcinoma, rhabdomyoblasts, fibrosarcoma, and retinoblastoma (Wang et al., 
2010; Liao et al., 2006; Huang et al., 2004; Zhong et al., 2010; Wu et al., 1997; 
Amuthan et al., 2002; Amuthan et al., 2001; Cook and Lockyer, 2006;  Wertz and 
Dixit, 2000; Lehen‟kyi et al., 2007). In addition, changes in expression profiles of 
Ca
2+
 channels and pumps in cancer cells were proposed to play important role in 
carcinogenesis (Parkash and Asotro 2010; Monteith et al., 2007).  
  - 271 - 
 
 Since high levels of intracellular Ca
2+
 ([Ca
2+
]i) can be cytotoxic, cells spend 
considerable energy in order to maintain a basal [Ca
2+
]i of <100 nM, while 
extracellular Ca
2+
 concentrations are at mM levels (Parkash and Asotro, 2010; 
Berridge et al., 2003; Berridge et al., 1998). This regulation of [Ca
2+
]i is carried out 
by chelation / binding, compartmentalisation and extrusion of intracellular Ca
2+
 
(Parkash and Asotro, 2010; Berridge et al., 2003; Berridge et al., 1998). On the 
whole, therefore, physiological changes in intracellular Ca
2+
 are brief (Parkash and 
Asotro 2010; Rey et al., 2010; Clapham 2007; Berridge et al., 1998). 
Ca
2+
 signalling can be mediated by influx of Ca
2+
 through plasma membrane 
and/or release of Ca
2+
 from internal stores (Roderick and Cook, 2008; Clapham, 
2007; Berridge et al., 2003; Berridge et al., 1998). In turn, Ca
2+
 influx can occur via 
many different membrane mechanisms including voltage-gated Ca
2+
 channels 
(VGCCs), receptor-operated and store-operated Ca
2+ 
channels (Berridge et al., 1998). 
However, a rise in [Ca
2+
]i can also result from slowing or reversal of Na
+
 - Ca
2+
 
exchanger (NCX) activity (Poburko, et al., 2007; Eder et al., 2005; Rosker et al., 
2004; Arnon et al., 2000). On the other hand, two main Ca
2+
-release channels have 
been characterized in endoplasmic reticulum (ER): ryanodine receptor (RyR) and 
inositol-triphosphate receptor (IP3R)  (Campbell et al., 1987; Streb et al., 1983).  In 
addition, several pumps have been implicated in Ca
2+
 signalling / [Ca
2+
]i regulation, 
including sarcoplasmic-endoplasmic reticulum Ca
2+
-ATPase (SERCA), plasma-
membrane Ca
2+
-ATPase (PMCA) and mitochondrial Ca
2+
 uniporter, as well as NCX 
(Berridge et al., 2003; Berridge et al., 1998). 
Liao et al. (2006) proposed that extracellular Ca
2+
 is a mediator of PCa bone 
metastasis. In addition, PCa cell motility, including galvanotaxis, was suggested to 
be regulated by Ca
2+
 signalling (Wang et al., 2010; Mycielska and Djamgoz, 2004). 
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In PCa, TRPC1, TRPC3, TRPC4, TRPV2, TRPV6, TRPM8 subtypes of transient 
receptor potential (TRP) cation (including Ca
2+
) channel family were identified 
(Abeele et al., 2003a; Abeele et al., 2003b; Abeele et al., 2004; Fixemer et al., 2003; 
Schmidt et al., 2006). In addition, some involvement of TRPV2 and TRPM8 in 
MCBs in PCa was documented (Monet et al., 2010; Gkika et al., 2010). For 
example, silencing of TRPV2 by siRNA reduced growth and invasion of PC-3 cells 
(Monet et al., 2010). Furthermore, TRPM8 activation mediated reduction in PC-3 
cell motility was recently documented (Gkika et al., 2010). 
Functional expression of voltage-gated Na
+
 channels (VGSCs) have been 
associated with initiation and progression of several metastatic carcinomas (Grimes 
et al., 1995; Blandino et al., 1995; Laniado et al., 1997; Allen et al., 1997; Grimes 
and Djamgoz, 1998; Abdul and Hoosein, 2002; Roger et al., 2003; Fraser et al., 
2004; Ou et al., 2005; Fraser et al., 2005; Onganer and Djamgoz, 2005; Onganer et 
al., 2005; Brackenbury and Djamgoz, 2006; Fulgenzi et al., 2006; Roger et al., 2007; 
Diaz et al., 2007; Nakajima et al., 2009; Gao et al., 2009; Gao et al., 2010; House et 
al., 2010). VGSC activity was shown to potentiate galvanotaxis, lateral motility, 
endocytic membrane activity, transverse migration and invasion in cancer cells 
(Brackenbury and Djamgoz, 2006; Gillet et al., 2009; Nakajima et al., 2009; Fraser 
et al., 2003; Mycielska et al., 2003; Djamgoz et al., 2001; Krasowska et al., 2004; 
Grimes et al., 1995; Laniado et al., 1997; Smith et al., 1998; Bennet et al., 2004). 
Concurrently, it was shown that strongly metastatic hepatoma and mammary 
adenocarcinoma have higher internal Na
+
 concentrations than corresponding 
nontumoural cells (Cameron et al., 1980). Similarly, the Na
+
 content is higher in 
advanced breast cancers than benign tumours (Ouwerkerk et al., 2007). 
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Interestingly, influx of Na
+
 through openings of VGSCs (Sagel et al., 1991; 
Gosling et al., 1998) as well as TRP channels (Poburka, et al., 2007; Eder et al., 
2005; Rosker et al., 2004; Arnon et al., 2000) was proposed to mediate Ca
2+
 influx 
by slowing or reversing NCX activity. 
Therefore, in this chapter we proposed the hypothesis that VGSC activity 
modulates the intracellular Ca
2+
 levels. 
 
5.2 Aims and scope of the present study 
The main aim was to elucidate some basic aspects of Ca
2+
 signalling in human 
metastatic PCa PC-3M cells. The specific aims were as follows: 
3. To test whether spontaneous Ca2+ oscillations occurred; 
4. To determine the possible role of VGSC activity in Ca2+ signalling; and  
5. To gain an insight to the subcellular regulatory components involved in 
Ca
2+
 oscillations. 
 
5.3 Results 
 
Fluo-4, a Ca
2+
 indicator dye, and high-speed confocal digital imaging system were 
used to record changes in intracellular [Ca
2+
] levels in human metastatic PCa cell line 
PC3M, human weakly metastatic PCa cell line LNCaP and rat highly metastatic PCa 
cell line Mat-LyLu in a comparative approach. [Ca
2+
]i was measured as “∆F/F” (as 
defined in the Materials and Methods” chapter) and plotted as a percentage of the 
value above the average baseline (treated as 0 %).  
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5.3.1 Spontaneous oscillations of intracellular Ca2+ in PCa cells: Basic 
characteristics and comparative aspects 
Of PC-3M cells, 24 ± 6 % showed spontaneous Ca
2+
 oscillations (n = 6; Figure 5.1A; 
Supplementary Videos 1 and 2). A transient event was accepted as an “oscillation” if 
it (i) occurred a minimum of 3 times and (ii) reached a minimum amplitude of 50 %. 
The [Ca
2+
]i oscillations did not appear to be localized to any particular part of the 
PC-3M cells. Both spontaneously oscillating and non-oscillating PC-3M cells 
responded to depolarization of membrane potential (induced by application of 100 
mM KCl) with increase in [Ca
2+
]i  (Figure 5.1A&B). There was no noticeable change 
in oscillation frequency or amplitude over 30 min of recording (Figure 5.1A). The 
basic characteristics of the Ca
2+ 
oscillations in PC-3M cells were as follows: 
amplitude = 172 ± 17 % and frequency = 0.5 ± 0.04 oscillation/min (n = 38). In some 
cases, cells discharged repetitively and cumulatively without returning to baseline. 
Such cells were excluded from the analyses. 
In contrast to PC-3M, the weakly metastatic human PCa cell line LNCaP did 
not have any spontaneous Ca
2+
 activity (n = 3; Figure 5.2A; Supplementary Videos 3 
and 4). Nevertheless, membrane potential depolarization (induced by 100 mM KCl) 
caused a rapid rise in [Ca
2+
]i (n = 3; Figure 5.2A). 
 In strongly metastatic rat PCa Mat-LyLu cells, no spontaneous Ca
2+ 
event 
was recorded (n = 3; Figure 5.2B; Supplementary Videos 5 and 6). In addition, 
membrane depolarization (induced by 100 µM KCl) had no effect on [Ca
2+
]i (n = 3; 
Figure 5.2B). This result agreed generally with the data of Ding et al. (2006) 
showing lack of functional VGCC expression in Mat-LyLu cells.  
In the remainder of the experiments, mainly the PC-3M cells were used. 
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Figure 5.1 Spontaneous Ca
2+
 oscillations in PC3M cells. 
Representative traces showing oscillatory changes in internal fluorescence intensity 
in PC-3M cells that were loaded with the Ca
2+ 
indicator dye Fluo-4: (A) A typical 
oscillating cell; (B) A typical non oscillating cell. Changes in fluorescence intensity 
are expressed as ΔF/F0 (%). Applications of given treatments are indicated by 
arrows. Vehicle control, control buffer solution (MPS) without any treatment; KCl, 
potassium chloride (100 mM).  
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Figure 5.2 Spontaneous changes in [Ca
2+
]i in LNCaP and Mat-LyLu cells 
Typical recordings showing internal fluorescence intensity change over time in 
LNCaP (A) and Mat-LyLu (B) cells loaded with the Ca
2+ 
indicator dye Fluo-4. 
Changes in fluorescence intensity are expressed as ΔF/F0 (%); black arrows 
indicate treatment application at shown time points. KCl was used at 100 mM.  
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5.3.2 Effects of VGSC blockers on Ca2+ oscillations in PC-3M cells 
 
5.3.2.1 Effect of TTX 
Blocking VGSC activity with 1 µM TTX significantly decreased amplitude of Ca
2+
 
oscillations in PC-3M cells by some 47 %, from 137 ± 17 % to 73 ± 17 % (p < 0.05; 
n = 23; Figures 5.3A and 5.4A; Supplementary Videos 7 and 8). In addition, 
frequency of oscillations was significantly reduced by 59 %, from 0.39 ± 0.04 to 0.16 
± 0.03 oscillation/min (p < 0.001; n = 23; Figures 5.3A and 5.4B). There was no 
change in the number of oscillating PC-3M cells following the TTX treatment: 13 ± 
6 % (control) and 13 ± 4 % (TTX-treated) (p > 0.05; n = 3; Figure 5.4C). TTX (1 
µM) had no effect on the internal Ca
2+
 level in non-oscillating PC-3M cells (n = 3; 
Figure 5.3B). Depolarization of membrane potential (induced by 100 mM KCl) in 
the presence of TTX (1 µM) increased [Ca
2+
]i in both oscillating and non-oscillating 
PC-3M cells (n = 3 each; Figure 5.3A&B). 
 
5.3.2.2 Effect of ranolazine 
Ranolazine was used as a selective blocker of the VGSC persistent current (INaP). 
Treatment with 20 µM ranolazine significantly reduced the Ca
2+
 oscillation 
amplitude by 43 %, from 149 ± 20 % to 85 ± 15 % (p < 0.05; n = 17; Figures 5.5A 
and 5.6A; Supplementary Videos 9 and 10). Oscillation frequency was also 
significantly decreased by 59 %, from 0.44 ± 0.04 to 0.18 ± 0.03 oscillation/min (p < 
0.001; n = 17; Figures 5.5A and 5.6B). Also, similar to TTX, ranolazine (20 µM) had 
no significant effect on number of oscillating PC-3M cells: 25 ± 12 % (control) and 
22 ± 13 % (ranolazine-treated) (p > 0.05; n = 3; Figure 5.6C). There was no  
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Figure 5.3 Effect of TTX on spontaneous Ca
2+
 oscillations in PC-3M cells 
Representative traces showing the effect of TTX (1 µM) on spontaneous Ca
2+
 
oscillations in a typical oscillating (A) and non-oscillating (B) PC-3M cell. 
Changes in fluorescence intensity are expressed as ΔF/F0 (%). Treatment 
application times are indicated by arrows. Vehicle control, buffer solution (MPS) 
without any treatment; KCl, potassium chloride (100 mM). 
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Figure 5.4 Summary of the effects of TTX on spontaneous Ca
2+
 oscillations in PC-
3M cells. 
Bar diagrams illustrates the effect of 1 µM TTX on the amplitude (A) and the 
frequency (B) of spontaneous Ca
+2
 oscillations recorded in PC-3M cells. Data were 
obtained in a „matched‟ fashion (i.e. from the same cells) under control conditions and 
then in the presence of TTX (15 min each). Paired t-tests were used for statistical 
comparisons (n = 23). (C) Effect of TTX (1 µM) on the percentage of oscillating PC-
3M cells. Paired t-test was used for statistical analysis (n = 3). Data are presented as 
mean ± SEM. Significance: (*) p < 0.05; (**) p < 0.001; (X) p > 0.05. 
* 
** 
X 
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Figure 5.5 Effect of ranolazine on spontaneous Ca
2+
 oscillations in PC-3M cells. 
Representative traces showing the effect of 20 µM ranolazine on spontaneous Ca
2+
 
oscillations in PC-3M cells: (A) an oscillating cell; (B) non-oscillating cell. Changes 
in fluorescence intensity are expressed as ΔF/F0 (%). Treatment application times are 
indicated with arrows. Vehicle control, buffer solution (MPS) without any treatment; 
KCl, potassium chloride (100mM); Rano, ranolazine (20 µM).  
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Figure 5.6 Summary of the effects of ranolazine on spontaneous Ca
2+
 oscillations 
in PC-3M cells. 
Bar diagrams illustrating the effect of 20 µM ranolazine on the amplitude (A) and the 
frequency (B) of Ca
2+
 oscillations in PC-3M cells. Data were obtained in a „matched‟ 
fashion (i.e. from the same cells) under control conditions and then in the presence of 
ranolazine (15 min each). Paired t-tests were used for statistical comparisons (n = 17). 
(C) Effect of ranolazine (20 µM) on the percentage of oscillating PC-3M cells. Paired 
t-test was used for statistical analysis (n = 3). Data are presented as mean ± SEM. 
Significance: (*) p < 0.05; (**) p < 0.001; (X) p > 0.05. 
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significant change of intracellular Ca
2+ 
concentration in non-oscillating PC-3M cells 
after ranolazine treatment (n = 3; Figure 5.5B). Finally, increases in intracellular Ca
2+
 
levels were recorded after depolarization of membrane potential with 100 µM KCl in 
the presence of ranolazine (20 µM) in both oscillating and non-oscillating PC-3M 
cells (n = 3; Figures 5.5A&B). 
It was concluded that VGSC activity, in particular INaP, played a significant 
role in regulating the [Ca
2+
]i oscillations in PC-3M cells. 
 
5.3.3 Effects of  Na+-free conditions on Ca2+ oscillations 
Role of extracellular Na
+
 in Ca
2+
 oscillations were studied by substituting NaCl in 
the bathing solutions with equimolar LiCl or choline chloride. 
 
5.3.3.1 Effect of Li
+
-substituted Na
+
-free solution 
No change was recorded in the Ca
2+
 oscillation amplitude of PC-3M cells when 
maintained in control and Li
+
-substituted Na
+
-free conditions (165 ± 13 and 172 ± 17 
%, respectively; p > 0.05; n ≥ 38; Figures 5.7A and 5.8A; Supplementary Videos 11 
and 12). In addition, there was no difference in frequency of Ca
2+
 oscillations: 0.52 ± 
0.04 oscillation/min (control) and 0.52 ± 0.04 oscillation/min (Li
+
-substituted) (p > 
0.05; n ≥ 38; Figures 5.7A and 5.8B). The number of oscillating cells also was not 
changed in the Li
+
-substituted Na
+
-free conditions: 24 ± 6 % (control) and 37 ± 4 % 
(Li
+
-substituted) (p > 0.05; n ≥ 3; Figure 5.8C). Depolarization of membrane 
potential (induced by 100 mM KCl) significantly increased intracellular Ca
2+
 levels 
in both oscillating and non-oscillating PC-3M cells under Li
+
-substituted Na
+
-free 
conditions (n = 3; Figure 5.7A&B). 
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Figure 5.7 Effect of Na
+
 free (Li
+
 substituted) conditions on Ca
2+
 oscillations in 
PC-3M cells. 
Exemplar recordings showing the effect of Li
+
 substituted Na
+
 free MPS on Ca
2+
 
oscillations in oscillating (A) and non-oscillating (B) PC-3M cells. Changes in 
fluorescence intensity are expressed as ΔF/F0 (%). Treatment application times are 
indicated by arrows. KCl, potassium chloride (100 mM).  
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Figure 5.8 Summary of the effects of Na
+
 free (Li
+
- substituted) conditions on 
spontaneous Ca
2+
 oscillations in PC-3M cells. 
Bar diagrams showing the effect of Na
+
 free (Li
+
-substituted) MPS on the 
amplitude (A) and the frequency (B) of Ca
+2
 oscillations in PC-3M cells. Data were 
obtained in a „matched‟ fashion (i.e. from the same cells) under control conditions 
and then in the presence of Na
+
-free MPS (15 min each). Paired t-tests were used 
for statistical comparisons (n ≥ 38). (C) Effect of Li+ substituted Na+ free MPS on 
the percentage of oscillating PC-3M cells (n = 3). Paired t-test was used for 
statistical analysis. Data are presented as mean ± SEM. Significance: (X) p > 0.05. 
X 
X 
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5.3.3.2 Effect of choline-substituted Na+-free solution  
Choline-substituted Na
+
-free conditions significantly decreased the amplitude of Ca
2+
 
oscillations in PC-3M cells by 28 %, from 165 ± 13 to 119 ± 9 % (p < 0.05; n ≥ 34; 
Figures 5.9A and 5.10A; Supplementary Videos 13 and 14). On the other hand, when 
the cells were exposed to the choline-substituted Na
+
-free conditions, oscillation 
frequency was significantly elevated by 63 %, from 0.52 ± 0.04 oscillation/min 
(control) to 0.85 ± 0.09 oscillation/min (choline
+
-substituted) (p < 0.05; n ≥ 34; 
Figures 5.9A and 5.10B). However, there was no effect on the number of oscillating 
cells: 24 ± 6 % (control) and 47 ± 12 % (choline
+
-substituted) (p > 0.05; n ≥ 3; 
Figure 5.10C). Membrane depolarization (induced by 100 mM KCl) caused increases 
in the intracellular Ca
2+
 level in both oscillating and non-oscillating PC-3M cells 
under choline-substituted Na
+
-free conditions, as in the control solution (n =3; 
Figures 5.9A&B).  
 It was concluded that extracellular Na
+
 played a significant role in regulating 
the [Ca
2+
]i oscillations in PC-3M cells. 
 
5.3.4 Involvement of extracellular Ca2+ in spontaneous Ca2+ oscillations 
In order to study the possible involvement of extracellular Ca
2+
 on the spontaneous 
Ca
2+
 oscillations, intracellular Ca
2+
 levels of PC-3M cells were recorded first under 
Ca
2+
-free conditions in the presence of the Ca
2+
 chelating agent EGTA (5 µM). Then, 
2.5 mM Ca
2+
 was re-admitted into the bath solution. In the absence of extracellular 
Ca
2+
, there was no oscillation in PC-3M cells (n =3; Figures 5.11A&B; 
Supplementary Videos 15 and 16). After the application of Ca
2+
 (2.5 mM), however, 
the intracellular Ca
2+
 level showed a sharp rise and this was followed by a rapid fall 
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Figure 5.9 Effect of Na
+
 free (choline-substituted) MPS on Ca
2+
 oscillations in 
PC-3M cells. 
Typical recordings showing the effect choline-substituted Na
+
 free MPS on Ca
2+
 
oscillations in an oscillating (A) and non-oscillating (B) PC-3M cell. Changes in 
fluorescence intensity were expressed as ΔF/F0 (%). Treatment application times 
are indicated by arrows. KCl, potassium chloride (100 mM).  
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Figure 5.10 Summary of the effects of Na
+
 free (choline-substituted) MPS on 
spontaneous Ca
2+
 oscillations in PC-3M cells. 
Bar diagrams showing the effect of choline-substituted Na
+
 free MPS on the 
amplitude (A) and the frequency (B) of Ca
+2
 oscillations in PC-3M cells. Data were 
obtained in a „matched‟ fashion (i.e. from the same cells) under control conditions 
and then in the presence of Na
+
-free MPS (15 min each). Paired t-tests were used 
for statistical comparisons (n ≥ 34). (C) Effect of choline-substituted Na+ free MPS 
on the percentage of oscillating PC-3M cells. Paired t-test was used for statistical 
analysis (n = 3). Data are presented as mean ± SEM. Significance: (*) p < 0.05; (X) 
p > 0.05. 
X 
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Figure 5.11 Effect of varying the extracellular [Ca
2+
] on spontaneous Ca
2+
 
oscillations in PC-3M cells. 
Recordings showing that extracellular Ca
2+
 is necessary for spontaneous Ca
2+
 
oscillations in PC-3M cells: (A) an oscillating cell. (B) a non-oscillating cell.  
Recordings were first taken in the presence of Ca
2+
-free MPS supplied with 5 μM 
EGTA, and then in the presence of 2.5 mM Ca
2+
. Changes in fluorescence intensity 
were expressed as ΔF/F0 (%). Treatment application times are indicated with 
arrows.   
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to a new level that was still above the original baseline (n =3; Figures 5.11). 
Subsequently, some PC-3M cells started to oscillate (n =3; Figures 5.11A).  
It was concluded that extracellular Ca
2+
 played a significant role in generating 
the [Ca
2+
]i oscillations in PC-3M cells. 
 
5.3.5 Effects of thapsigargin and EGTA on spontaneous Ca2+ oscillations 
Thapsigargin was used as an inhibitor of SERCA (Sagara and Inesi, 1999; Wei et al., 
2009). First, the intracellular Ca
2+
 levels of PC-3M cells were recorded under control 
conditions for 10 min. Then, thapsigargin (5 µM) was added to the bathing solution 
and [Ca
2+
]i was recorded for a further 40 min. Finally, effect of membrane 
depolarization was monitored by applying 100 mM KCl. Immediately after 
thapsigargin application, intracellular Ca
2+
 level elevated sharply and this was 
followed by a small drop and then a second elevation of intracellular Ca
2+
 level; this 
sequence of events was seen in both oscillating and non-oscillating PC-3M cells (n = 
3; Figure 5.12; Supplementary Videos 17 and 18). Following the second rise, [Ca
2+
]i 
steadily fell to a new level that was higher than the original baseline (n = 3; Figure 
5.12). Interestingly, depolarization of membrane potential in the presence of 
thapsigargin caused decreases in intracellular Ca
2+
 level in both oscillating and non-
oscillating PC-3M cells (n = 3 each; Figure 5.12). 
 Next, intracellular Ca
2+
 levels were recorded under Ca
2+
-free conditions with 
EGTA (5 µM) added for 10 min followed by application of (i) thapsigargin (5 µM) 
and/or (ii) after 40 min, membrane depolarization using 100 mM KCl.  Under the 
initial Ca
2+
-free conditions, there was no [Ca
2+
]i oscillations (n = 3; Figure 5.13A). 
After thapsigargin application, the internal Ca
2+
 level increased sharply followed by 
a fast decline to baseline that was maintained for at least 40 min of recording (n = 3; 
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Figure 5.12 Effect of thapsigargin on Ca
2+
 oscillations in PC-3M cells. 
Example recordings showing the effect of thapsigargin (depletes the Ca
2+
 store in 
ER) on Ca
2+
 signalling in oscillating (A) and non-oscillating (B) PC-3M cells. 
Changes in fluorescence intensity were expressed as ΔF/F0 (%). Treatment 
application times are indicated by arrows. KCl, potassium chloride (100 mM). 
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Figure 5.13 Effect of extracellular and intracellular [Ca
2+
]
 
on Ca
2+
 oscillations 
in PC-3M cells. 
(A) Traces showing the effect of thapsigargin on spontaneous Ca
2+
 oscillations in 
PC-3M cells in the presence of Ca
2+
-free MPS (supplied with 5μM EGTA). (B) 
Same as part A but 2.5 mM Ca
2+
 was added following thapsigargin application. 
Changes in fluorescence intensity were expressed as ΔF/F0 (%). Treatment 
application times are indicated with arrows. KCl, potassium chloride (100 mM).  
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Figure 5.13A; Supplementary Videos 19 and 20). Membrane depolarization with 100 
mM KCl caused a small increase in [Ca
2+
]i (n = 3; Figure 5.13A). 
 Next, Ca
2+
 oscillations were recorded under Ca
2+
-free conditions in the 
presence of EGTA (5 µM) applied for 10 min followed by treatment with 
thapsigargin (5 µM) to deplete ER Ca
2+
 stores. Finally, 15 mins after thapsigargin 
application, 2.5 mM Ca
2+
 was reintroduced into the external bath and recordings 
were continued for a further 5 min. Finally, the membrane was depolarized with 100 
mM KCl application. Again, under the initial Ca
2+
-free conditions, there was no Ca
2+
 
oscillations in PC-3M cells (n = 3; Figure 5.13B). After addition of thapsigargin, a 
sharp [Ca
2+
]i transient was generated which then returned back to baseline and no 
further change was recorded (n = 3; Figure 5.13B). After the re-addition of Ca
2+
 into 
the external bath solution, there was no change in [Ca
2+
]i (n = 3; Figure 5.13B). 
Finally, depolarizing the membrane potential caused an increase in internal Ca
2+
 
concentration (n = 3; Figure 5.13B). 
It was concluded (i) that release from internal stores contributed to the [Ca
2+
]i 
oscillations in PC-3M cells and (ii) that SERCA had a significant role in this process.  
 
5.3.6 Effects of caffeine and ryanodine on spontaneous Ca2+ oscillations 
The possible involvement of RyR-induced release of Ca
2+
 from internal stores in the 
[Ca
2+
]i oscillations was studied using caffeine and micromolar ryanodine as an 
activator and inhibitor of RyR, respectively (Williams and Sims, 2007; Mariot et al., 
2000).  
Intracellular Ca
2+
 levels of PC-3M cells were recorded under control 
conditions for 10 min. Then, 10 mM caffeine was added to the external bath solution. 
Finally, the membrane potential was depolarized by 100 mM KCl. In oscillating PC-
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3M cells, caffeine (10 mM) suppressed Ca
2+
 oscillations without significantly 
changing the steady-state baseline level (n = 3; Figures 5.14A; Supplementary 
Videos 21 and 22). In non-oscillating cells, application of caffeine significantly 
elevated the [Ca
2+
]i level without inducing oscillations (n = 3; Figure 5.14B). 
Depolarization caused increases in [Ca
2+
]i in both oscillating and non-oscillating PC-
3M cells (n = 3; Figures 5.14A&B). 
 Inhibition of RyR with 50 µM ryanodine significantly decreased the 
amplitude of the Ca
2+
 oscillations in PC-3M cells by 59 %, from 204 ± 23 % to 84 ± 
17 % (p < 0.001; n = 26; Figures 5.15A and 5.16A; Supplementary Videos 23 and 
24). In addition, oscillation frequency was significantly reduced by 72 %, from 0.71 
± 0.08 to 0.20 ± 0.05 oscillation/min (p < 0.001; n = 26; Figures 5.15A and 5.16B). 
There was no significant change in number of oscillating PC-3M cells by 50 µM 
ryanodine treatment (p > 0.05; n = 3; Figure 5.16C). Ryanodine (50 µM) had no 
effect on [Ca
2+
]i in non-oscillating PC-3M cells (n = 3; Figure 5.15B). Depolarization 
of membrane potential (with 100 mM KCl) in the presence of ryanodine (50 µM) 
increased internal Ca
2+
 levels in both oscillating and non-oscillating cells (n = 3; 
Figure 5.15A&B). 
 It was concluded that RyR had a significant role in regulating the [Ca
2+
]i 
oscillations in PC-3M cells. 
 
5.4 Discussion 
 
The main findings of this study are as follows: (1) A subpopulation (~25 %) of 
human strongly metastatic PC-3M cells generated spontaneous, „global‟ Ca2+ 
oscillations; (2) no such activity was found in human weakly metastatic LNCaP cells  
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Figure 5.14 Effect of caffeine on Ca
2+
 oscillations in PC-3M cells. 
Representative traces showing the effect of 10 mM caffeine on Ca
2+
 oscillations in 
PC-3M cells: (A) an oscillating cell; (B) a non oscillating cell. Changes in 
fluorescence intensity were expressed as ΔF/F0 (%). Treatment application times 
are indicated with arrow. KCl, potassium chloride (100 mM). 
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Figure 5.15 Effect of ryanodine on Ca
2+
 oscillations in PC-3M cells. 
Typical recordings showing the effect of ryanodine (50 µM) on Ca
2+
 oscillations in 
PC-3M cells: (A) an oscillating cell; (B) a non-oscillating cell. Changes in 
fluorescence intensity were expressed as ΔF/F0 (%). Treatment application times 
are indicated by arrows. Vehicle control, buffer solution (MPS) without any 
treatment; KCl, potassium chloride (100 mM).  
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Figure 5.16 Summary of the effects of ryanodine on spontaneous Ca
2+
 
oscillations in PC-3M cells. 
Bar diagrams showing the effects of 50 µM ryanodine on the amplitude (A) and the 
frequency (B) of Ca
2+
 oscillations in PC-3M cells. Data were obtained in a 
„matched‟ fashion (i.e. from the same cells) under control conditions and then in 
the presence of ryanodine (15 min each). Paired t-tests were used for statistical 
analysis (n = 26). (C) Effect of ryanodine (50 µM) on the percentage of oscillating 
PC-3M cells. Paired t-test was used for statistical analysis (n = 3). Data are 
presented as mean ± SEM. Significance: (**) p < 0.001; (X) p > 0.05. 
** 
** 
X 
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or the strongly metastatic rat PCa cell line, Mat-LyLu. (3) The averages of the basic 
characteristics of the [Ca
2+
]i oscillations in PC-3M cells were as follows: 172 % 
(amplitude) and 0.5 oscillation/min (frequency). (4) TTX and ranolazine reduced 
both frequency and amplitude of Ca
2+
 oscillations but did not affect the percentage of 
oscillating cells. (5) Substituting extracellular Na
+
 with equimolar Li
+
 had no effect 
on frequency and amplitude of Ca
2+
 oscillations or the number of oscillating cells. 
(6) Substituting extracellular Na
+
 with equimolar choline
+
 reduced the amplitude but 
increased the frequency of Ca
2+
 oscillations (7) Under Ca
2+
 free conditions, no 
oscillations were detected in PC-3M cells but after addition of Ca
2+
 some cells 
started to oscillate (but not after also thapsigargin pre-treatment).  (8) Efflux of Ca
2+
 
from internal stores by thapsigargin treatment induced influx of external Ca
2+
. (9) 
Stimulating RyR caused an increase in intracellular Ca
2+
, whilst inhibiting RyR 
decreased both amplitude and frequency of Ca
2+
 oscillations. These results are 
summarised qualitatively in Table 5.1. 
 
5.4.1 Calcium signalling in PCa cells 
Intracellular Ca
2+
 signalling regulates many cellular processes, particularly, motility, 
invasion, transcription, cell cycle/proliferation and apoptosis, which are also relate 
directly to the metastatic potential of cancer cells, as in PCa, breast cancer; head and 
neck squamous cell carcinoma, pulmonary adenocarcinoma, rhabdomyoblasts, 
fibrosarcoma and retinoblastoma (Wang et al., 2010; Liao et al., 2006; Huang et al., 
2004; Zhong et al., 2010; Wu et al., 1997; Amuthan et al., 2002; Amuthan et al., 
2001; Cook and Lockyer, 2006;  Wertz and Dixit, 2000; Lehen‟kyi et al., 2007). 
Here, we studied Ca
2+
 signalling in several PCa cell lines, PC-3M, LNCaP (both 
human) and Mat-LyLu (rat), in a comparative approach.  
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Table 5.1 Synopsis  of results 
 
 
 
 
TREATMENT AMPLITUDE FREQUENCY RESPONSE TO 
KCl 
TTX - - 0 
Ranolazine - - 0 
Na
+
-free: Li
+
 0 0 0 
Na
+
-free: choline
+
 - + 0 
Ca
2+
-free - ND ND 
Thapsigargin (locked) - (baseline reduction)  
Caffeine - - 0 
Ryanodine - - 0 
 
 
 
 
- : DECREASE 
+ : INCREASE 
0  : NO CHANGE 
ND: NOT DETERMINED 
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The results depended on the cells‟ metastatic potential as well as species of 
origin. Thus, only human strongly metastatic PC-3M cells generated spontaneous 
Ca
2+
 oscillations. It is not clear why the analogous rat PCa cell line did not show 
Ca
2+
 oscillations, although Mat-LyLu cells share many of the ionic characteristics of 
PC-3 cells, including the subtypes of VGSC (Nav1.7) and voltage-gated K
+
 channel 
(Kv1.3) expression (Diss et al., 2001; Fraser et al., 2003). Nevertheless, the present 
results on Mat-LyLu cells complement the previous findings of Ding et al. (2006) 
who also could not reveal any spontaneous activity of [Ca
2+
]i and showed 
additionally (i) that Mat-LyLu cell membranes were insensitive to changes in 
extracellular Ca
2+
 levels and (ii) that membrane depolarization had no effect on 
[Ca
2+
]i. Taken together, these results would imply that the Dunning cells may not be 
a valid model of human PCa, at least as far as intracellular Ca
2+
 signalling and 
regulation are concerned.  
Interestingly, only ~25 % of PC-3M cells showed spontaneous [Ca
2+
]i 
oscillations. This is in line with the well known heterogeneity of cancer cell lines. In 
the case of functional VGSC expression also, only subpopulations of prostate cancer 
cells were positive, 10 % and 50 % of human and rat strongly metastatic cells, 
respectively (Laniado et al., 1997; Grimes et al., 1995). It could be suggested that 25 
% expression of VGSC cannot make significant changes in MCBs. However, it is 
well established that blocking VGSC activity does cause significant suppression of 
MCBs of these cells. For instance, Laniado et al. (1997) showed that 10 % of the 
„parent‟ strongly metastatic human prostate cancer PC-3 cells expressed functional 
VGSCs. On the other hand, blocking VGSC in these cells using nanomolar 
concentration of the specific VGSC blocker, TTX, caused 31 % reduction in 
invasiveness. Although, our data and current literature taken together would suggest 
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that Ca
2+
 oscillations could be important in modulating VGSC-dependent MCBs 
(e.g. directional motility and invasion), further experiments are required to establish 
the precise role of Ca
2+
 oscillations in MCBs. 
The present study is the first characterization of [Ca
2+
]i oscillations in human 
PCa cells. As discussed earlier, Ca
2+
 signalling is important generally for functioning 
of cells. On the other hand, prolonged increase in [Ca
2+
]i can cause cell death 
(Roderick and Cook, 2008; Wertz and Dixit, 2000). Accordingly, Berridge et al. 
(1998) proposed that cells avoids cell death by delivering Ca
2+
 signals that has to be 
relayed over long time periods as repetitive brief „transients‟, i.e. as “Ca2+ 
oscillations”. It was suggested that cellular information can be encoded in the 
frequency and/or amplitude of the Ca
2+
 oscillations (Berridge et al., 2003; Berridge 
et al., 1998).  
 No change in intracellular Ca
2+
 levels under control condition was recorded 
in weakly metastatic human PCa cell line, LNCaP. Previously, a store-operated Ca
2+
 
entry mechanism was described in LNCaP cells (Lallet-Daher et al., 2009; Lehen‟kyi 
et al., 2007; Gackière et al., 2006; Abeele et al., 2004; Abeele et al., 2003a; Abeele 
et al., 2003b; Gutierrez et al., 1999). However, similar to our results, no spontaneous 
oscillation was reported in LNCaP cells. On the other hand, here, we demonstrated 
that membrane depolarization can regulate the intracellular Ca
2+
 level in LNCaP 
cells. In contrast, Lallet-Daher et al. (2009) reported that hyperpolarisation via 
activation of Ca
2+
-activated K
+
 channels, would cause influx of Ca
2+
 in PCa cell 
lines. In addition, Gutierrez et al. (1999) showed that fluctuations in membrane 
potential between -80 and +80 mV did not affect the Ca
2+
 permeability of LNCaP 
cells. Further work is necessary to decipher these apparent inconsistencies. 
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5.4.2 A model of intracellular Ca2+ oscillations in PC-3M cells 
From the present findings, taken together with published data, a working model of 
spontaneous Ca
2+
 oscillations in PC-3M cells can be proposed, as illustrated in 
Figure 5.17. In this model, the oscillations in [Ca
2+
]i are generated and modulated, 
and these occur in compartmentalised fashion (i.e. in a cellular micro-environment), 
as follows: 
1. PC-3M cell membranes are tonically depolarized at rest and, consequently, 
VGSCs spend a significant time in open state. This is consistent with the highly 
reproducible effects of TTX (an open-channel blocker) on strongly metastatic, 
including PC-3/M cells, reported over many years (Grimes et al., 1995; Nakajima et 
al., 2009; Onganer et al., 2007; Mycielska et al., 2005; Scorey et al., 2006; Laniado 
et al., 1997). 
2. The VGSC activity leads to Na
+
 influx, possibly mainly via INaP and further 
depolarize the membrane potential (Vm). Indeed, Cameron et al. (1980) have shown 
that strongly metastatic cells have higher levels of Na
+
, and malignant versus benign 
tumours are also higher in their Na
+
 content (Ouwerkerk et al., 2007).  
3. The influx of Na
+
 (and the depolarization of Vm) can raise [Ca
2+
]i by 
slowing or reversing NCX activity (Poburko, et al., 2007; Eder et al., 2005; Rosker 
et al., 2004; Arnon et al., 2000; Blaustein and Lederer, 1999; Matsuoka and 
Hilgemann, 1992; Miura and Kimura, 1989). The latter is electrogenic with a 
stoichiometry of 3Na
+
: 1 Ca
2+
 (Blaustein and Lederer 1999). 
4. The increase in [Ca
2+
]i  can activate RyR receptors and result in further rise 
in [Ca
2+
]i (Berridge et al., 2003).  
Steps 1 – 4 can explain the rising phase of given Ca2+ „spike‟. In order to 
return [Ca
2+
]i back to baseline and repeat the cycle, a Ca
2+
-sensitive negative 
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Figure 5.17 A basic model explaining possible mechanisms underlying 
spontaneous Ca
2+
 oscillations in PC3M cells. 
Influx of Na
+
 through VGSC activates NCXrev. Extracellular Ca
2+
 is exchanged 
with intracellular Na
+
 by NCXrev therefore [Ca
2+
]i increases. Increased [Ca
2+
]i  
activates RyR and more Ca
2+
 is released in to the cell and produces growth phase 
of Ca
2+
 transient. Plasma-membrane is hyperpolarized by IKCa channel which is 
activated by increased [Ca
2+
]i . Membrane hyperpolarization inactivates VGSC. At 
the same time, cytoplasmic Ca
2+
 was removed by PMCA, SERCA and Uniporter to 
extracellular solution, into ER and into mitochondria, respectively, until [Ca
2+
]i 
reaches equilibrium. [Na
+
]i, intracellular Na
+
 concentration; [Ca
2+
]i intracellular 
Ca
2+
 concentration, VGSC, voltage-gated Na
+
 channel; NCXrev, Na
+
-Ca
2+
 
exchanger working in reverse mode; RyR, ryanodine receptor; SERCA, 
sarcoplasmic-endoplasmic reticulum Ca
2+
 ATPase; PMCA, plasma-membrane Ca
2+
 
ATPase; Uniporter, mitochondrial uniporter; IKCa, Ca
2+
 activated potassium 
channels; ↑ increase activity; ↓ decrease activity; VM, membrane potential . Red 
line shows actions in activation/growth phase of a Ca
2+
 transient (inset) and blue 
line shows actions in decay phase of a Ca
2+
 transient. 
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„feedback‟ mechanism is required. In oscillating networks, such feedback is 
frequently provided by Ca
2+
-activated K
+
 (gKCa) channels (Fridlyand et al., 2009). 
KCa3.1 and KCa1.1 subtypes of gKCa (IKCa) channels are also expressed in PC-3/M 
cells (Yan and Aldrich, 2010; Bloch et al 2007; Lallet-Daher et al., 2009; Parihar et 
al., 2003;  Laniado et al., 2001). 
5. Increased intracellular Ca
2+
 up to a level would activate gKCa channels 
which would then hyperpolarize the plasma membrane Vm and thus reduce VGSC 
activity (Lallet-Daher et al., 2009; Félétou, 2009).  
6. The increased [Ca
2+
]i (locally up to mM level) would result in inhibition of 
RyR (Berridge et al., 2003). At the same time, further decrease of [Ca
2+
]i would 
result from (i) extrusion of Ca
2+
 from the cell by PMCA, and (ii) uptake into ER and 
mitochondria by SERCA and uniporter, respectively. 
7. As [Ca
2+
]i recovers back towards baseline, gKCa channels are inactivated, 
Vm starts to depolarize and the condition in (1) is re-established, leading to repeat of 
the cycle and resulting in the [Ca
2+
]i oscillations. 
 In this model, amplitude would be increased by activities of VGSC and RyR, 
and decreased by all Ca
2+
 sequestration mechanisms (PMCA, SERCA etc.). On the 
other hand, frequency would be controlled in a complex manner by all mechanisms. 
In addition, we cannot rule out the possibility that other Ca
2+
 entry and / or efflux 
mechanisms are involved in the model of Figure 5.17. Such additional mechanisms 
could include TRPC1, TRPC3, TRPC4, TRPV2, TRPV6, and TRPM8.  
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5.4.3 Role of the various subcellular mechanisms in Ca2+ signalling / 
oscillations  
In the following, with reference to Table 5.1, we discuss / re-evaluate the role played 
by the various subcellular mechanisms investigated in the Ca
2+
 oscillations in PC-3M 
cells. 
  
5.4.3.1 VGSC and cation (Na
+
) influx  
Blocking VGSC activity with TTX or ranolazine produced similar effects, indicating 
that it was INaP that was mainly responsible for the involvement of VGSC activity in 
the Ca
2+
 oscillations. Thus, both frequency and amplitude of Ca
2+
 oscillations were 
reduced. On the other hand, when extracellular Na
+
 was substituted with equimolar 
Li
+
, there was no change in the amplitude or frequency of the oscillations but rise 
and decay time constants were reduced. These effects can be due to multiple reasons. 
First, it is well known VGSCs are permeable to Li
+
 (Blaustein and Santiago, 1977; 
Hille, 1972). Therefore, we can assume that Li
+
 influx occurred and Vm depolarized 
as normal. Second, in the absence of extracellular Na
+
, NCX will initially work in 
reverse (driven by the Ca
2+
 and Na
+
 gradient) and this mode will be facilitated by the 
Vm depolarization. Subsequently, however, intracellular Li
+
 would not be able 
substitute for Na
+
 in NCX which will be inhibited (Blaustein and Lederer, 1999).  
Nevertheless, the initial rise in [Ca
2+
]i with RyR can enable [Ca
2+
]i to reach normal 
amplitude and oscillations may continue with regular frequency.  
 Interestingly, when extracellular Na
+
 was replaced by the large organic 
choline
+
, there was a decrease in amplitude but an increase in frequency of 
oscillations. These effects can be explained by the facts (i) that NCX again would 
tend to work in reverse (Palty et al., 2004; Blaustein and Lederer, 1999) but (ii) that 
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since there will have been no Vm depolarization (due to the VGSC impermeability of 
choline
+
), and hence any rise in [Ca
2+
]i would be limited. As regards the frequency, 
return of [Ca
2+
]i back to baseline might be quicker without the Vm depolarization, so 
the cycle would be repeated more frequently.  
  
5.4.3.2 Extracellular Ca2+  
In the absence of extracellular Ca
2+
, PC-3M cells had no spontaneous Ca
2+
 
oscillations. After re-administering Ca
2+
 into the external bath solution, however, an 
increase in internal Ca
2+
 was observed which, after some delay, returned to a new 
baseline (higher than the original). Following the return to new baseline Ca
2+
 levels, 
some cells did start to oscillate. These results are consistent with the proposed role of 
NCX. Previously, Lehen‟kyi et al. (2007) demonstrated in LNCaP cells that 
increased extracellular Ca
2+
 would induce an increase in intracellular Ca
2+
. However, 
when the cationic channel TRPV6 was knocked down by siRNA, extracellular Ca
2+
 
did not affect the intracellular Ca
2+
 levels (Lehen‟kyi et al., 2007). Therefore it was 
proposed that TRPV6 was „constitutively open‟ and mediated tonic Ca2+ influx into 
LNCaP cells (Lehen‟kyi et al., 2007). A similar mechanism could also be involved in 
the role of extracellular Ca
2+
 in PC-3M cell [Ca
2+
]i oscillations.  
 
5.4.3.3 Thapsigargin  
Possible role of sarcoplasmic-endoplasmic reticulum Ca
2+
 pump (SERCA) on the 
spontaneous Ca
2+
 oscillations was investigated using thapsigargin as a specific 
inhibitor (Sagara and Inesi, 1991). Thapsigargin caused a significant rise in basal 
intracellular Ca
2+
 level in PC-3M cells indicating that SERCA was active tonically in 
PC-3M cells. This initial increase was immediately followed by a second Ca
2+
 peak 
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and then [Ca
2+
]i decreased and levelled off higher than the initial resting condition. 
On the other hand, when PC-3M cells were maintained in Ca
2+
-free conditions, 
which would result in the emptying of Ca
2+
 from ER stores, thapsigargin did not 
produce the second peak and [Ca
2+
]i returned to baseline. This suggested strongly 
that the secondary peak and elevation of [Ca
2+
]i were mediated by influx of 
extracellular Ca
2+
. Previously, a store-operated Ca
2+
 entry mechanism was described 
in LNCaP, DU145 and PC-3 PCa cells where ER depletion indeed caused influx of 
Ca
2+
 from extracellular solution (Lallet-Daher et al., 2009; Lehen‟kyi et al., 2007; 
Gackière et al., 2006; Abeele et al., 2004; Abeele et al., 2003a; Abeele et al., 2003b; 
Gutierrez et al., 1999). Furthermore, Lallet-Daher et al. (2009) proposed that 
activation of an intermediate-conductance Ca
2+
- -activated K
+
 channel (IKCa, 
KCa3.1) would hyperpolarize plasma membrane and this change in Vm mediated 
store-operated Ca
2+
 entry via TRPV6 cation channels in PCa cells. Similarly, 
depolarizing plasma membrane of PC-3M cells after efflux of Ca
2+
 from ER caused 
decrease in internal Ca
2+
 level. Therefore, similar to LNCaP, DU145 and PC-3 cells, 
PC-3M cells are also likely to possess a store-operated Ca
2+
 entry mechanism. 
Following inhibition of SERCA, no spontaneous Ca
2+
 oscillations were 
observed in PC-3M cells. This was probably due to „swamping‟ of the Ca2+ 
homeostasis resulting from Ca
2+
 release and influx. Consistent with this, the 
secondary elevated of [Ca
2+
]i was close to the peak reached by the oscillations.  
 
5.4.3.4 Ryanodine receptor 
Ca
2+
 signalling works mostly by producing brief changes in intracellular Ca
2+
 levels. 
These changes in intracellular Ca
2+
 can be mediated by influx of Ca
2+
 through 
plasma membrane and/or release of Ca
2+
 from internal stores (Roderick and Cook, 
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2008; Clapham, 2007; Berridge et al., 2003; Berridge et al., 1998). Two families of 
Ca
2+
 release channels were identified in the primary Ca
2+
 storing organelle, ER: RyR 
and IP3R. Rayanodine receptor is generally found in excitable cells (Chen et al., 
2009). However, expression of RyR was shown in breast and prostate cancer cells 
(Abdul et al., 2008; Mariot et al., 2000). This agrees with the notion that metastatic 
cells possess some of the characteristics typical of excitable cells such as neurones 
(e.g. Onganer et al., 2005). Furthermore, strong correlation between RyR expression 
and breast cancer grade was reported (Abdul et al., 2008). It was shown that LNCaP 
cells express functional RyR and the caffeine can mediate Ca
2+
 efflux from 
intracellular Ca
2+
 stores via RyR (Mariot et al., 2000). Accordingly, in the present 
study, caffeine was used to confirm the presence of functional RyRs in PC-3M cells. 
Indeed, caffeine (at 10 mM concentrations that would stimulate RyRs) increased 
[Ca
2+
]i and suppressed Ca
2+
 oscillations. Conversely, inhibiting RyR with a high 
concentration of ryanodine reduced both amplitude and frequency of the spontaneous 
Ca
2+
 oscillations, without affecting the baseline level. These results suggested (i) that 
functional RyRs were present in PC-3M cells and (ii) that RyR activity plays a 
significant role in generation of the spontaneous Ca
2+
 oscillations. 
 
5.4.4 Possible pathophysiolgical consequence of Ca
2+
 oscillations in PCa (PC-
3M) cells and future perspectives 
As already noted in this chapter, Ca
2+
 signalling is important for both the physiology 
and pathophysiology of cells. In particular, since prolonged increases in [Ca
2+
]i 
would be cytotoxic, Berridge et al. (1998) suggested that intracellular Ca
2+
 signalling 
would be more expedient as repetitive brief „transients‟ (i.e. as “Ca2+ oscillations”) 
that can be allowed to occur over long time periods. Importantly, Berridge et al. 
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(1998, 2003) also suggested that cellular information can be encoded in the 
frequency and/or amplitude of Ca
2+
 oscillations. Such oscillations can subserve a 
wide range of cellular functions from fundamental gene expression to proliferation 
and motility/migration (e.g. Dolmetsch et al., 1998; Ding et al., 2010; Komura and 
Rakic, 1996). Most such processes are common also to cancer cells and most 
probably relate to the metastasis. Accordingly, [Ca
2+
]i oscillated in the strongly 
metastatic PC-3M but not the weakly/non-metastatic LNCaP cells (Figures 5.1A vs 
5.2A). It was proposed that information of Ca
2+
 signal can be encoded in the 
frequency and/or amplitude of oscillations (Berridge et al., 2003; Berridge et al., 
1998). For example, De Koninck and Schulman (1998), showed that amplitude and 
frequency of [Ca
2+
]i spikes can modulate CaM kinase II activity. Further work is 
required to relate the amplitude / frequency characteristics of the [Ca
2+
]i oscillations 
to the different components of the metastatic cascade. 
 Here, we presented a simple cycling model of [Ca
2+
]i oscillations in PC-3M 
cells. Whilst the model is well supported by the pharmacological evidence presented, 
it should be tested further and possibly expanded at least along the lines of the 
following: 
1. At present, the [Ca2+]i signal is treated as „global‟. Higher temporal and 
spatial resolution would be useful (i) to determine if the proposed spatial 
compartmentalization of the signalling components indeed exists and (ii) 
to reveal if [Ca
2+
]i travels intracellular as „waves‟ (Subramanian et al., 
2001; Wei et al., 2009). 
2. The possible role of the membrane potential (Vm) should be elucidated 
experimentally using voltage-sensitive dyes, such Di-8-ANEPPS 
(Valverde et al., 2010). Similarly, whether the proposed influx of Na
+
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indeed occurs can be tested using Na
+
-sensitive dyes, CoroNa Green or 
SBFI (Meier et al., 2006).       
3. The proposed role of NCX (in forward and reverse modes) can be tested 
using mode-selective pharmacological blockers (Hobai and O‟Rourke, 
2004; Laskowski and Medler, 2009). 
4. The possible role of other cation channels, such as TRPV6 (Fixemer et 
al., 2003), should also be investigated. However, exposing the cells to 
100 mM KCl consistently elevated the [Ca
2+
]i level. This is not consistent 
with the role of such a passive mechanism. In turn, this raises the 
possibility of Vm having effects upon other electrogenic mechanisms. 
These would be additional to NCX since the KCl treatment was still 
potently effective under Na
+
-free conditions when NCX activity would be 
expected to be impaired. 
5. Finally, it is possible that the proposed Na+ influx and/or the Ca2+ itself 
can activate kinases and these may modulate the [Ca
2+
]i oscillations by 
phosphorylating the regulatory components. In particular, Na
+
 can 
stimulate PKA (Brackenbury and Djamgoz, 2006) and Ca
2+
 is a substrate 
for CaM kinase (Colomer and Means, 2007).    
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  Chapter 6 
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According to Office for National Statistics (2010), 1 in 4 deaths in the UK were 
caused by cancer in 2008 and prostate cancer (PCa) is second commonest cause of 
cancer death in man. Ionic mechanisms, such as voltage-gated sodium channel 
(VGSC) activity and Ca
2+
 signalling, were shown to play important role in metastatic 
behaviour of PCa, as reviewed by Onkal and Djamgoz (2009) and Prevarskaya et al. 
(2010). Therefore, it was proposed that targeting these mechanisms could be a novel 
and effective strategy to tackle cancer, including PCa (Onkal and Djamgoz, 2009; 
Prevarskaya et al., 2010). On the other hand, microenvironmental effects such as O2  
and Ca
2+
 levels could modulate metastatic cell behaviours (MCBs) in PCa (Alqawi et 
al., 2007; Watson et al., 2008; Ackerstaff et al., 2007; Liao et al., 2006). 
Importantly, hypoxia has been detected in cancerous tissue of prostate (Movsas et al., 
2000). Therefore, the main aims of this thesis were (i) to study effect of „long-term‟ 
(24 h or longer) hypoxia (2 % O2) on VGSC expression and possible consequent 
effect on MCBs in a comparative approach to strongly and weakly metastatic PCa 
cell lines, Mat-LyLu and AT-2, respectively; (ii) to investigate effects of clinically 
approved pharmacological VGSC blockers on VGSC expression and Matrigel 
invasion in Mat-LyLu cells to evaluate their anti-cancer potential; and (iii) to 
characterise transient changes in intracellular Ca
2+
 level (“Ca2+ oscillations”) and 
possible involvement of VGSC in this signalling in strongly metastatic human and 
rat PCa cells (PC-3M and Mat-LyLu, respectively) and weakly metastatic human 
PCa LNCaP cells.  
6.1 Summary of key findings 
The main findings of the studies described in this Thesis are as follows: 
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1. Hypoxia (2 % O2) longer than 24 h significantly decreased the 
number of Mat-LyLu cells while not effecting AT-2 cell number. 
On the other hand, Nav1.7 and VGSCβ1 subunits (predominant 
VGSC α- and β- subunits expressed in PCa) mRNA levels increased 
significantly by long-term hypoxia (2 % O2, 24 h). However, a small 
but significant decrease in VGSC α-subunit level was detected in 
the hypoxic Mat-LyLu cells; VGSCβ1 protein level was not 
affected. Similar hypoxia had no effect on lateral motility and 
Matrigel invasion of Mat-LyLu cells but transverse migration was 
increased by in a VGSC dependent manner.  
2. At micromolar concentration, clinically used pharmacological 
VGSC blockers (ranolazine, riluzole, procaine and lidocaine) (i) 
reduced Nav1.7 mRNA expression, (ii) decreased VGSCα protein 
level and (iii) decreased Matrigel invasion of Mat-LyLu cells under 
both normoxia (21 % O2, 24 h) and hypoxia (2 % O2, 24 h). 
3. Spontaneous transient changes in intracellular calcium activity 
([Ca
2+
]i), - “Ca
2+
 oscillations” - occurred in ~25 % of PC-3M cells; 
no such activity was detectable in LNCaP and Mat-LyLu cells. 
Ranolazine and TTX modulated both oscillation frequency and 
amplitude in PC-3M cells. Both extracellular and endoplasmic 
reticulum (ER) Ca
2+
 played a significant role in the oscillation 
process. Ryanodine receptor (RyR) was also involved in the Ca
2+
 
oscillations. 
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6.2 Hypoxic regulation of VGSC expression and MCB in PCa 
Tumour microenvironment plays important role in MCB of PCa cells and it was 
proposed that cancerous cells would not be able to acquire metastatic phenotype by 
only genetic alteration without the impact of microenvironmental factors (e.g. Chung 
et al., 2005). One of the distinct characteristic of the microenvironment in PCa is 
decreased tissue O2 level, ~1.5 % vs. ~4 %, in cancerous and normal tissue, 
respectively (Movsas et al., 2000). In addition, androgen-deprivation therapy was 
proposed to cause tissue hypoxia (Rudolfsson and Bergh, 2009). Accordingly, 
changes in MCB were detected in hypoxic PCa (Alqawi et al., 2007; Watson et al., 
2008; Ackerstaff et al., 2007). VGSC expression and function were correlated earlier 
with metastatic potential of PCa (e.g. Grimes et al., 1995; Laniado et al., 1997; Diss 
et al., 2005). In a different area of research, it was shown that hypoxia in neurons and 
cardiac cells increased the persistent sodium current of VGSC, and, therefore, could 
increase intracellular Na
+
 concentration and thus lead to intracellular Ca
2+
 overload 
(Hammarström and Gage, 1998; Ju et al., 1996; Wang et al., 2007). Increased 
intracellular Na
+
 was also shown to increase Nav1.7 mRNA and plasma membrane 
(PM) trafficking of VGSC α-subunit while having no effect on total protein level in 
Mat-LyLu cells; these effects were largely mediated by  the adenylate cyclise (AC) / 
protein kinase A (PKA) pathway (Brackenbury and Djamgoz, 2006). The increased 
Nav1.7 mRNA expression in Mat-LyLu cells under hypoxic conditions shown in the 
present study is consistent with the earlier work (Brackenbury and Djamgoz, 2006). 
However, decreased VGSCα protein level in PM was detected in hypoxic Mat-LyLu 
cells. Similarly, Préze-Pinzón et al. (1992) showed that reduced O2 level decreased 
VGSC α-subunit protein expression in turtle brain and O‟Reilly et al. (1997) 
proposed that reduced O2 level could cause a decrease in VGSC expression in 
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neurones, as a part of a process to conserve energy during metabolic stress. 
Consequently, the metabolic phenotypes of PCa cells were shown to be effected by 
hypoxic stress (Higgins et al., 2009). In addition, mRNA and protein could be 
differentially regulated (e.g. Orphanides and Reinberg, 2002).  On the other hand, 
Onkal (2010) showed that peak current density of VGSC in Mat-LyLu cells 
increased significantly in hypoxic (2 % O2, 24 h). This would imply that VGSC could 
be regulated post-translationally, independently of protein expression.  Thus, it 
would be appear that VGSC expression in Mat-LyLu cells can be regulated 
independently, at least partially, at a hierarchy of levels (from transcription to post-
translation). 
 Increased VGSC activity was shown to enhance lateral motility, transverse 
migration and Matrigel invasion of Mat-LyLu cells (Fraser et al., 2003; Brackenbury 
and Djamgoz, 2006; Grimes et al., 1995). Accordingly, in the present study, 
transverse migration of Mat-LyLu cells increased with hypoxia (2 % O2, 24 h) and 
this effect was VGSC dependent. However, the hypoxia-mediated increased VGSC 
activity did not cause any effect on lateral motility and Matrigel invasion. These 
observations suggest that, under the hypoxic conditions induced, the effect on MCBs 
was specific to transverse migration, paralleling intra/extravasation, which has been 
suggested to be one of the critical components of the metastatic cascade (Wyckoff et 
al., 2000). Importantly, TTX decreased both normoxic and hypoxic Mat-LyLu cell 
invasiveness equally, supporting the proposed role of VGSC in invasion (Grimes et 
al., 1995; Laniado et al., 1997; Smith et al., 1998; Bennett et al., 2004; Nakajima et 
al., 2009). On the other hand, the hypoxia-mediated increase in VGSC activity did 
not further increase the invasiveness of Mat-LyLu cells probably because VGSC was 
already working maximally under normoxic condition, as suggested earlier 
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(Brackenbury and Djamgoz, 2006). In addition, Gillet et al. (2009) showed that 
VGSC activity leads to intracellular alkalization and perimembrane acidification. In 
same study, they showed that VGSC activity dependent increase in invasiveness of 
strongly metastatic human breast cancer (BCa) MDA-MB-231 cells was caused by 
pH-dependent activation of cysteine cathepsins, which play crucial role in BCa cell 
invasion (Gillet et al., 2009). Since, hypoxia was shown to be involved in changes in 
lactic acid production (Higgins et al., 2009), the resulting acidification of 
intracellular pH could be one reason for not detecting VGSC activity dependent 
increase in invasion of hypoxic Mat-LyLu cells.  
 Similar to the results presented here, Alqawi et al. (2007) reported that 5 h 
hypoxia (1 % O2) had no affect on Mat-LyLu cells invasion. On the other hand, they 
showed that after 3 weeks of hypoxia (1 % O2) only 5 % of Mat-LyLu cells survived 
and after 8 weeks (1 % O2), the surviving cells were found to be significantly more 
invasive than normoxic cells. Therefore, it was proposed that hypoxia acts as a 
selective pressure on cancerous cells and selects for highly invasive and apoptosis-
resistant phenotype (Alqawi et al., 2007). In addition, these results, taken together, 
clearly show that different periods of hypoxia can have different affects on PCa cells. 
 
6.3 Ca
2+
 signalling downstream to VGSC activity possibly leading to MCB 
regulation 
Like hypoxia, other microenvironmental factors can also play important role in 
cancer development and progression. In particular, the high Ca
2+
 concentration in 
bone environment was proposed to facilitate metastasis of PCa to bone (Liado et al., 
2006). Interestingly, Mat-LyLu cells, which spread to lymph node and lung but not 
to bone, was shown to be not responsive to extracellular Ca
2+
 (Ding et al., 2008). 
  - 316 - 
 
Accordingly, no [Ca
2+
]i oscillations were detected in the present study. This result 
alone may indicate that Mat-LyLu cells are only a limited model of metastatic PCa. 
Also, LnCaP cells, which are weakly (and non-skeletal) metastatic, did not show any 
spontaneous [Ca
2+
]i activity. On the other hand, 25 % of PC-3M cells, which are 
skeletal metastatic, had spontaneous Ca
2+
 oscillations. These Ca
2+
 oscillations were 
dependent on extracellular Ca
2+
. Accordingly, the parental cell line of PC-3M, PC3, 
which is also skeletal metastatic, was shown to be more adhesive when extracellular 
Ca
2+
 concentration was elevated (Liado et al., 2006). In addition, increase in 
extracellular Ca
2+
 level was reported to induce increase in proliferation of PC3 and 
C4-2B (a metastatic variant of LnCaP) cells but not the parent LNCaP cell line 
(Liado et al., 2006). These results would indicate that Ca
2+
 signalling / oscillations 
could be important for metastasis of human PCa cells to bone.  
 It was proposed earlier that Ca
2+
 signalling could be downstream to VGSC 
activity leading to MCB, including galvanotaxis (Mycielska and Djamgoz 2004; 
Mycielska and Djamgoz 2003; Onkal and Djamgoz, 2009). Therefore, having studied 
this hypothesis, we found that VGSC activity was indeed involved in modulation of 
Ca
2+
 oscillations. Accordingly, Na
+
 entry via VGSC was proposed to mediate 
increase in [Ca
2+
]i by slowing or reversing Na
+
/Ca
2+
 exchanger (NCX) (Poburko et 
al., 2007; Eder et al., 2005; Rosker et al., 2004; Arnon et al., 2000; Blaustein and 
Lederer, 1999; Matsuka and Hilgemann; Miura and Kimura, 1989). In addition, this 
local increase in [Ca
2+
]i could be amplified by activation of ER Ca
2+
 release channels 
including ryanodine receptor (Berridge et al., 2003). In the present study, we showed 
that disruption of ryanodine receptor or depletion of ER Ca
2+
 stores had negative 
effect on Ca
2+
 signalling. Therefore, our results taken together with the current 
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literature further support the notion that Ca
2+
 signalling is downstream to VGSC 
activity and has important consequences for metastasis.  
 
6.4 Pharmacological VGSC inhibition and clinical implications. 
As described above, tumour microenvironment, in addition to genetic modifications, 
can play a key role in the acquisition of metastatic phenotype (Chung et al., 2005). 
Indeed, reduced O2 level is one of the characteristics of cancerous tissue (Vaupel et 
al., 2007; Harrison and Blackwell). In addition, Movsas et al. (2000) reported a 
positive correlation between hypoxia and clinical stage of cancer and patient age in 
PCa patients. Therefore, non invasive imaging of tissue O2 levels was proposed as a 
promising tool for cancer diagnosis. Long-term hypoxia, could lead to cell death in 
Mat-LyLu cells, as shown by Alqawi et al. (2007). Accordingly, androgen 
deprivation therapy was shown to cause prostate tissue hypoxia leading to cell death 
due to changes in O2 supply and demand (Rudolfsson and Bergh, 2009).  However, 
this hypoxic microenvironment would select for apoptosis-resistant cells and 
increased metastatic ability which could be a cause of the relapse and re-emergence 
of metastasis in PCa undergoing prolonged androgen downregulation (Rudolfsson 
and Bergh, 2009; Koochekpour, 2010). Since the aim of research is to understand 
and establish novel therapeutically strategies for cancer and metastatic disease, in 
vitro studies should be carried out under microenvironmental conditions similar to 
those found in vivo.  
 Because VGSC activity was shown to increase MCBs, it was proposed as a 
novel and promising target for cancer therapy (Onkal and Djamgoz, 2009). However, 
when pharmacological VGSC blocker used at a concentration necessary for complete 
block of both transient and persistent currents of VGSC (INaP and INaT), they would 
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be lethal, e.g. by stopping heartbeat. However, at lower concentrations, these 
pharmacological blockers were shown to preferentially block INaP (Chen et al., 2009; 
Samudio et al., 2010; Rajamani et al., 2008; Antzelevitch et al., 2004; Weiss et al., 
2010; Le et al., 2010; Parihar et al., 2003; Doble, 1996; Zona et al., 1998; 
Hammarström and Gage, 1998). Specifically, ranolazine and riluzole were proposed 
to mediate anti-anginal and neuroprotective effects by blocking INaP (Antzelevitch et 
al., 2004; Fredj et al., 2006; Urbani and Belluzi, 2000; Zona et al., 1998). In 
addition, low doses of lidocaine were shown to preferentially block INaP 
(Hammarström and Gage, 1998). Therefore, here, we used clinically approved 
pharmacological VGSC blockers - ranolazine, riluzole, procaine and lidocaine - at 
clinically safe micromolar doses, to study their possible effects on VGSC expression 
and Matigel invasion of Mat-LyLu cells. We concluded that these agents reduced 
invasiveness of PCa cells and thus could be used as anti-cancer drug.  
 
6.5 Future perspective. 
There are still many aspects of PCa that need to be elucidated, as follows: 
I. We showed here that hypoxia increased mRNA levels of VGSC and 
transverse migration (by VGSC-dependent mechanism). Brackenbury and 
Djamgoz (2006), proposed that VGSC activity increased VGSC mRNA 
expression and migration via the AC/PKA. Therefore, involvement of this 
pathway in hypoxia induced increase in migration could be studied. 
II. Previously, the hypoxia-induced increase in VGSC peak current density was 
reported in Mat-LyLu cells (Onkal, 2010). In addition, enhancement INaP was 
reported in hypoxic cardiac and neuronal cells (Hammarström and Gage, 
1998; Ju and Gage, 1996). However, there is no electrophysiological 
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evidence on hypoxic effect on INaP in our model cells. Therefore, INaP activity 
can be further examined in both normoxia and hypoxia using 
electrophysiological techniques. 
III. INaP and INaT components of VGSCs in various cell types were shown to have 
different sensitivity to ranolazine, riluzole, procaine and lidocaine, depending 
on concentration (Chen et al., 2009; Samudio et al., 2010; Rajamani et al., 
2008; Antzelevitch et al., 2004; Weiss et al., 2010; Le et al., 2010; Parihar et 
al., 2003; Doble, 1996; Zona et al., 1998; Hammarström and Gage, 1998). 
However, differential effect of these drugs on INaP and INaT was not studied in 
Mat-LyLu cells. Therefore, dose-dependent effects of these drugs on INaP and 
INaT in Mat-LyLu cells could be examined by electrophysiology. 
IV. In vivo effects of these pharmacological VGSC blockers on PCa metastasis 
can be studied using appropriate animal models. Such models could be the 
Copenhagen rat (Lamb and Zhang, 2005; Blouin et al., 2005) or the TRAMP 
transgenic mouse model (Gingrich et al., 1996; Kaplan-Lefko et al., 2003). 
Such studies could further validate the anti-cancer potential of these drugs 
and asses their safety. 
V. In the present study, we showed that 25 % of PCa (PC-3M) cells showed 
spontaneous Ca
2+
 oscillations. Such Ca
2+
 signalling was shown to play 
important role in many cellular processes including invasion, migration, 
motility, adhesion, galvanotaxis, and secretion (Amuthan et al., 2002; Wei et 
al., 2009; Huang et al., 2004; Komuro and Rakic, 1996; Giannone et al., 
2002; Liao et al., 2006; Tse et al., 1993; Giannone et al., 2002; Liao et al., 
2006; Mycielska and Djamgoz 2003; Mycielska and Djamgoz 2004). 
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Therefore, the role of the oscillations in PCa can be determined by 
investigating differences in MCBs of oscillating vs. non-oscillating cells. 
VI. of VGSC activity in Ca2+ signalling could be further examined by (i) 
measurement of changes in intracellular Na
+
 concentrations, (ii) examining 
changes in membrane potentials and (iii) observing changes in [Ca
2+
]i 
following increase in intracellular Na
+
. 
VII. Other proposed component of this Ca2+ oscillation signalling including NCX 
and Ca
2+
-activated K
+
 channels could be further studied by (i) using selective 
mode dependent pharmacological inhibitors and (ii) colocalization of VGSC 
and NCX (e.g. in caveolae). 
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Appendix 1 Hypoxia (2 % O2, 24 h) increased peak Na
+
 current density in 
Mat-LyLu cells.  
(A) Typical whole-cell VGSC current in (i) normoxic (~21 % O2, 24h) and (ii) 
hypoxic (2 % O2, 24h) Mat-LyLu cells, elicited by 60 ms pulses to between -80 
mV and +45 mV from a holding potential of -100 mV; interpulse duration was 2 s. 
(B) Bar diagram showing average peak current density in normoxic and hypoxic 
Mat-LyLu cells. Inset: bar deagram showing whole-cell capacitance in normoxic 
and hypoxic Mat-LyLu cells. (C) Mean I-V relationship for normoxic and hypoxic 
Mat-LyLu cells. Current density was larger in hypoxic Mat-LyLu cells in the 
voltage range -15 to +15 mV. Un-paired student t-test was used for statistic 
analysis. Data are presented as means ± SEM (n = 21 - 25). Significance: (**) p < 
0.01; (X) p > 0.05. (Modified from Onkal, 2010) 
 
 
